var title_f22_46_23264="Spectral computation RPA";
var content_f22_46_23264=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Spectral computation of repolarization alternans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 469px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two consecutive QRS beats from a sequence of 64 are aligned, allow corresponding timepoints within repolarization to be compared between beats (panel A). STU power spectra between beats are computed at successive timesamples and the 0.5 cycles/beat magnitude indicates alternate-beat periodicity (panel B). Summating these spectra across all timesamples reveals repolarization alternans (RPA) as ST, distinct from respiratory modulation (0.1 cycles/beat). T wave alternans ration (TWAR) relates ST to noise (0.33 to 0.48 cycles/beat) and TWAR &gt;3 predicts ventricular arrhythmia (here TWAR = 67.6). Panel C shows RPA temporal distribution (time domain reconstruction) showing ST for each STU timesample. T is the timepoint of the center-of-area of this reconstruction normalized to STU duration, and may be early (T&lt;0.5), late (T&gt;0.5) or symmetric within repolarization (T = 0.5, as here). V",
"    <sub>",
"     alt",
"    </sub>",
"    , voltage difference of alternation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_46_23264=[""].join("\n");
var outline_f22_46_23264=null;
var title_f22_46_23265="Ankle anterior drawer test";
var content_f22_46_23265=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Anterior drawer test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5lJpp54pSaaKYEZ+/T6Y33qdQAtOU/nTaDxQBL1FMZeopyGpETeQByaQ0QQ20k8yxxrlmNes+CtMSytkUDJPU+prnfBukCa8XIzjknFeo6fpwhZcDiuKvPmdlselh6Xs1d7suRQAgHHUVbhh20+NApAqyEzWKR1JlVyE4zTMCQ1LMnYD86gQ7DjPFJl3EaEKfWvMPidDd2Wp299aoXikTbKMZAI6H2r1csNvSuV8dWj3ugXaw5Lqm4D1A60QajLUyrJyjoeb6fqSTjn5XHUVrQSjjFchaAq4I4NdPpsbMATWlSKWxnSk5LU2oGJ6VbQZ5qG3iIA9atIvB7CszVCAcU9QO/anhRimnjJ5qWhjX2oQSTzwBU8eR6GoN2Rg5qWPoKnQGVvEMYa0jk7q2PzrnyBkCuo1VPM0qb1XBrmDwy1PU0pP3RNu1QDTlxkUj/eHBpe9I0Qo4Y4oxxzQAQc06kUICDwODSuOKaOTkU6Q46UhjFA9KaOKceBmkB/OmICKCPSl9PendvrQIjHB57CtfwbCLnxLYp1CvuP4CskDczD2rqvhlah/EZfHEURP4mtaavJGGIdqbZ65UUnMij0qSousx/KvQPGJh0opB0opgLSUUUAJSUtJQAUlFJQAh60hopM0CCikzSZoAdSpywplSxDkmmBLSGikpgAoNFFABSUtITjqaAENVL++trGEzXMipGBkkntWN4s8VWOh23zyCS4P3YlPP1PoK8R8T+J77WruR5pWEJ4WJTxj0pgejeJfiPbwIy6ViSQ8Kx6D3orxkOSfmHWiiwrmV1+lFLQelaGZC33qd1FNPWnDpSAKWk6UA0wHKcGtHThukHrWaa1vDMD3OoCNRlQMk1nU0ia0fjSPUPBFuIowxHJrt4W6VzGgxiKNVAxXRxsMVwHp3L0ZBI9anQncBtyMdSaqxnIFWVJGD/Kgdx0q5HSqjw5JwKubeh708qOmKhotGY0Z25FU5UJJVuQRzWvMpxxiqDxsZMt0qGVbQ8j1/Qzpusuqj/R5Dvj+np+FaWmw7UHFdzr+lrqFgQB+9T5kPvXJwIYwFOcjrWildamSXKWYxUoA4yaZH71IP1pFId25qN24OAT7U7PagipaGQgYNWIzwPWmgDinA9agTJZhus7hcdUNci/QGuwUZhk75Q/yrjz1pMuj1DcScZ4pT1poB3heuOtOHU0M2QozuzT15bimgHrTk65qWMFHNI696cp+akkzu5pDGP0GKMdMD8aRqUZ2/zpgHSjNBPFNHAyaaEwjGGNd98KIczX9wfZBXAZ9K9S+F9uE0F5SOZJSa3oK8rnHi5WhY7Q1FD94n1NPlcJGzHoozWHDr8AHKNXaeW3Y3qWsT/hIbf+49IfENv/caqsLmNukNYn/CQ2/9xqT/AISG3/uNSsHMbZpM1iHxDb/3Go/4SG3/ALjUBzG1SGsT/hIbfujUjeIbb+41OwcxtU01inxDb/3Hpp8RW/8AcalYXMjaNGawj4it8fcamnxHbf3Wp2C6N/PNTp92ucTxBbMyjkZPet+GZZI1dTkHvQFyeimg0tA7i0UZrP1XVrXToTJcSqoAycntTC5auriO1gaWZ1RFGSWOK838VfECBbSWDTCWmOVEnYH1rkfFniy81y4dBIUtVJCoD19zXJzSEgKO3Jp2C4t/dSSyNJJIzyN1Zjkk1RKYRiTg805mLsfoaRv9QMnpxTJIxygI+8RRQFIC457UVSBFGRCjsrAhgcEGm12fxE0M2V811Cv7tj84HY+tcXTTJGsOaRak4NIy8UwGkU2n9qYwNADhXd+B7RYbd3b/AFrnJ9hXAiTYwOMkGuz8J32+VUDcHtWGIvy6HThrc2p6Xp3ygVrRNyKx9POUHrWtFjIJrhTO80YfrVuInpmqEB4AzV6HgDJFUmBbjGakaM8EUyE1aHNVZMd7FVoSW5qN4QCeOKvgKT8vXuKYyA8+lRKJSZmyRdsVx3iGx+zXXnIuEkPPsa71o81napZLd2zxMOo4PoaztYTOARsmpAT2ps8UltM8Ugw6nFIDg9aoESZH40ucVFnnvS5//VUsY4NktxjFOB7UwHgE8UZINQxMuwco4/2T/KuNkOASO1djbn91If8AYP8AKuLJ5NDLo9SSI4UseppVPNRg5/3R3oXgZpG5MDz1pyk84qIHBOKkU4HFSxjk5cn0ok5bNNRvm5prtknmlYBCetAOFwaTOBmmMwwMmrAl4xSY3Aj2qIuAByKduGByMUaiBWxGQe1ez+B4Db+GbJSMEpuP414zHGZZQqcljgCveNLi8jTrePH3UA/SuqgtWzz8a9kLrEnl6bO3+ziuFU4HNdX4pmC6dtzyzAVyWa6onnMfmkJpuTSZNUSOzSE+9NJOKYSaAHM2KQPntSdaTtQApY9jRnjmm0hoAcTTGNITTGNACMfeoXbmnsagbOaaESxcsK63w3qO0i3lPB+6a5OEVdhJVgRwRQwPSFNO3Y5rK0fUFntCZGAaMfN9K57xVrhFybG3c7iRux157f59aktajfFfiwxbbeyILMWbdn+Ef14rynxBqlxfXTCeVm7nng1a8SXDfagkhXepOSp4xXOXkpLsw6YGM9TTQCs4Htjg1FEd4Zv4jnimyPtXAORSJngrwaoQhGARnnHNMchoyPX+dPncbi3qO1QEkdO5qhEitiMY6jrRTA4LAkY5waKNBnuninS47yycMoORyK8G1exfT72SFwcA/KfUV9Kyp5kZBHFeV/ELQ9+ZY1+ccilsDR5kDindaawIYg9RQDirJEIIpJDtWpOtRTjpSAhrU8OXP2bVISThWO01mVLbI8k8aQqWkZgFA6k9qUldWKjLlaZ7jpkuUUit2EkrXLaSs1qqwXShZ1ADgeuK6S1bKivKejsete+peiyMVoQnpuqhF04q7FwOaaA0YMMvB/GrUf3cCqETYAIwKuI2OR3rVCJ0RA7Mow7feIp2zAxSKflp6kBfeqsBAsW1QCSSOMnrTHi4IxVojP1phU1m4jucl4l0rz4vOiX98np/EK4/Br1WeLd2FcN4m002k/nxjEUh5A6A1GwJmJxgUD3oX60ucVDKF+lIelKOlN71DEzT0y2a7Y2yHDyqUB9M0yH4X3QlBkvSV71q+EE3apCT2Oa9FAGa6qUU43Zy1JtPQ8x/4VkQP+Pp6P8AhWhx/wAfb16hnNITWns4mXPLueYH4aEf8vT0o+GnrdPXp4yKXij2cewc8u55j/wrMHpdPR/wrJe9y9em9ehpc496fs49g55dzzFvhgh63D/nSP8ADCNVJ89zivUgaU8inyRFzy7nj/8AwgFkeDcSA1JB8Nradysdy/TNeiS6azTvtYAE5Aqaz0+W2mEgZSO49aXIuxTem5wtn8NBazxTpcOzRMGCk8HHau0Vb5B81nwP7r1tq3K5HWpvwq+VdDJu5xmr2V7qBjC2rKicncRyazv7Fux/y6H/AL6FehMSDimsM8YqloTZHAf2NeD/AJcyf+BCj+xrz/nz/wDHhXe7MdqTaaLiscINFuz/AMuoH1alOhXecfZk/wC+67jFRzuIoy5BIHXFFx2OMOgXYXJgj+m6lHh+7PWGMf8AAq6YalCw+6/PtVi1nWZOM5HY0cwcpyn/AAjlx3WIfjQfDc2P+WVdicZxikKjqBzTuKyONPhqc9ohSf8ACNS9zFXY7eKTbSuFji38NzY4MX5VBL4cnUE/uj7V27xBhio2j7U7hY82ntDE5G3BHBFIi4rqvENhkfaIh04bH865eU+Urse1U2S0RXV+1gUKNzyxX1x0/WuVvL2RL24udwZsbeerE8k1NqNw0ztNKflI2j0A65rAeZZ0lR2+UDIqSrWKt4GlYSyE5bJ56EDjisy5jJQEnnPNbeq6e1miEOWSaPcucZ/MVjE5VhkggdMVSYMrOMt6inQOpOT09KAcEqSMHoaZCvlyEnBBNMkQEFSGHzVC2Vf6VJKnztz70wgsMgg+xpgO4ORn3FFNYggEj5hwcUUxo+l1Py1z3ia3E0J4zxW9HyBVLVEDRkd6h7FNHg/irTTaXXnIv7uTr7GsDNev61pS3tvNAw++OD6HtXlsOl3c+oNZwQs86sVIA4GPX0pwlpYlplQHFRSNubPYV6FY/D7cgN/eMD3WIcfma6LTvB2jWZDfZBM4/ilO6m5ofIzybTdKvtSkCWNrLMT3A4H49K9P8EeCTpVwt9qbJJdKP3ca8rGfXPc12FtEkSBIkVEHRVGBVgemeKhzvsUopGRrkWyeK5Qdfkb+lTWcuVFXbqEXNtLGR1HHsaxrKQrw+cjgiuGrHllc7aErqx0UDHgk8HtV6N/UVk2suFxV6N+eDUo3NSJgRgCrcTZrJikwQO1XIpc5zWiZLNFW6VKD0z6VTV/Q1MsmOf0rS4iwfnBwaQEGo1Oef0oLAnB4qWgHNwDVG/tUurd4pBlWGKuMTx6U3FQ0B5bqNo9jdPDIOnQ+oqsCeprv/EOmC/tyVAEq8qa4B0eOQpICGU4IPrWTKTuSLwKF+93xQp4oQZNZsDrfBEe7Uk46Ka9AMJ6iuK+HqBtROeyGvRPK9BXdSXunHVfvFHyjigRGrvln0pfK/KtLGVyn5fPWjyiOvSrnle1HlZFAXKflYHFJs2nHrV3yj24prIQM7QTQFynsbtTlUgc81ZCknpxQY6AK+35qdg1J5ZGeTS7R1piGBTkYIqYZ280iJyDmpcUCIR1pGOCOCalCetBTPFMCLHNJg7ulSbTmkdCRxSAjK014wVIIyDxU208Z60FaAMX+y/mO2RlHYVNbWRgk3eYTxgg1oMpByMfSkYHHAzSshuTGY/Kgrkc1IELDmlC470ySAjtTSmec4NWcCmFV3A4yRQBAI+/eoyo5q0RzUUoUjNMCpNCroyt90jkV5l4uxY3awk4jc4z6A9K9PupEgiaR2AUd68d8UXZu9ekZ42aD5QMfwnH/ANai4WOburiPyZY5WAcHHX3rGljAj+6+9jwR/Kt+fTZprZ5V2mNWLtyM4B649qdqFrZNZRLayOZnTedxGEA655zRewHPpLPPGFbLIgPzbTWY+9S5YnJ5zW5LKIIniklj9FKg5xn0rFvHxICGyuetOLuJlCUkPyeT3qWF9zFWOM9/WmOCBgjcv6rUQwrg5PNaEk5OSW/A/Wo2IU7kOQ3UUuc7sdT2qLcO/TvTAcWw2V5B6iioicHAORRTQH0ypOOKimj3KSasxqAOaZcMNmKyZqYN1AN5OKrR28UTMyRqrMcsQOT9a07hc5NUpFIOKgBmRmpIwTTUTJqcAKKAHZAFOXJOBTFyzYFWokEY9WpAATav4Vi30PkXQkUfJJz+NbpwVNVbmAXFqydxyv1qKkeZGlOXLK5UtZOc1fR+nrWLbuQcHgg1owv+NciO5F5HI5zVuGTBGazwwOc9KkV+e9WmM24pMgGplfNZVvLjIOatQyln3AjZxj1q07kM01binA5brgCqiNk8VIjEjk1YItgk9aOMZqFGzUmc4z+dJoBJE3DFcd4r0vH+lxL8w++B3HrXZHOSd2Riq9xEJUZXAIPrWUlcWx5cP0qSL7w4q5rFibC8ZMYjblT/AEqmpAPNYu6NN0d18Ox/xMZD6RmvRRndz0rzLwTO8E8jxgElcV6ZC26JW9RXdS+E4aq964p9qAeaX6jFOABrQyGDJPIpwpMMfu8CnkAfePNAEbZ3UhGRg1KRnqKTGKQyHGO2KQA455qVgDg4puD2FAiNlzQB2xT+Bxg0Yxg0ANAI7Zp5yBwKUEKOhP0p2c9uKdwI+eKGXI61JxijH50CI8UMPyp5HJpDxjjrQAwqMUzB6Y4qVlJHy9aQL70AMKj0qMEBiuanI61GyZA9qAEI9OKaB6kmn4JOc0h4+tADdvy9aQIAOKeeTjFNUEdelAhjDioZF9OlWduKdBB5z8kImcFjQ3YDjfHshi8Py4yC2AMeuRx/OvO9BgfU79yJ0TGXUlNw47YyK9d+JekRL4UvmSVg8ahxkA8g141BF9kgF3bO6q8XLou75iTgEH1wehqXJW0KsW9WtNTSExNAitkozoWQjcM5Kn+lcjdRy3V6xZZDtAVFAbj2Fdde6+08DyFV8xkVX2vgAgema5+/1cNPMJ4FMLZYmJlBBwORxURbaFoc9eReXEZHBcdMsDn9ayHwVwORnp6Vranfl4ERUUE5yWO4/j2rn5XcNljz2x0reF+pLCU4OV4NRFhzu5BpzuHXI4PeozggdK0JHb+RjqOlNZiSSBn1FMOVbFJuyeaYCls4zRSHnr1oppAj6hkcKOKqsxYmnsCxp20KOax3NSpItVJF5q5KarsM9BUgQ4ApuSxwKcyk1NDGE5P3j+lAx8KeWP8AaPWpAKQDHWlHNIQ6mJ3qQCm4w5oAydTt/LlEyD5G6/WmQP8AjWxNGskTRsODWC6PBKUPb9RXNVjZ3OyjO6szSDflT1PQng1WjfjtU6HNZnQWopDuq/E4IGayg2eT1qzFJgCnFks1EkANTh8YPrWYHyMk8+1WI5M9/wAK1TJNFWz6VIrZ4NUVkwamV/b60wLikYNIeRzUHnEFAELAnGR2qYk4yOtSwMnXdPW+tHQf6xeVPvXB4ZJCjjDKcEelenPytcn4n03bILyJeDxIB/OspLqC7Gv4At0ubiVXzgJnivQ40McaopO0dzXAfDRx/aUi+sZ/nXo5Az9K6qXwnJW+Kwwg4oVTknPFOzz0OPWnjpWhkMAxSsM0ufXg0oBoAaeB3pqqT161NtzTtvpQBX/WjBqYrjPFJt9KQGLqUssEpCuRnkVTF3cY+aQ1v3NtHMy+YoOKiOnW55MdJplqStqOtpA8CP2IqUqSQc0RRJFHtQYX0pQBnqfpTMxCCRQCMcU7FNKjOaYBkZxQRz7UmOaQ5B6/hQApXNIO9Oxn600jFADT79aNufejAJq1oiQI8gQl5O5Pb2FS5JAURgNj1pcZ6itWbT7WeXeIzG+fvqcfpUEli4YhDux2PFJTTCxRI9aTBJAAz9K0Y9NJP75sD0FXEjhgHyqB796bkkBn22ntJhpsqv8Ad7mtHykWF49oCjtTop45DhTgjqDSO4DsBzurKck46DSOW+IN3Bb6dE1z/qZGEUoJwNrcZz7da8Qto59LMlpdKlxbNHtxGcYySVJPcEcjFetfFiJp/A92wCsbdgSrHqAeD74rwq3upJrSGQDzHEezA+bDKehHYYP61Kd4IbNPXPssLbrq1jWVcBw6nDnHHHX+lczq9xZTDPksrgqQu0np1BJ9vbtWxd6oTa7JYVfYP9YF5x2GSOtc9f6hLMFRoWUDIDORgfhgZq43uLoYt/cJIxVDkA/LgYFZsm7+KrV6WFwdzb3PtVeQhweMH0NdMSGRLkHcp9iKQ8DB4oIK89vWgHdkcsP1FWSNIOOORSN2NKQc8Ufe68UwEooIIHtRVIaPqNwEFVpWqWZvm5qEKXNYNmhBgsanjt+MmrUNsAMtwBVe7n3nZH93+dG24irJtDfKOlIB3pSuKTvipYxaeooUU7FAAOtNYYenjmkkHSgBOoqrqNt58WU/1i9Pf2q5SEVLV1ZlRbTujAhcg4PUVbjb04p2o2nJmiH+8P61Vik6Z5FcsotOx2wmpIvRsSSMcDvUp61VR+eOasI2OvNI0J0c4xmpon21WB9BT1Y55/SqRNi+jgEc1ZjYd6zUPvVlHIParuIvo3PNWFYHBqlG4PFTo42mh6gTEZ6GopYlljZJACGGCKcCDT8/L71DAy/CEDab4pjibPlyKwRj3r03HtXCIfLuYptoLRMGFdrZ3Ud3AssJyD1HcH0rai9LHLXTvcnHtR14HBpM/NjinA961MAANL0NO6/Wk5zzQA35QTjrTgQRzSgHPIFO4xQAwnnHFJ7UpUdTQenHWgY0rkHjmkAyKeM4OaapIyDSEN28/NjFDIM5xUmMjn8KQ5PWmBERnOelRMNoO0Z9qsEZOD0phHzYHX3oAiAJwTwcUfrT2ByD2FNI54pANOM88Up/ShlzUkMTythV47ntQBSuW8tCq/eb9Kl8Oh1u3LAhSvU1qQafGG3yfvD79KsSgLJHtAGM9K5pJuXMyr9AfmNxjkUy1uhI3lsRv7H1qbIPNYmoRmCTehIGc8dqyk3B3Q1qbvQ4NMeJSc1n22rRMFS5IRj0PatAklQVIYeorRSTFYpXcBQiSM8jrSxsGXPrU5BOQe9VNpjYjtUtjMPxSEbT7+2dQY7qBkGeBuxx+tfMkEL2eptCzqgyGUO5UkZ4GR37GvqfXbX7VaMpAPHINfNPj7TX03Ungmz9l3F42/iQnqPcf40UpWk4PZjauh2uvJ5HnvBIHA+ZsffX1yDz+Nc8ZfP8+I7ZGZMgljlSOMEnGKn0++mibyXZZVAACOM7hnsc9PpVGVpBdyfKUwTuUEgAdOnFbpdCLmReM2SshXcpx8vf8e9U5GOTjIFaWpFFuDtIIHYcis1ySuRXTDYhjQ+RioycHIODTgQ3+yaRl/OtCRScjI4pM5780zBFGcdaAHBsHnmimnH0oqkNH1GIy71cjgWJNz8CnxqsSl34FZ13cNO5xwg6CsdEjRi3lz5nyR8L/OqyjA96MYpwHFTuIYVyaTbzUpAFNAzQxiKKcaXFLikAmMU2T7tPIzSMPkNADRR1oTpTsUgDHasnUbMwnzYx+7PUelbAFPADAhgCpHQ1Mo8ysXCTi7nORP055qyjYovbM27F4gTH/KoFf0rnaadmdkZ8xdVhwKeHqsrcCpQcgHFIpllD78Gpo5Oe9U1YCpQwAqkI0Ebpg81Zjk6c81mRvirMMmcH/Jp3GaCuWU9qcj8njiq8b5FTx+p6UMEThcjNWLC6ksbnenMZ+8vrVcEY4p2M9RUbaoUoprU7O3mjnjWSNgwPPFShsnGK4mMyQuJIXZHHdTWna+IJYmC3sfmL/wA9Ixg/iK3jWT3OV4eW8dTpScelNaRV4YmoLW+trofupVJ/uk4P5VY2AnJBrVNPYxaa3HJ0yeKUnjNJwaKBDhzzim7uTk5/ClMgHB6npRkmgBu4ZwTSthcN2pGUMeetJuK/KeR60gHdT7UpNJkYHYmj60AFMZcHNLk7sYzU8dtJJ1G0epobS3AqtzTVhaRwEVifXtWrHZRrgvlj71ZUKo+UACs3UXQDPh09jzK2PYVaEYiTaOlTFhUUxyvHUVl7RjIw4zgVFMxMmB1AxUiADJOAo5zXN6rrqW7t5ciBj3zSlNJXY0jpI1IXBNUdSVvL+5kH07VzVp4jkLjkv7LW9Bqkdwm1gUJ9az54z2HZowL5MsVYkEdKqWms3enybQ5K+h5BqbXjdC4wyfIfusvQ1izJKRyprlk9dNy0d3pviO1ugFnHlSH8jWqwiuBmN1NeQu7oecirNprF3akbJGKjsTTVZr4hcnY9Pmtn29eK8f8Ai5oS3FozoiLKuWQngMO4H+eK7PT/ABkQAtxwfU0eI72z1XSpoW+YOvUngH1raFSLd7i1R8uXdlK0StExmhJyNv3o29COxrNuiz85k3Dghjx+ddl4itmtdTnNlDICQPMg35PHU9OQc5BHSsa5EVwwZ4LhJeO2Q2e5PrXfGTM2c46sY8gg46+31qIKcZyfcVfuHeN3iLEMp5+Xbke9UiSshyOD2HSt436kkUiKW+Xg1HnBww4qaZAeQDioc44zke9WSGP7v5UxhSnHbp6GkY8UCGUUHFFUikfU99dNcPtUYX0qsflA9adjHSm4y1c5oCrmpMBRSquBmmSHNMQwnJpwHFIo9adSGAFLilApcUANpMcU6jHNICFOlSDBpmMMRUvQUAIaUnHFJnnNM3ZagZKo3ZBGQaztQ01oszW4JXqV9K0o+oHrVndSlFSWo4zcXdHKoxHWpletC+03zCZLcYfqV9ayxlSVcEEdjXNKDizrhUUiyCKctV1b8aljYHOKkssK/SpoJCVGQAfrmqqn6VLG350wNGNs8ZzVqOQgCs1JD0qzG9MdzRjYHHrU6/N3qhG/zD1q6nzDOcCi1xkzL8nFMT5SGxkd6m5KHGAcUiJ0Ddcc1m0CdnclkiVk3EYPYiqwmvLU5huXC/3Scirlo2A0TfwjI+lVmwzEEdaS02K0ejLcHiSaMgXNur+6HB/KtW31yznGPM2P/dfiuYuIBnI4x2rPlUnir9rKPmZSw8JbaHokdzDJyHUkelTpIrg4IrzJGkAzG7p/uk1YTUL6B9yXEn0YVaxC6oxeFl0Z6P1pruqjlgMetefSa5eMApuDx/dGDVaS5urkktcSsOhy1N4iPQFhJ9TvLzVrKzQmaVT6Acn8qwr7xPJLhbKIx/7b8/pXPrCsa5JyxqMy7Rl2GB6VnKtJ7aGsMNFb6np/hW+TUdMWVlX7RGdkmBjJ9fxrXLV554F1RI9Tmt8kCaPIB9V/+tmuze6GTU810ctWHLNous+KYZR61nvdjHWqsl4M9aLkWNczKO9RPcqByaw5L3r81Vze/NxSAb4g1K7uVNvbBbeAcNK5yWPsP8axrLRoJpC0zSvN1O49fcVpTXaM+BC0jnnIGaqSyyRSK4jMRByHLjj61DSer1KRO9uluMBAuPQUyK6WNvf6VbTWbaVQt1EN/wDeRgRT/wDiWy8hmU/TNVp0C5LBdR3Uflvgg/pVG+j8k7SmQeh9asmGzU5jucEe1PZQ8eDMrqOmcCpkCOauY1kzhay7i32E46V1klkjIW80qO4FZNzBGmSF/FuTWMlfQaZz5jPfgepphlaMEQsy54zmrt0u7kA496znIBrN09SrnGeLFuVkVnCyxZ3JgYYHuAeMVypu5S8ggndgwyQrYbr1IP8ASvUL63ju4mjmUMh7GuH1/wALyRnzrJlZRkspPzf/AF67KE18MiZI4++E13O8pcSMf4s9fz5qkyuhwwFW7uF0lO6NkbqVAquokxgA49+1eknZENEG4/w8EdRUTjPO38RVtkRhksFI7CmhQc7SGPeqTIcWUtq01lI6HirLoCSGG0+lRbcfxcVVyCDAz0/Kinup9KKtDR9P45oGByae3A96iwSa5zQUkt9KaRUgXAqNuvFAg7+1OApoGTTwKBi0UtLigQ0ikxTjSGgCMj58+tONDDoaG4FIYxzgVGnJoc5oztX3pAWIjlifSrMS7qpRNtAz3NaETADiqQiRQqnpUF9p8N2uR8ko6MP61YXBpQQSQtDSejGm1qjlLq1ltJdkq49D2NNRvSuyeCKeIpModT61zupaU9qS8WXi/UVzzpuOqOmFVPRlIHPFSo2KqgkGpQ1ZG1y3G1Wom4rPVuKsxtwKLgaETZI54q7E+2suJwDxUxmwcA4qrhc2IZOcGrCuu4etczLqSwj71XtPNzO6NJmJGHAI+Yj6dqzckaRg3qbac3sW3k87selLdIFk+QcetPQpChC8N3J61UN2hdstnHvUOb6DS7DJ1duhqq0RB+cgZqa8v0CnaRmsia9LtwSaSaZorFx3RCNoyajkbcMt1PSqEszDBqGO8YTYOMCmx6GgIlDAt17VMsscUeTjPastr8s56VnXl0V+82anQls2Z9QGCV5ArEu9SY521QnuzI2C2E9qQX1urDK8Dt3NJ6hqaOh393bataXODsSQbj2weD+hr1KS9/2s15BcaxM0e2KERrjq3FdbZ6qbixgl3D5kGcHv3oTsc2IhqmdTJf471Wkvv9quekvveqsl82eDRzHNynQve5bGeKZ9s965w3ZyMmkN41DkHKdE96QOvB9Dgj6UNdOIWDurRsMb2Utj8K5mS+YclgPc0LrAh+YzRhe5LDBqottaA0Wp4oVY+Rc7h78VX8yRfuyN+dVW1bT7os8d1bBu4VxVG41vT7cHzL2AY7b8/wAqlwfRBdGyLmQD/WN+dPg1K5gbdHKSPRuc1xl14z0yIHynkmP+yuB+ZrFuvG88mRbW6J6Fzk1ccPUfQTmj2my8UxkBbqNk/wBpea1o7+wu1G24hJPYnBr5oute1G4cM91IvoEO0fpVaS9nl5knkY+7E1usJLqzPnXQ+lL6xjkBKyIF/wB4Vzmoi2tATLPGoHcsBXiSaheJwl1OF9PMOKZJcGUZldifUkmj6pfdjUz0q88R6fG5SGcSv6JyPzrNtPFUttf+d9nhdRxskGf8mvPVlaGcH+E961Hm3Yb1FbQw0IC5rnWeJ9as9eGbu2jicniVVJK+xxyR+Fcjd6TbFS9pfCLA481uGP1xxntmh5fl61YtLkxYYDPpmtbMVzmXiaKX94BIe5Rs0yVmIOxNq138OtW5P+kabC7/AN5SR/8AWrOvrKwnR54ZCnJJi6kD60ubrYpK/U43LYAIB+tDLGc5xmujOkIFyqgg87s1Ru7JbcE4G3HUZ5qVWTdinRaVzBc7emcUVNKASe1FdMWZI+mdpPWnhQvJqTAAqNzxWRRHIc9KjNPIptIQLwKcKQU5aYC45opeg96BSAMUhHFOpDTAaRmoZGzUrng+9V2PNIBvemM2TgUMfSiNBnJpAWIxlRntVmPiq6sKkVsU0Ba34GB1NSIcCqqnuetSq3FMC0kmKSScEEGoQ1RTKWHFDAqXtgkhLxYVvTsay2QxkhxgjtWvukXgjNQzAS8MvNYTpX1RtCo1ozPX2qVG5xRJC0Z9V9aYGxiud3judCkmW0cBetVLy5cEJENzscADuafvyuBREBDMlweiHJ/xqW9Cla5JY2otCbi8AkuEG4Lnhfwq5a6yfN+bByc5rK1C7kSYyRbXR+OvUGsKe6e1c4ZfpmpnFaOLOtHb3uriOAszjcD61gSauS7HOK5UTXV7cERh3B6AdBW1ZeHbq6BN43lp2CnrUO+w5SUVYs3Os543j86ba6kCSSfxqY+DrFh8wZj3JNVrjwTGFJtLqeFvY8VMYNGV4stPqqNySMDpVKTUlPmOSAMYrNm8MaxEW2Xkcij++KzL7QdfWMshjdRyUXg1pyt6XHojYfVViT5DuY9TWfLeySnJY1j2gvZnMS2txJMOCqxsTn8q9E8G/Di+1NPtOuebY2vVYcYkk/8AiR+tEabbsgnOFNXZxzT4HJJ+ppsc8sj7bdGdvSNSTXv+m+CPD9gQYNOhdsdZh5h/Wt+2tbe2ULbwRQgdkQL/ACreOHOWWMvsj5yg0HXbvmLTL189C0ZA/WukTStV8P6GsusW/wBngVjhy4IUE8Zx05Ne3YbJLHNeP/tI6wLbw5Y6UjYe7l8xx/sJ/wDXIq/q6elzGeJlJamW15uUEBmB6Ed6jM0rt8qY+teR6Tr19p8aRw3MipnhScgfga0b7xLqcse37SVU8fINv8qxlgqrektCParsd5qeq22nLvv7xIvRAcsfw61zV94uklDCwXZGRxI/Lfl0rz+/LPOXdmZnGcscmlsboxnYx47V0UsFGGsndmcqrehsXd5dysWmuJZM9csaovKwI5PHvU7OGX2qtMPSutIgk8zcOgqFW8uT2Paolfa2DUj/ADCmIex2tweDSq+TUaHcpU/hTASCQe1AFzfTlbK/SqqvxT0bDUrDLQenFsiq27ml30AOlG5flOCKtW82YVz1qiWoR8KfY0AaTOOOak8wKRk1S35K4pWOWLMcClYZe+084FSpdkcSBSPQ1hPdGR9lv07tUqDaQNxJ7k0WFc04rl7dmERLQk52HtU8rpdwHYOvXI6VnLJj2NeoeDPC63vhyK8eMM0zMSpHVelc9WKjqbU6rWh5Fc2hMrBRgD8aK9Y1HwHKsbvasxcc7CM8UUKs1sVywetzumJNRt1p7U3Hc1qZDGpuKf3puPyoEAp2cDNIKXqfamAD3pxooosAU3qcnpS4yfalf5VoAglbn6VXdvTrUkjYqu2TzUsAVecmpBxUSZFSA8cigB4bFPjOeTUKjc3sKmHFAEympFaoFNSKaaAsKaeDUAY04NimBK5XHAGTTfswPJ60RjLZap1amBWa07VRudPbkoPwrZDU8AHqKmUFLcpScdjkJA0bEMCMUomwpB6V1FzZQ3K4YAH1rn7/AE+W1JON0f8AeFcdSi4anRCopaGX9kt3kJcsFJ6A1ci03SyBujDH/aOag2qfamOrJyM1gnY2uzatYrSA/uY1HpgVoI4fFcvDcOp5zWhb3XvVcwI6OJVI5qdY17isq2uQccjNXXuNkLP6DNMq4ksUbyhQoOD+v/1qspYxYwUyO+R1qnYn5tx5xwP6/rWqslPfQCK1jl0+QvYuYy3LL1VvqK2LXWISR9rjeJv7ynK1TxkZprR7iTinGcokypxnudNa3MNwuYZY3+h5qz+HNcTJAucr8reoqe2vb624Scsv92T5hW0a3cxlhn9lnW5NfKvxz1r+2PHdzHG2YLJRbrj1HLfqf0r6Jk1yYwuv2dfM2kKytwDXz5rHwx16W6nuVntrl5HLsdxUkk571pGrC+rMZUJroebgZVgOo5qzFJ5kOPSuil8AeI7c/Np+8f7Ein+tUR4T8QQTEHSLzae4TNbKrB9TN05rdGHdLuTPcVSI+bIrrV8I+IHz/wASm6wfVcVm3XhbXbaTEmk3oHtEWH6U1Uj3JcJdjPtrj+F85qwTmmT6TqEPzSWF2nuYW/wpIVmI2tDJn/cNPmTCz6jZFz0pInzwakYFThgQfQjFQuMHIp7iJCcHIpZBvXcOtMVty05G2nB6UANVqfnFRSDa2R0oDcUwLG7IzmgvUCtS7qQXJS3FMVuvNMLU1W+b60AW92VX1qK6uJJWEKmkLgJ61BCwMjFutCAvQKI0AHWpozj3NQK3Az0qTOOQaQFmJTJIqIMuxCge56V9PaBZLYaVZ2igAQxKn4gc18+fDqxOpeMdNiK7kSTzm+ijP88V9HySLbwl5PwHqa5a8rPUqJHqdyIIgi/fb9BRWFdzPNMWY5JPNFeZUqOTNUrAaQ0YOM0jcV7LIG4ptONJQIAO3rS9uKT+Z60v0piDk0v3jgdKaTztXr3qRRgUDF6Cq07fNirDnapNUJWyTQBG7ZakAoA5qVEyKkBqrSkEkAdal24HvUkcW0ZPU07AQqm0YFOANSlaAvpRYBgFPWnbaULQAClHJpD0pyjAoAlFPBqMU4UwJAacDTAKeKYEqH3qXaCh3YI96ijGTx0qRwSMDpTAw9S0qOQl7c+W3p2rEkSa2bbOhwe9dg6c+wqG4SNrZzMoKkdDXNVoRlqtDWFWSOU8oNyvSnbGUcE1LcWctvH9ojVjbltufQ+lOgkRxXG4taM6lJMrxXpjuGjYEbV3ZrSt74SRg9iO9U5oUYMeORio4VVAFVuB70WGb0FwFQBeAKuQ3W5ec5rASTFXYW3AYNNLUfNZG8lwQPvcVOtznHPFYaykEBjxUouEJxuq3oNNM2vOHFMM6k4GM1kibj73FOWXnk0mCNMMOv6U7f14HPFZyzY96nSXI5pJlXJiw9AfrREYucoOKiZgeRUZbaM0FJlmURYzsP4Gq7Mi9Awp4cEf0psuDESvWkDuhUWJjk054ImPCp+Qrn7pdVWTEESup6fOBSQ399A+y/t5Iv8AaIyD+IpD1LWpWNhcKy3dpbzJnGHjBJNcbrfgPQ71Ga2glspDwGhbK591Paupvbm3uFUQTqsgOcMeDWPd3zWUMrXDKNozw3GPWuiFoQvfU1dKEoe8jw3VrCXStTuLOcgvC20leh9DVUnPNXtdvv7S1W5ujx5j5H07VQHA9q7o7K54U0lJpbDs5XBqEnacVJ3psi5HFUQNDcin54qDNSxnIxQAppufmBpxHrSHpQA5/u9ahTpU7cx59qhj70AWIpCOKsIfyqotWIQzsqICzMQqj1J6VLGexfAjTVL6lqsi4CAQIT/3039K9B1G6M8vH3Rwo/rVDw/pq+H/AA1Z6XGR5irvmb+855b9ePwp7gjk15GIq80tNjaCsrhgGikBBIormavsUSMccZ5prUuOaTGTXuMzEppOKfwP61H1OfyoEKBQzYGB1oJCjNLGpPzN1pgLGuKkFIKSV9iE9zQIr3MnOB2qtjNOJJOaciE0twEiTPUVbWPaOnNS20OevQVbWIccVSiBTjhJO5qkMdXBHxwOKTy807AUmjNASrhj56UhiI5FKwFTZRtxVnZ7U1kJpWArbec0oFSlD6Um2iwxgFOWl2GlCmgBRT1FMUVNGvemBKnyjNBPHvTTyaYXwaYiTqMdzWbq8wUrEv1NaCsERpGPGM1hQK2oajjsxyfYVlUeli4LW5uIVs/CF3PKgceWz7WHB9K8207VI5mdSwSVDgjPB+leneIMf8I3eRKML5WBXnEmlwLapshDbxlm7muaondJHZh4xlFtlp70gcjiq5l83JMMbKf9rBNVxYXS/wDHu3mQ4+63X8DS2/ll2R8ow6g8YNYKVzV07bF61ZUbKx7f+B5rXtJcjNYQR4ycEEVYguvLG1qpPXUzaN5pQwGTiojIFJyeKz1uQ4HNShwwINVuStDSimU9easAq3AOKxVbbwDVuCTdwDgmkWmX/M2nB5qSNxjqappkNhuatxspG30qSvQsBieBSPk0KuOhpcNuxijqaRdiaPGORUV7I0KbgjOo/ujJpJnliQsELAelZ41uDcYy3lyejcU2F7j11eCOQGcSQk9DKhUfma0o9QjlUFHVlP41El8kkOx9ki4+63IrMu7CGd1GlJ5F233QnCt9RT12WpSVxL7SItVjnuAiIYzjdHww9yO4rw3xrrN3/aVzpjHbDA5Ripz5nv8ASvTfE3iB9CtWXUopLa6ZSoCE4l9q8Kv7iS8vZ7mbmSVy5/GuqjSje9jnxtTlioJ6knUAjpQOB1qCJ8cHpU/bPUV1HlibfTilXntzThyKMUDIZkwcio1ba1WyMgg1WkTaTmmhE+Ny0wjFEDZ4NSutADF5iPtUMf3yKni/jU1CBiSgCTFdT8ONLk1bxhpsSLuSKQTyHsFU5/wrmO2a9J+Bt3DB4juoXwJp4NsZPXg5I/z6VjWbUG0NHtdxbCXJ71n/AGWVpljQbixxXQPEWUFByetUnUxXMbf3WBNeRb3kb30MXxRbJ4e0k380ofDphQmVzzwQTyD6UVveJLODV9Glsrxd0Ei7Xx1GDwR7jrRXrRoQSskRdsxcZNBXHHelB46fN6UjttH+0f0qgIn64H40hwBk07GBTVXe2T0FIQRqWO5qk46ClxQBVCFHTJ6CqM7+Y/t2qe7k2rsXqetVB1pMByLkjir1tDkjjk0y2izya17aHaMkcmmkAkcQVQKlWOpVSnhD2FWIjCUnlg9qsCM+lPEVFgKvl8etN2D0xVzy8U0pk0WAqFAaaYse9XDEMUzbg0rAUmj9qjMftWgVpjRilYLlHy6NlW2jxTSlKwyuEp5wi+9ShMDJqCbnntQA3PPWmFhvAprHaMk9ajRuCxNIZBrt0IrXy0PL8fhTtAjWGHe333/QViyTC91JncjyY/WtiOQYBUjHtWLd3ct6Kxpaud+kXQX5iU6V5w1xJbs0UjHyH+6390+hr0C2uTuKsODx9ayNc0JJEaayXIPLxY/UVlUT+JG9CrGKcZdTL02VVG0npxgVektoLmPEkayD17iuYmd7ZhtOQBjPpVmw1VlkAYnHrWEZLoejGSaLNzpkse4285CdlfmqEVrqLBvMiiODwA/JFdFDMkyjoQamKw5BUgnODVJJobSa8zlxOYHxMrxN/tDj86vQzBsHOfpW0bdJlKttZTkEMM1nXGlRx/Nat5T9Sv8ACf8ACnytI55QQ+PkU7YexxWct75UnkzAxyejd/pV2O6TjkEUk7mTjYv2k2MLIPxq8DjGOtZkU8bY96vQOuQCcqaLFIuQSHNXFuI05kA/Gq0YQd+aW4NsyFZ1VlIx1otYta6Flr6FwfLkUkdgaybuw0zUwwu4djn+JG2kVn3Oj6TPkxy3Fu46NHKcisC+vr/SS/nF721TpMg+cD/aH+FPl7l8llcv6h4dutPjV9F1JnfdkRTDdkenFZo8UR2Ujx6uGsrlRkZJwfdTRaeLNPZFnN/EuzkEtgj8Oted+PfFB8R6krj5o48gSEYLn1/StaVK77EVasacbp3YnjzxNL4hv0xI8kEX3Xfqx9a5nZ5nbmkzmr+l2kl3dw28IzJK4RR7k126RR5U5ucuZmYyFTg9qdG5U4PSvqa7+FHh2/0Sztp7YwXcUQU3EJwxOOSfWvNPEvwS1ezLSaLcRX8XUI3yP/galVL7omzPK19QeDTqtapo2qaLMY9Tsbi2I4/eIQD+PSqikEZHSqTT2AcDg4pJYwy8UpHFKjdjTApnMb5q2CHTNMuYweRUVs+1thpsWxInEwHrUcgxIamlGGV/Q0ycc5oAcOUrS8N6g2l65Y3qkjyZVY/7uef0zWYnKUqcmpaurMD7EsphLboynIIyD61FcRZOe9cl8J9Y/tXwjZ7mzNBmB8+q9P0xXW3M2WMUZ5H32/u//XrxprldjZO6IGm5BPQHkex6/wA6KqJIvnEDGw8c+2f6H9KK9WErxTJ2M1JDy7delAyWy3U02QYfj608c8CgAxuOO1SYwOKAMDAp3amhDKR2EaFjTgOao3Uu99q/dFPYCMksxJPWpreMu1QxqWYACtezt844pJXAs2cGcEjgVfUUkabVAFTotaWECpUqihRUgFMQBadtoFOFAEbLSbKnI4pNvFAEGymMoqxtpClAFYpzTDHVopTSlIZUK0gXJq2Y6GjCpk0gKE/AwBVKQMeD0q5cttGcViapeywsoTAU8VLdhoJiM4BrO1i8EFt5cZ+eT5R9KJLnyYXlmPvWAk7Xd008nQdB6VlOXRGkV1ZctotqbZMHPNads6ogVRx6VmLLk4NXbYjtxWRL11NaJsgVo2rFcDNcZd+KdM03UGs72V45FAJbYSvP05/St/SNZ06/KrZ31vKx6Ksg3fl1q7MCTX/D8V/E89qgW4xyB0f/AOvXnU8BjlI5VlOCpr2a3B44rD8TeFU1Qm4tWWK6P3gfuv8A4GsZ0r6xOijX5dJbHnttdmMGN8jHRqu210ysMnIJ6g1Ld+FtZsYmd7YSoOpjIbH4VhmcRkjBUjqKwacTuhVjLqdQbkhs5/GpkdnXJPPauat7wjuGX0Na9jdqwwDzVXZTsx+p2C3Uex1znnI7VyWpQahpZzFI0sQ/vDOK9DtlDe/rVbUrZGQtMAIgMkGjzMrnmieLWtTm4XCjqR/hXT6V4pt7iMPFKrjuAeRXn/iNE1DUJJbWHbCDhePvD1rnpLaW3kzGWR88FTiuxULq99TjeKtKyWh73Hrsbx9cGqd3qMkgJV8Adz0rx/T9R1Yv5SXbqBwd2DWy5nuUC6hJJKB0+bj9KxnTcXZs6oVudXijpZ/EdnDO0bXyhh1wCR+dQX3jWzgtZEtGe4kcdMYXOO5NZFv4Sa/XzY5DCjc5YZz9Ko6r4R1CzJaBftMQ7p1/Kqg6V7cxjUxVZXRzMhLuzN1JzUZFTzRPExSRGRx2YYNR45rtXkeeCDkV6R8F9JGoeMrVpFzHbAzt9R0/WvPIVya91+ANjtt9TviMFisKn6cms6j0sNHs4OOM0jvxUAJyMnJFPD8dOagrULiCC8hMV1DHPG3BWRQw/WuB8R/CPw7qm+SxjbTbg87oT8ufdTxXfK2DTi4yM0BY+ZPFPwv8QaEXkjg+3Wo58235IHuvWuDkjZGIYFWBwQRjFfbJb9a4Pxz8OtJ8Rq88aiz1A8ieNeGP+0O9UpNCsfMStkbT1qvcRlTuWuk8WeFdT8M3pg1GHCk/u5k5Rx7H+lYancCD1rVO5IyJhNF79KJOYwfao2Bhl3D7p61KeYzjpTAZF0pUOFJpsXBIp38GPU0Aem/A3Vza6hfac7Y+0KJI8/3hwf05/CvZbuRYbbCd+c9zXy1pN3Lp1/bXluSJYHDr747V9LWF3Fq2mW13AcxToHX2z2rzcVDllzdzSD6FaCUl2VshWIwfQ/54oq1dwRpAyN/EMUVNGvyR5ZDd+hWl5cetSxj5eeveoW55p0T9Aeo4ruETUdqBQTtBJ7VSEQ3coij2j7xrPXk/WieQySk9qntYizDiluBZsoMkE1u20WxRxzUNjb7VDMKvitErCFReamVaagqZaYgVaeopVxTwPWmAgFOC0uKUjAoAaBk+1LingYoA5oAZtpCtS4o20gIttNKVY20beaAIFj5z2qG49B0q+yhE96zrk4+poAzb0gIRXPahJGcknOwFvpWnqcwXI3fhXNatOLfTZpG+84wKym7FxRzupai13IEjz5YP50+FtiBemKzLbk7jV1GziuW99Waz091F6JiSMGtO0PSsy1XmtaAcCmiDg/E/hbWbzVrq8hhSdJGyoRxkKOBkHHOAOlcpe6be2P8Ax+Wk8HvJGQD+Ne6RE7gQeK0LLhSrncCe/pW8arS1J5TwbTfEes6bj7FqV1Eo6J5hK/8AfJ4rrNM+K+u22FvIrS8XuWTY35rx+lek3fhjQ9SB+06XasT1ZF8tvzXBrAvvhPpNwM2d3dWjnscSKPwOD+tXzRe6FZofpnxg0uXaNR0+6tmPGYyJVH16H9DWlc3/AIJ8UqSmo20F03R2Pktn6NjNcNqXwj1mDLWF1aXa9gSY2P4Hj9a5TUvCWv6bk3ek3aqOrInmKP8AgS5FJwhLQFJrU9I1PwNfWqedpsiXsBGfkPJ+nY1zd19rsXAmhmicf3lxXFWOo32myFrG7ubVwefKkZDn3xW/D491wR+XeSw30X926iDfqMH9axlhesWbxxEludVpWvEssc3ysOM1R8feIhFZpZwvl5+XweQvp+Nc43iGCWTebMw9yI3yPwB5H5mue1q5lvrt5QCV6LnrippUZKd5IuriE4Wjuzf0m6t2MaTkKnXPoaq6yY7/AFGO006LLOcL/wDFGudWRkX5sgD1rX0K+l0fUI7oxJJJjLI/oecZ7HFdkr203OOCV9dj0fT/AA7p6WccLW4VwvzPjqfWt/w74Ctrmf7TOv8Aoy9F/vn/AAqTwXqFh4tuoreyfyp+skL8MqjqR6j6V6/HYRQQpDCoCIMAV5c4u7ud9SqlFRicRJ4ZtsBUQADgAVCPDEKnNdy9pjpTPsTGs+VHPdnAah4N0y+jKXdtFKD/AHl5H41w2ufB61k3SaTeSW79RHIN6/n1Fe8/2bnrSHSgRWkZuOxLSe58l6z4H1zRMvcWZlgX/lrB84/xFe3/AAktPsXgmy3KRJKWlbI9TXfvowIJJ4qK30uOEgZITso6Vsqzl8QuW2pAGz7U8NkVZmsiD+7ziqrQzIOUP4VqpJiF384yMinBqRLOeQZWPn1NSLZ3C/eTH40XQADke9ANBhlUfd/WoW4IycGqTERapptnqlnJa6hbRzwOMFXXNeJ+N/hBcWzPd+GnM8PU2zn51/3T3r3JiWHBxQuVHJz9aa7gfGt5azW00lvdwvDMhwyOuCPwqtENpKdscV9a+KPCekeJoCupWy+bj5Zk+V1/GvDPG/ww1XQma508Nf2K870HzqPdf6irU+5LR50OHNShcsopsqESDIxzU8KjLk9hWggchQQOa9R+DXiNQr6JdvggmS3JPUfxL/X865Xwr4F1vxOwks7fybMnm6nysf4d2/CvYvCfwz0bw9JHdXBa/vovm86X5VQ/7Kj+ZzXJXlCUeW5Sv0Ne6Tew9KK0fMEr4WEFAfSivNaizWzMaRMCq4+V/rWjKvFUp0I5r2GrEEinIFNuyRbkDqaIuf50t2MrimIzrddzAEVu2MSgDis21h+fOK3LZNq04oTLKMQMAVZhweoqvGM1ZTirQiYR5pwQinR9qlxTAhxipFpStGPSgBy0oHek9qcOlABSgUgpwNAC/WnAUg5pwoAAKcqihetLMQie9AFe4cZ6/KKw9UuSFIXgVfvZginmuU1e7JbaOpqZOw0Up/3snzN8o5Ncf4qv/tFyLeM/InXHrW1ruoCwsyAcyv0+tcMGLyFmOSeSa5akuhtBWXMy0jEL8o5q1bu2MsuPpVWKr1uOlZkmlZMGUNzWrCTWXaqQck59q0YulNAXASF+QjPvVy3ZlAycms5TnlcZ96sQM6/eIP0qgN22l4GK0YZMjJrBt5ccVowy471SEaySHdzjFZ3iDxFp2gW3n6jOsYP3VHLN9BTbu+W0tpZ5cCONSxJNfPt1rEnivxK810wZWYiNGPCr2qkrsm53GrfEzw/qcrLdeHVvEHR5UQt+BPIrBlu/Aeoud9jqWlk/xQvuGfod1Yd94bmgmIj27jzgVh3ay2xZW4cHFaJNaIrlur3OyPhPR77/AJAvia0dj0iu0MR/Pn+VYWt6Be6PcrDdeQ7MMqYplfcPYZz+lYgvHK/6RAHz0bGDUNxKJwFYsqD1PSq94zuXpoJIW2zxPGTzh1I/nTCSTkkk+prQ0zV7u10yS1juTJEwIaOQb1AIxwD0PvWfg5xjmmnfcZJbXE1rcRz2sskM8bbkkjYqyn1BHSvavAHxlZTHY+LvmH3VvkXkf9dFH8x+XevIrDQ9R1CQJaW5kcjON6g49eTXR2Hw08Q3eMpawZ/56Tjj/vnNRU9nJWkwVz6ns7q3vbaO4tJo57eQbkkjYMrD1BHWrS4rxb4e+C/FXhe5DQ65Yraucy2u15Y39wDtwfcfr0r2KOXOOa4JxSejuaJlkCnYFRK4NNnm2rgdTUIYkrB22joOtV5R++jHpT4+eaZndOT2HFWImKelJ5YPUVKtNmmSJSWpuQCnCr6ViazrUFoCgYNIeijk1m6rrVzdz/ZdNXcQcM/YVe0bSTB+9udrStySeTXM6zm+Wn95VrbmJ9tvLg5VZFU+xqVGuRgtk/WuwYjHJBqJwvcD8quNGS15hNmBG7EfMMGmbmXcNxOf0rbkWI9UUn6VVmtonbPKn1FdUJtK0ibFBXbbjGcVDHNcSMVeIIueuc5q5JAy/dIIp/kKgBmbn+6K19pFImx87/E3wfeT/ENbfRbN5mv0EyJGMBT0Yk9AM85PrXeeCfhRp2jhLrXSmoX3Xyv+WMf4fxH68e1ekgKHLKihiMZxzj0zSMaynUctFsPlGnCqFACqowFAwAPQCoLlS0W3+9UjH16UkpGe1YSWmhSEEaxRIBwKKrXDtt60Vk58uhSVzKPNQyx7lIp6+tOGK9cyKUQ2vg1I67qneLJ3DrTkTj3pWAS2h6cVoqu1KbbRip5RjAq0hMIRlqsA4NQ24zk1MR6UxE8bVYQ5qiCRUqSYNMC2RSAd6jWVT3qUEGgBMfnR3p/Wk2igBKKXbSUAOFOBqPmnA0AWI6qXkuGPPAqyW2Rkn0rA1G6ChjnFDYyhq94AMZrmbq4VN88pwqDPNT3lyZZDjn0rjfFWokv9ljOEXliO5rCc7GkI8zsZOrX73920jfc6KPQVDGAKzraUyXTj+EDitKPjHPNc7Rc3rZFqIcCr9sCKpRe/NaEByKViC/CcAc8VchbceDVGLGO5q/ApOCv41SAtoO4FTJ0Bpka54HWpwp9qLASRMM/SrsUozjPNZ3Q4Pep4sqPlqgOd+K19NB4ZKREhZHCuR6V4LDNJaXIkjYqynIIr6C8cae2p6BcRJy4G5R7ivn+ePZIY5Bgg4+lbU30M5bnb6F4rQAi5UM78F+4rL8SWxnkZrdg5kbKjpmuXwyHKnBFbGlakFYC5OccA98VruJOxQnt7+BAJYnCD34qO1XzpNkr+WD1b0rqtQeDUbTbayHzB/DtxXLBjal0dATyCTSEPguzajbAw3q52uOpFP+2zfMxcl2/iPWs+MDfkdBU/pSaHcuWt9PZTLPbSvHODnep5r1Lwd8SUkaO11giGboJh9xvr6GvIGOcUE8YNRKnGW40z6603V1kVSHBBGQQa3rS+yAc18m+FPGd/oDrEzNcWXeJjyv8Aun+le5+FvFNrq9os9nMHXoynhlPoRXHUpuBadz1GO5UrnNVpLomTgE56Vk2V3520LyTW3HlYkESBiB1PaojuMkjlZI8vwT0FJGxJ4qMR5bMzZPoKtwquMgYFNgSCTy4SzHgVz1y1xq9w0NuSluDiST+gqHxHqUsl1Hp9mQoYZkfuBW1p5jgtEjQABRiudv2snBbIrYLHT7exjCwKAR3q02TUEk4HemLdITgmuiEVFWRLLBX8aiak89Om6lyDyKu4ETDAyTge9QGZc461DeTkylF7UkKFiC3Qc1lKfRDsWlwRk4wBk1nvN5szNnjPFGt3Rs9PYrzI/Qe5rHS6MU21j0pQleVgtobnaonNJFJvQEUN3rVkkEzcEetVYpiGKOeR39anlrMvZPKdW9KT2GXpTlaKrQTrKo5orCUbsqLOa8L6mL+wUOf38Q2uPX0NbQry3RdQbTtQSYfc+649RXp8MiSxI8bBkYZBHevVTujNlhD2NP2Z5B5qFTUyGmhFy1YZw3FNmkDPgEU+HBqPyU3n61Qi7bpiIVNtqtuZQAMUpudo+dGx6jmqETFaaV701LuFzgOufQ8VLuVqQEYzU8bECoyPSl7UAWA9PVuaqg04E0XGWPM54pwII96rCnjrQBOBSoOaiVyKmBAXNAFXUpxGm3NcVq96ZJCi9O9aniC9ZWbHeuZGXYs31qJvoNEF3OtvbSzPxtH6151dzGaZ3Y5LHJrq/F90Egjtwfmb5mrkAu5smuWbuzaPuxv3HRIB0UfhVyPgA1XiXBxVyPAIBqXuSWYRmrkanAzkVXgA3Y5zWhFHu4NFg3LEAJ6cmtS1Q8A1UtosAYFakKYAqkIdHCN27J57VMVzTkHFPA9KoBgXmpgMDgZNMAOakAJHpQIaylhhgAO4ry34g+DyzPfafHnu6D+der4zUE0IZCCMg9qadthNXPmBg0TbXBwD+VIyZ5XpXsPi3wPDe77iwAin7js1eV6lpl1pk7R3ETRsOxHBraM0yGrFFGkjIZWIPsaV2eUkuSxJo3gnDDFSRgE/KRmtBWG+RjHlMGPp3pnIOCCDVkIAdxGT9aYSTw/zfXrSGQt70mcipTGrcK+0+jVFJFIhyVzjuOaBBV7RtVu9HvVurCUo4+8v8LD0IrN3du9Lmhq+jA+kfhj4vh1+UpCRHfIuWgc9fXB7ivTba4fdkq6buoavjfwtrM+g+ILLUrZsPBKGIPRlzyD7Yr7D0fV7XU7VGUqVcBsZ9a4atPkehpF3NUDcQB1pmp3S2lqxzjApluzRTOjsHjxlG7j2PrXP67cm8lECHgnB+lc9SdkWkVdHDXFy91KPmkbI+lb3nFDVaxtSiAKvAFPmRvSopR5UDdyVpQ3eq082wcGoWYjr1qtK5J5re+gh7XchPBNXNOvJxOEc5Rh+VUYWUH5hV61CmTcByAaQEtuPNuHY+tX1A3ADvVOyG3casRyZkfH8IrOL0GZOrqbq9CDlI/mrJvI2zuAro7KHfHcSt95gayZlDJipoq92Nsh0q658tj9M1r9a5iUGGUMvat2ynE0SkNk1un0JZJKvBrG1IEgitxxxWVfoDmmIx4pWicEGiiVMc0Vg3YbPDbbU5Y8ZO5fQ16F4A8SxTsNNnba55i3fqK88u9Fu7fJVd6j061QWWa2lV13RSocqehBFepFpmd7H0hnFSIa5vwbr8fiDR45xxOnyTL6N/ga6FTVAaFs2SBUg5uCKqW77XFWYebxj7VQFllzSEVMBSMtUIryQRyffVTVdrNk5t5XT2zkVeIIptKwFDz7yE/vEEi+o4NX4LqOUDawz6Hg0deO1VbuwWXlThvajYLmmCpp2OK5/bfWn3HLr6Hmp4tYKkC4iZcdxU3QG4o4p2M1VtL6Cf/VyKT6dDVxSDVDFUUkzYjNLUdzwhoA4/XzmX2rMjT5ST91eTWjrXzS/jWZrMwsNHmfuFzj3rJ9WUjzzxBcm51OYg5AOBVFFJGBkZpqsXYs3UnNW4EycVyu5bdws4m24bJ56mtKGHOOKS3i/KtG3h4p7iEhhz0FX7eE5Hy0tvDjoK0ILY7t24gelVYB9vDxyKvRKG6c4oijGMHoasqgUYXAqkhETLjHFOAqUrkYpu0bDkGgCPP8A+upB0piqFAA4HpTqGCFzxxQB3PJpOh47UFwBQAyRAwrG1bR7XUE23USuK2iDnFI6ZU55FDEeV6v8PIJGLWUxjz/C3IrmL3wTfWxPzIw9a9tmh+bNVJovMUo68U1JrZi5UeD3Gh3tv1Gfoapus0XEqEivY9T0cHLR9TXL6hpIywdMH1xTVV9RcpwiEMcoefQ0g4fJJXmtbU9HMQLqMY5yKw1mIOHG4frWsXzbCJHbcecH6io9qH+H8jUhRXXchyKiZCDwasQ7y0wTlx+td14G8ey6KI7S7Mj2ycJIOWQehHcVwYLCnRBmbrgVE4Kasxp22PrDw54ni1GOGSOVXRxwwPWtizt0ivS1w3Dn5W7Yrw34VWk5hnlDOlv/AAH1b1Fex6RqiSxi01D5X6K/Y15lak7+hopXO1gWIJhBxSS2ysOBXLXF/daUQ0imS27SLyB9a1NM1+2vFGyRSfTNEJqWnUdiS5sAc44NZs1k6mukEiuvXrUUkakcVpYRyssTKO9XNIy/mA8kCr9zbAg4FZMsklhMJI+OxqbDNW6dbSD5j8x7VU0ubzWnGecVnTyPcuXdix9KlhlFmY3P3c4b8ai2tkM3bXi2ZfYisNl6itqCRMblIwaimt0diy4FUotbCuc3cw5B4qpaTm1uNpOFNdDc23B9K5/UrcjkdRTaaA6COQOnWqt0m7NYunak0TeXIeK3EuElXIIpp3EZVxF7UVfmjDdKKzlEDz+50/OTt4Hp3rGvtFhnU+ZEPyrtGAzjFVZo0f5SM13tE2OT8KwroF+XiDCCU4kH9a9MjZXQMhBBGQRXKXNmpU4Har2hXJt1FtOfk/gY9vaqg+gjfSTa1XLOUNcsfaqkaAsM060BMrMO5rRAbgk96BIPWqZZgMGm7jVXEXtymmsvp0qp5hp6zGmBYReaJG29KWPlc4pkpGaQEfmnowqGVIpAdyipWUEVEyso9aAM9rHBLJkVItzeWw4csPRuavpjbzTXwe1Ra2wxtprLZAnjx7rV2a/hkj+SRTntnms4wKW+7XK+PbV4tNjnjLLtkB3A4IpOTirlJXdjV1BhJcjbyM1zfjyUrpiKP42AqvoWs5iAvJcurBQzHk56VH8QXMkVmiNg5JNZyknFsbTTscaiMZMkgKK0oEGB3qrBGc8cmtC1ilaQfIEXv3rFbjLtoFJwSAa14YRxVa3txwSoz61rW8YIHHNUhD7eEelaEKBTjHNNghIHH61dSL5h1qgBFGMYpiRSCYszAr2GKtiLHNKUpiINp6UEYxxUwUjvn60hU9qBkO2o8Zycg1OUbdyePQUeWFGKAK3AbNOAAPAqQximyHaVGDz6UgExQw4pjOBIFLYPYetSN8oyTxQIqSYZsDqKhMK7iTk1fKhucc03ZkUAZLxgknaSPeqN3p8c4wVG6ugeLiqzxAHOOaAOJv8ARSAw25U9RXnuv+GJrZmmtFLJ1KdxXttxEzK+0ZPQA1RaxV4v3qbW6Y6003HVCep89qWjfjKt3BqYuJD0CmvVdf8ABVtfbpIR5UvqorgNU8LanYOcwmROzIM1qqie5FjJEfr+dW7C3jkuYozmR2YAKOlQpp94x2i3k/I1u6JFHo8v2m5CyTj7qZ4WnJ3Wg7XPY9CEUFlHGqrGiKBjoKra54y0XS0ZJpvtEn/POAbj+fQV5TqviO9vcoZWEf8AcXgVhPHLMfuk5qI011KvY9S0740NbXTRzWDmxPC5fc4Hv2rbXxZ4d1phNp12tjeHnGdmT7jpXhx0y5f7sTZ+lTw6WtuN958z/wAMY7fWonhqcgUmfQ+k+NZ7F1i1AiSPtKhyK77S9ctdQiV4JVYH0NfHoNypzbySJ7KxAq9puv8AiDSZhJbXLgjnkcH61mqElpe4+ZH2IzbhWdqkIlt3HfFeO+EPjKoZLfxFAYT089OV/EdRXrVlqdlrFmJtPuY5kYZBVgazlCUdwTuYNjqCRy+TcfKwOMnvWtc+XNbnBBBFYGtWB8xmwQTWJ593a52SOF9O1Ye0S0ZdjrdM1Ax/u3PTituO4DrnNeb2d/I0zeZ97qPeul0/UdwGTWkWJnSMwYYrMvogc1ZhnVwOafIgdeKq1xHHahblGLKKhtr54WwTxW/fW2c1z93bFGJUVm9CtzbtdQV8bjRXNRyNGwoo5hGk2CeDzTGFSHqaaehrvJKrZO4EcDvUbRjvU7/damtSJNLTL392YpT+8A+U+ta1imEB9a5i0/4+0rrrX/VitYu4yYj1ppSnmkqxDNlCJg1KelIvWgRYXhKqzNk1Z/gqo/3jTAQE+tOJOcGkHWk7mkBKuAOaaygnIo7UCkMVVFY/jS3E3hy5HdRuH4Vtj7tU9fH/ABJL0f8ATI1M17rGnbU8MYknJq5e389+YfPIPlrtFVTUkXWuNM0bvqWrWIkjtWxax9KoWnVa2bXtVJEluCM4HpWlbJVS261pW/WrSAsWhDMVwcj1q+q8VFH0FWE6VQhvCjczEAetCSLKP3bK2OMinTAGJgQCPem2yKqfKoH0FLrYY7GT0pGUk4qXtSGmIgIwenNMaMk5B/CrIqOTrRYV9CEK3fBoZalpKQyswx0XJpSuRzU3eoRQBE5kVgqx7h9aUA/Q1J2/GmDqaAGP05PSq8gPU81Zl6CqOqsyabcMjFWCHBBwRQkBFPdQQn9/LFHj++4FZE/iPSElKm9Qkf3ckV5jIzSyM0jF2JOSxyTTrZQW5ANXyoD1SPU7CWDzUuoTH67qyr7XtOjQ4DSn2GB+dcg3AGOKp3JOOtHIgsLq+qy3cjbAEXPCr2rLSxkmO6Q4FWoQC/NWHqvILXIEtLWEZYb296nj2k4jVVX2FV2+9VpeIOOKARBeXSwrsjJL9zWdFE0zFnJ9abKSZTmrkf8AqxTsA4IsYAUcU1iCOaDUZ60hEE0Eb/eUH8Kbp19qWjXgl0W7lt3J5Cn5T9R0NWG6fhUNv/rhRZCPR9M+K80CRQ+JLRZgRgzQDkfVf8K6/TtY0XX4d+m3kbk/wHqPqOteBav99KzhI8F1G8DtG4YfMhwfzFY1MPFq4+azPoLUrF7ZhLEvTnKmktrs7QymmeHpZJtFiaWR3YqMljmq0P8ArpR2zXFbldkaLU6ax1IcBjW1b3quo5GK4aA/NWzYk5HJq07isdHMwcdqzLqDdmrEZOBzRL0pvURz9xbc9OaKu3PWis2h3P/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The test is performed with patient's foot in neutral position. The lower leg is stabilized by the examiner with one hand. With the other hand, the examiner grasps the heel while the patient's foot rests on the anterior aspect of the examiner's arm. An anterior force (direction of the arrow) is applied to the heel while holding the distal anterior leg fixed. Excessive anterior displacement suggests ligamentous injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karen Maughan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_46_23265=[""].join("\n");
var outline_f22_46_23265=null;
var title_f22_46_23266="Patient information: Aseptic necrosis of the hip (The Basics)";
var content_f22_46_23266=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17211\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"         Foods and drinks with calcium and vitamin D",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?42/25/43409\">",
"         Patient information: Hip pain in older people (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/34/23075\">",
"         Patient information: Hip replacement (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/58/35746\">",
"         Patient information: Osteoporosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/4/42050\">",
"         Patient information: Preventing falls (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?23/46/24289\">",
"         Patient information: Hip pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/49/25366\">",
"         Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/30/21987\">",
"         Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Aseptic necrosis of the hip (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/aseptic-necrosis-of-the-hip-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H16325933\">",
"      <span class=\"h1\">",
"       What is aseptic necrosis of the hip?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Aseptic necrosis of the hip is a condition that causes hip pain. It happens when bone tissue inside the hip doesn&rsquo;t get enough blood and dies.",
"     </p>",
"     <p>",
"      Aseptic necrosis of the hip is also called &ldquo;osteonecrosis of the hip.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16325948\">",
"      <span class=\"h1\">",
"       What are the symptoms of aseptic necrosis of the hip?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain in the groin, especially when walking",
"       </li>",
"       <li>",
"        Pain in the buttocks, thighs, and knees",
"       </li>",
"       <li>",
"        Limping &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16325963\">",
"      <span class=\"h1\">",
"       Are there tests for aseptic necrosis of the hip?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your symptoms and do an exam. Other tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        An X-ray of the hip",
"       </li>",
"       <li>",
"        An MRI &ndash; This is an imaging test that takes picture of the inside of your body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16325978\">",
"      <span class=\"h1\">",
"       How is aseptic necrosis of the hip treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Bed rest",
"       </li>",
"       <li>",
"        Using crutches",
"       </li>",
"       <li>",
"        Medicines &ndash; These include pain-relieving medicine such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"       </li>",
"       <li>",
"        (sample brand names: Advil&reg; and Motrin&reg;) and drugs to prevent bone loss, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?42/29/43477?source=see_link\">",
"         alendronate",
"        </a>",
"        (brand name: Fosamax&reg;).",
"       </li>",
"       <li>",
"        Surgery &ndash; Different kinds of surgery can help reduce pressure and pain in your hip. They include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Core decompression &ndash; For this surgery, the doctor takes out some of the inner layer of damaged bone tissue.",
"       </li>",
"       <li>",
"        A bone graft &ndash; This is when the doctor takes healthy bone from another part of your body and puts it into the damaged area of your hip. It might be done together with core decompression.",
"       </li>",
"       <li>",
"        Osteotomy &ndash; In this surgery, the doctor reshapes your hipbone. &nbsp;",
"       </li>",
"       <li>",
"        Hip replacement &ndash; This surgery replaces your hip with a man-made hip joint, called a prosthesis. A prosthesis can be made out of plastic, metal, or ceramic.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16325993\">",
"      <span class=\"h1\">",
"       Can aseptic necrosis of the hip be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting aseptic necrosis of the hip by keeping your bones as healthy as possible to avoid breaking a hip. To do this, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Eat foods with a lot of calcium and vitamin D, such as milk, yogurt, and green leafy vegetables, and fish from the ocean (",
"        <a class=\"graphic graphic_figure graphicRef79375 \" href=\"UTD.htm?18/13/18647\">",
"         figure 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Take calcium and vitamin D&nbsp;pills",
"       </li>",
"       <li>",
"        Be active for at least 30 minutes, most days of the week",
"       </li>",
"       <li>",
"        Avoid smoking",
"       </li>",
"       <li>",
"        If you drink alcohol, limit yourself to 1 drink per day (for women) or 2 drinks per day (for men).",
"       </li>",
"       <li>",
"        If you take medicines called steroids, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28230?source=see_link\">",
"         prednisone",
"        </a>",
"        (sample brand name: Winpred",
"        <sup>",
"         TM)",
"        </sup>",
"        or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?38/10/39072?source=see_link\">",
"         prednisolone",
"        </a>",
"        (sample brand name: Orapred&reg;), work with your doctor to take the lowest possible dose.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Do your best to keep from falling, too. It sounds simple, but you can prevent a lot of fractures by trying not to fall. To do that:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Make sure all your rugs have a no-slip backing to keep them in place.",
"       </li>",
"       <li>",
"        Tuck away any electrical cords, so they are not in your way.",
"       </li>",
"       <li>",
"        Make sure all walkways are well-lit.",
"       </li>",
"       <li>",
"        Watch out for slippery floors.",
"       </li>",
"       <li>",
"        Wear sturdy, comfortable shoes with rubber soles.",
"       </li>",
"       <li>",
"        Have your eyes checked.",
"       </li>",
"       <li>",
"        Ask your doctor or nurse to check whether any of your medicines might make you dizzy or put you at risk of falling.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16326031\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/25/43409?source=see_link\">",
"       Patient information: Hip pain in older people (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=see_link\">",
"       Patient information: Osteoporosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/4/42050?source=see_link\">",
"       Patient information: Preventing falls (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=see_link\">",
"       Patient information: Hip replacement (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"       Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/46/24289?source=see_link\">",
"       Patient information: Hip pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=see_link\">",
"       Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?22/46/23266?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17211 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_46_23266=[""].join("\n");
var outline_f22_46_23266=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16325933\">",
"      What is aseptic necrosis of the hip?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16325948\">",
"      What are the symptoms of aseptic necrosis of the hip?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16325963\">",
"      Are there tests for aseptic necrosis of the hip?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16325978\">",
"      How is aseptic necrosis of the hip treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16325993\">",
"      Can aseptic necrosis of the hip be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16326031\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17211\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"      Foods and drinks with calcium and vitamin D",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/46/24289?source=related_link\">",
"      Patient information: Hip pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/25/43409?source=related_link\">",
"      Patient information: Hip pain in older people (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=related_link\">",
"      Patient information: Hip replacement (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/4/42050?source=related_link\">",
"      Patient information: Preventing falls (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=related_link\">",
"      Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_46_23267="Bladder exstrophy male";
var content_f22_46_23267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Bladder exstrophy in the male",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Dr. Joseph G Borer.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_46_23267=[""].join("\n");
var outline_f22_46_23267=null;
var title_f22_46_23268="Polyethylene glycol electrolyte solution and bisacodyl: Patient drug information";
var content_f22_46_23268=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Polyethylene glycol electrolyte solution and bisacodyl: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/27/2484?source=see_link\">",
"     see \"Polyethylene glycol electrolyte solution and bisacodyl: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HalfLytely&reg; and Bisacodyl",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11215245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to clean out the GI (gastrointestinal) tract.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702755",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to polyethylene glycol, bisacodyl, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Hole in the GI (gastrointestinal) tract, bowel block, or a slow-moving bowel tract.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696831",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 1 hour of the bisacodyl tablet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696847",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take any other drugs 1 hour before or while drinking the solution.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697903",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bloating.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694702",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat solid food while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow bisacodyl tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695433",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix powder with water only as you have been told.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2879393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Only add flavors that come with the kit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695674",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Start drinking the solution after first bowel movement or 6 hours after taking the bisacodyl tablet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chill the solution to make it taste better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694816",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink 8 ounces quickly every 10 minutes until gone.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11832 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-BD74261493-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_46_23268=[""].join("\n");
var outline_f22_46_23268=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211176\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11215245\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012989\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012988\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012993\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012994\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012996\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012991\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012992\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012997\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012998\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/27/2484?source=related_link\">",
"      Polyethylene glycol electrolyte solution and bisacodyl: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_46_23269="Penicillin V potassium: Drug information";
var content_f22_46_23269=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Penicillin V potassium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/32/18948?source=see_link\">",
"    see \"Penicillin V potassium: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/52/15172?source=see_link\">",
"    see \"Penicillin V potassium: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F207857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Pen VK&reg;;",
"     </li>",
"     <li>",
"      Novo-Pen-VK;",
"     </li>",
"     <li>",
"      Nu-Pen-VK",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F207877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Penicillin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F207860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Actinomycosis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Mild:",
"     </i>",
"     2000-4000 mg in 4 divided doses for 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Surgical:",
"     </i>",
"     2000-4000 mg in 4 divided doses for 6-12 months (after I.V. penicillin G therapy of 4-6 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Erysipelas:",
"     </b>",
"     Oral: 500 mg 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pharyngitis (streptococcal):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Manufacturer&rsquo;s labeling:",
"     </i>",
"     500 mg 3-4 times daily for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Acute treatment, group A streptococci (IDSA guidelines):",
"     </i>",
"     250 mg 4 times daily or 500 mg twice daily for 10 days (Shulman, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Chronic carrier treatment, group A streptococcal (IDSA guidelines):",
"     </i>",
"     500 mg 4 times daily (maximum: 2000 mg daily) for 10 days in combination with oral rifampin (Shulman, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prophylaxis of pneumococcal or recurrent rheumatic fever infections:",
"     </b>",
"     Oral: 250 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prosthetic joint infection (unlabeled use):",
"     </b>",
"     <i>",
"      Chronic oral antimicrobial suppression (Enterococcus spp [penicillin-susceptible], streptococci [beta-hemolytic], Propionibacterium spp):",
"     </i>",
"     Oral: 500 mg 2-4 times daily (Osmon, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F207870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/52/15172?source=see_link\">",
"      see \"Penicillin V potassium: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Community-acquired pneumonia (CAP) due to group A",
"      <i>",
"       Streptococcus",
"      </i>",
"      , mild infection or step-down therapy (preferred) (IDSA/PIDS, 2011):",
"     </b>",
"     Infants &gt;3 months and Children: Oral: 50-75 mg/kg/day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pharyngitis (streptococcal) (IDSA guidelines):",
"     </b>",
"     Children: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Acute treatment:",
"     </i>",
"     250 mg 2-3 times daily for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Chronic carrier treatment, group A streptococci:",
"     </i>",
"     50 mg/kg/day in 4 divided doses (maximum: 2000 mg daily) for 10 days in combination with oral rifampin (Shulman, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pharyngitis (streptococcal), acute treatment (IDSA guidelines):",
"     </b>",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prophylaxis of pneumococcal infections:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &lt;5 years: 125 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;5 years: 250 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prophylaxis of recurrent rheumatic fever:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &lt;5 years: 125 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;5 years: 250 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F207861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F207862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 8-12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 12-16 hours.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F207833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral: 125 mg/5 mL (100 mL, 200 mL); 250 mg/5 mL (100 mL, 200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F207836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer on an empty stomach to increase oral absorption",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F207834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of infections caused by susceptible organisms involving the respiratory tract, otitis media, sinusitis, skin, and urinary tract; prophylaxis in rheumatic fever",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F16055098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chronic antimicrobial suppression of prosthetic joint infection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F207884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Penicillin V procaine may be confused with penicillin G potassium",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F207875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Mild diarrhea, vomiting, nausea, oral candidiasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute interstitial nephritis, convulsions, hemolytic anemia, positive Coombs' reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F207839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to penicillin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F207821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolonged use: Extended duration of therapy or use associated with high serum concentrations (eg, in renal insufficiency) may be associated with an increased risk for some adverse reactions (neutropenia, hemolytic anemia, serum sickness).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F207852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Decreases drug absorption rate; decreases drug serum concentration. Management: Take on an empty stomach 1 hour before or 2 hours after meals around-the-clock to promote less variation in peak and trough serum levels.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5720583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Penicillin crosses the placenta and distributes into amniotic fluid. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects. Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of penicillin V may be altered in the second and third trimester. Higher doses or increased dosing frequency may be required.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F207866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F207843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Penicillin V is excreted into breast milk (low concentrations) and may be detected in the urine of some breast-feeding infants. Loose stools and rash have been reported in nursing infants.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F207844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take on an empty stomach 1 hour before or 2 hours after meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F207842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Penicillin V Potassium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg/5 mL (100 mL): $3.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/5 mL (100 mL): $4.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Penicillin V Potassium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $45.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $77.77",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F207831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic renal and hematologic function tests during prolonged therapy; monitor for signs of anaphylaxis during first dose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F207845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abbocillin VK (AU);",
"     </li>",
"     <li>",
"      Anapenil (MX);",
"     </li>",
"     <li>",
"      Beapen VK (MY);",
"     </li>",
"     <li>",
"      Cilicaine VK (AU, NZ);",
"     </li>",
"     <li>",
"      Fenocin (ID);",
"     </li>",
"     <li>",
"      Kaypen (IN);",
"     </li>",
"     <li>",
"      L.P.V. (AU);",
"     </li>",
"     <li>",
"      Len V.K. (ZA);",
"     </li>",
"     <li>",
"      Megacilina Oral (PE);",
"     </li>",
"     <li>",
"      Milcopen (FI);",
"     </li>",
"     <li>",
"      Oracillin VK (ZA);",
"     </li>",
"     <li>",
"      Orvek (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ospa-V (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ospen (AT, FR, MY, SG, UY, VE);",
"     </li>",
"     <li>",
"      Pen V (HK);",
"     </li>",
"     <li>",
"      Pen-Rafa V-K (IL);",
"     </li>",
"     <li>",
"      Pen-Vi-K (MX);",
"     </li>",
"     <li>",
"      Penilevel (ES);",
"     </li>",
"     <li>",
"      Penoxil (MY);",
"     </li>",
"     <li>",
"      Pentranex (PH);",
"     </li>",
"     <li>",
"      Pota-Vi-Kin (MX);",
"     </li>",
"     <li>",
"      Prevecilina (CO);",
"     </li>",
"     <li>",
"      Robicillin VK (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Semicillin (TH);",
"     </li>",
"     <li>",
"      V-Cil-K (BB, BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, PR, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      V-Cillin K (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F207820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F207838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 60% to 73%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed to kidneys, liver, skin, tonsils, and into synovial, pleural, and pericardial fluids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 30 minutes; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 0.5-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/46/23269/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dajani AS, Bisno AL, Chung KJ, et al, &ldquo;Prevention of Rheumatic Fever. A Statement for Health Professionals by the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, The American Heart Association,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1989, 8(5):263-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/46/23269/abstract-text/2726321/pubmed\" id=\"2726321\" target=\"_blank\">",
"        2726321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/46/23269/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman ST, Bisno AL, Clegg HW, et al, &ldquo;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 55(10):e86-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/46/23269/abstract-text/22965026/pubmed\" id=\"22965026\" target=\"_blank\">",
"        22965026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Slots J, Research, Science and Therapy Committee,  &ldquo;Systemic Antibiotics in Periodontics,&rdquo;",
"      <i>",
"       J Periodontol",
"      </i>",
"      , 2004, 75(11):1553-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/46/23269/abstract-text/15633334/pubmed\" id=\"15633334\" target=\"_blank\">",
"        15633334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL and Bergman SA, &ldquo;Antibiotics and Their Use in the Treatment of Orofacial Infections, Part I and Part II,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1994, 42(5):398-402, 498-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/46/23269/abstract-text/7489869/pubmed\" id=\"7489869\" target=\"_blank\">",
"        7489869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9751 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_46_23269=[""].join("\n");
var outline_f22_46_23269=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207857\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207877\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207860\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207870\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207861\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207862\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207833\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207817\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207836\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207834\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055098\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207884\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207875\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207839\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207821\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299843\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207826\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207852\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720583\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207866\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207843\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207844\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207842\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207831\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207845\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207820\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207838\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9751\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9751|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/32/18948?source=related_link\">",
"      Penicillin V potassium: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/52/15172?source=related_link\">",
"      Penicillin V potassium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_46_23270="Pulmonary tumor embolism";
var content_f22_46_23270=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary tumor embolism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/46/23270/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/46/23270/contributors\">",
"     Gerald L Weinhouse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/46/23270/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/46/23270/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/46/23270/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/46/23270/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/46/23270/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lungs are a prominent target for the embolization of any material larger than approximately 10 microns that gains access to the venous circulation. This includes thrombi, air, amniotic fluid, fat, injected foreign material, and tumor. It is important that the correct type of pulmonary emboli be identified, since treatment and prognosis vary considerably.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of pulmonary tumor emboli are reviewed here. The embolization of thrombi, air, amniotic fluid, fat, or foreign material is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link\">",
"     \"Overview of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15016?source=see_link\">",
"     \"Amniotic fluid embolism syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25942?source=see_link\">",
"     \"Fat embolism syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31353?source=see_link\">",
"     \"Foreign body granulomatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor cells gain access to the circulation via the invasion of small veins or the release of tumor fragments into the tumor's neovasculature. Most of the circulating tumor cells are then destroyed by circulatory mechanical forces, shear forces, or the host&rsquo;s immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/1\">",
"     1",
"    </a>",
"    ]. However, some tumor cells reach the lungs and become trapped within pulmonary capillaries.",
"   </p>",
"   <p>",
"    Tumor cells trapped within pulmonary capillaries may trigger the coagulation cascade and obstruct the pulmonary vessels. The obstruction is primarily due to both the tumor cells and associated clot, but reactive concentric medial hypertrophy and intimal fibrosis of the pulmonary vessels may also contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Such secondary changes may progress to complete and irreversible obstruction of pulmonary vessels, whereas occlusion by pure thrombi or thromboemboli is generally followed by recanalization. When the pulmonary vasculature becomes obstructed, ventilation-perfusion matching becomes impaired and pulmonary vascular resistance increases, which may impair gas exchange and cause cor pulmonale [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intraluminal tumor emboli do not proliferate or spread locally; thus, they should not be considered metastases. Lung metastasis requires malignant cells to adhere to lung-specific adhesion molecules on the endothelium, produce enzymes that degrade the basement membrane and lung extracellular matrix, and grow in association with lung-specific growth factors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. It has been proposed that tumor emboli may contribute to lymphangitic carcinomatosis, but this is uncertain since the two entities are not universally found together and their clinical manifestations are different [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autopsy series demonstrate tumor emboli in up to 26 percent of patients who die from cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. However, the diagnosis is made antemortem in as few as 6 percent of autopsy-proven cases. Histologic examination of the involved lung tissue demonstrates the embolized tumor cells, often mixed with thrombus and associated with an obliterative arteritis. Degeneration of tumor cells within pockets of organized thrombin is also sometimes observed.",
"   </p>",
"   <p>",
"    Tumor emboli have been grouped into four categories [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tumor emboli that are microscopic and occlude small pulmonary arteries and arterioles (most common) (",
"      <a class=\"graphic graphic_picture graphicRef60872 \" href=\"UTD.htm?4/16/4357\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tumor emboli that occlude large, proximal pulmonary arteries (",
"      <a class=\"graphic graphic_picture graphicRef80194 \" href=\"UTD.htm?42/5/43090\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tumor emboli characterized by diffuse microvascular invasion, which may include lymphatic obstruction",
"     </li>",
"     <li>",
"      Combinations of the above",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pulmonary tumor thrombotic microangiopathy (PTTM) is a related phenomenon. It differs from pulmonary tumor embolism because it is associated with the activation of the coagulation system at the surface of the tumor emboli, as well as intimal proliferation in small pulmonary arteries. PTTM may explain why some cases of microscopic tumor embolism are associated with pulmonary arterial hypertension and an elevated D-dimer level [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24781564\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancies that may result in tumor emboli are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef67921 \" href=\"UTD.htm?18/54/19307\">",
"     table 1",
"    </a>",
"    ). The risk appears to be the greatest with mucin-secreting adenocarcinomas of the breast, lung, stomach, and colon. However, tumor emboli also complicate hepatocellular carcinoma, prostate cancer, choriocarcinoma, renal cell carcinoma, and other malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/4,11,12\">",
"     4,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clinical presentation that is specific for tumor embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/4,13,14\">",
"     4,13,14",
"    </a>",
"    ]. Dyspnea is present in the majority of cases and is generally subacute and progressive [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/12\">",
"     12",
"    </a>",
"    ]. Pleuritic chest pain is also common. Fatigue, weight loss, cough, and hemoptysis occur less frequently. The physical examination usually reveals tachypnea and tachycardia. Signs of pulmonary hypertension and cor pulmonale, such as an increase in the pulmonic component of the second heart sound, a right ventricular lift, cyanosis, and jugular venous distention may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/15\">",
"     15",
"    </a>",
"    ]. Adventitious sounds are usually absent. Most clinically apparent pulmonary tumor emboli occur in patients with a known malignancy, although tumor emboli are rarely the presenting manifestation of an occult neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings of dyspnea, hypoxemia, right heart strain, and clear lungs suggest either thromboemboli or tumor emboli. Differentiating these entities clinically may be difficult, as illustrated by a study that compared 56 patients with solid tumors and thromboemboli to 17 patients with solid tumors and tumor emboli [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/2\">",
"     2",
"    </a>",
"    ]. The only difference was that cough was significantly more common among patients with pulmonary tumor emboli. There were no differences at presentation in the respiratory rate, heart rate, white blood cell count, bilirubin, LDH, or the frequency of dyspnea, pleuritic or nonpleuritic chest pain, hemoptysis, respiratory rate, fever, or cyanosis. The primary purpose of the diagnostic evaluation is to definitively determine whether the patient has pulmonary tumor emboli or thromboemboli, since the prognosis and management of these disorders are different.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2576116\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several ancillary studies may be helpful in distinguishing pulmonary tumor emboli from thromboemboli:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventilation-perfusion lung scans in patients with pulmonary tumor emboli may be without abnormalities or may demonstrate multiple small, peripheral, subsegmental perfusion defects (ie, a \"mottled\" appearance) with normal ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. This pattern is similar to that associated with fat embolism or idiopathic pulmonary arterial hypertension, but different from the pattern typically seen with thromboemboli.",
"     </li>",
"     <li>",
"      Pulmonary angiography is insensitive for pulmonary tumor emboli [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/21\">",
"       21",
"      </a>",
"      ]. Subtle abnormalities, such as subsegmental filling defects, pruning and tortuosity of the third to fifth order vessels, or delayed filling of segmental arteries, may be the only clues to the presence of tumor emboli [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/16,22\">",
"       16,22",
"      </a>",
"      ]. As a result, the primary role of pulmonary angiography is to rule out thromboemboli. Pulmonary angiography is the gold standard for diagnosing thromboemboli.",
"     </li>",
"     <li>",
"      Right heart catheterization or echocardiography frequently documents mean pulmonary artery pressures greater than 50 mmHg in patients with pulmonary tumor emboli [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/16,21,23\">",
"       16,21,23",
"      </a>",
"      ]. Pressures of this magnitude are only possible when the development of pulmonary hypertension has occurred subacutely over weeks, as is typical for tumor emboli. Acute, large occlusions of pulmonary arteries due to thromboemboli rarely raise mean pulmonary artery pressure above approximately 40 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      FDG-PET (18F-2-deoxy-2-fluoro-D-glucose [FDG] positron emission tomography [PET]) may be useful because large tumor emboli are FDG avid, whereas thromboemboli are not [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. The role of FDG-PET imaging when pulmonary tumor emboli are being considered has not been completely defined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, other ancillary studies produce similar results in patients with thromboemboli or pulmonary tumor emboli. Arterial blood gas analysis generally shows hypoxemia, a respiratory alkalosis, and an elevated alveolar-arterial oxygen gradient (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?30/51/31539?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). Electrocardiograms are generally normal, although right ventricular hypertrophy or strain may be present. Chest radiographs and computed tomography are usually unremarkable, but occasionally show enlargement of the cardiac silhouette, prominent pulmonary arteries, and interstitial infiltrates if concomitant lymphangitic carcinomatosis is present [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/12\">",
"     12",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69355 graphicRef79160 \" href=\"UTD.htm?10/37/10839\">",
"     image 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although ancillary studies may be suggestive of pulmonary tumor embolism, confirmation requires that tumor cells be demonstrated in the pulmonary vasculature. This can be accomplished via lung biopsy or cytologic examination of pulmonary arterial blood:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lung biopsy can be performed open or thoracoscopically. It is the gold standard diagnostic test for pulmonary tumor emboli.",
"     </li>",
"     <li>",
"      Cytologic examination of blood aspirated from a wedged pulmonary artery catheter consists of positioning the pulmonary artery catheter in the wedged position, slowly aspirating 10 to 15 mL of blood, discarding it, and then slowly aspirating another 5 to 10 mL of blood. This aliquot should be placed into a heparinized tube and sent to the laboratory for cytologic analysis. Cytologic examination of blood aspirated from a wedged pulmonary artery catheter has a high degree of accuracy for the diagnosis of lymphangitic carcinomatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/27,28\">",
"       27,28",
"      </a>",
"      ], but less is known about the accuracy of this technique for the diagnosis of pulmonary tumor emboli. It appears that false-negative results are reasonably common and that negative pulmonary wedge cytology is insufficient to definitively exclude pulmonary tumor emboli [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/23\">",
"       23",
"      </a>",
"      ]. In addition, false-positive results may be a consequence of megakaryocytes being mistaken for malignant cells because of their large size, multilobulated nuclei, densely staining chromatin, and prominent nucleoli [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/4,29\">",
"       4,29",
"      </a>",
"      ]. It is imperative that the specimen is read by an experienced cytopathologist to avoid erroneous interpretations. Given these limitations, patients who undergo cytologic examination of blood aspirated from a wedged pulmonary artery catheter often end up still undergoing lung biopsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2576236\">",
"    <span class=\"h2\">",
"     Diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians believe that a presumptive diagnosis of pulmonary tumor emboli (a typical presentation and exclusion of thromboembolic disease) is sufficient to inform judgments regarding prognosis and management. Such an approach does not require tumor cells to be identified in the pulmonary vasculature and, thus, spares patients from the risks of invasive diagnostic testing. We acknowledge that there is a role for presumptive diagnoses of pulmonary tumor emboli, but we also believe that there is an important role for definitive diagnoses.",
"   </p>",
"   <p>",
"    In our clinical practice, the decision about how aggressively to pursue the diagnosis of pulmonary tumor embolism generally depends upon the nature of the underlying tumor. For patients with chemotherapy-resistant tumors, a presumptive diagnosis is probably sufficient because confirming the presence of pulmonary tumor emboli is unlikely to alter the patient's outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. The major reason to diagnose pulmonary tumor embolism in such patients is to spare them the potential morbidity of anticoagulation or inferior vena cava filter placement. In contrast, for patients with either a chemotherapy-sensitive tumor or a suspected (but unconfirmed) malignancy, more aggressive efforts to confirm the diagnosis are warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2576343\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary tumor emboli are not metastases. Nevertheless, survival appears to be poor after the onset of symptoms, probably because pulmonary tumor emboli are often associated with concomitant lymphangitic or metastatic carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of pulmonary tumor embolism is directed at the primary tumor. Complete resection of the primary tumor has resulted in gradual resolution of the tumor emboli without any specific therapy in cases of atrial myxoma and renal cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/1,17,30\">",
"     1,17,30",
"    </a>",
"    ]. Chemotherapy does not generally affect prognosis of patients with pulmonary tumor emboli unless the patient has a very responsive neoplasm, such as Wilms tumor or a trophoblastic malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/31\">",
"     31",
"    </a>",
"    ]. Embolectomy and inferior vena cava filter placement have been employed in rare patients suffering from large, central emboli from infradiaphragmatic tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23270/abstract/17,32\">",
"     17,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24781406\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary tumor emboli are tumor cells that spread to the lungs via the venous circulation and became trapped within pulmonary capillaries. They are not metastases because they do not proliferate or spread locally. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malignancies that may result in tumor emboli are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef67921 \" href=\"UTD.htm?18/54/19307\">",
"       table 1",
"      </a>",
"      ). The risk appears to be the greatest with mucin-secreting adenocarcinomas of the breast, lung, stomach, and colon. (See",
"      <a class=\"local\" href=\"#H24781564\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no clinical presentation that is specific for tumor embolism. Dyspnea is present in the majority of cases and is generally subacute and progressive. Most clinically apparent pulmonary tumor emboli occur in patients with a known malignancy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The findings of dyspnea, hypoxemia, right heart strain, and clear lungs suggest either thromboemboli or tumor emboli. Differentiating these entities is difficult. However, the primary purpose of the diagnostic evaluation is to determine whether the patient has pulmonary tumor emboli or thromboemboli, since the prognosis and management of these disorders are different. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision about how aggressively to pursue the diagnosis of pulmonary tumor embolism generally depends upon the nature of the underlying tumor. For patients with chemotherapy-resistant tumors, presumptive diagnosis is probably sufficient. In contrast, for patients with a chemotherapy-sensitive tumor or a suspected (but unconfirmed) malignancy, more aggressive efforts to confirm the diagnosis are warranted. (See",
"      <a class=\"local\" href=\"#H2576236\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survival is poor after the onset of symptoms due to pulmonary tumor emboli. (See",
"      <a class=\"local\" href=\"#H2576343\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of pulmonary tumor embolism is directed at the primary tumor. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/1\">",
"      Bassiri AG, Haghighi B, Doyle RL, et al. Pulmonary tumor embolism. Am J Respir Crit Care Med 1997; 155:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/2\">",
"      Goldhaber SZ, Dricker E, Buring JE, et al. Clinical suspicion of autopsy-proven thrombotic and tumor pulmonary embolism in cancer patients. Am Heart J 1987; 114:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/3\">",
"      Shields, DJ, Edwards, WD. Pulmonary hypertension attributable to neoplastic emboli: An autopsy study of 20 cases and a review of the literature. Cardiovasc Pathol 1992; 1:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/4\">",
"      Roberts KE, Hamele-Bena D, Saqi A, et al. Pulmonary tumor embolism: a review of the literature. Am J Med 2003; 115:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/5\">",
"      Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997; 78:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/6\">",
"      Soares FA, Pinto AP, Landell GA, de Oliveira JA. Pulmonary tumor embolism to arterial vessels and carcinomatous lymphangitis. A comparative clinicopathological study. Arch Pathol Lab Med 1993; 117:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/7\">",
"      Winterbauer RH, Elfenbein IB, Ball WC Jr. Incidence and clinical significance of tumor embolization to the lungs. Am J Med 1968; 45:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/8\">",
"      Kane RD, Hawkins HK, Miller JA, Noce PS. Microscopic pulmonary tumor emboli associated with dyspnea. Cancer 1975; 36:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/9\">",
"      von Herbay A, Illes A, Waldherr R, Otto HF. Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer 1990; 66:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/10\">",
"      Tashima Y, Abe K, Matsuo Y, et al. Pulmonary tumor thrombotic microangiopathy: FDG-PET/CT findings. Clin Nucl Med 2009; 34:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/11\">",
"      King MB, Harmon KR. Unusual forms of pulmonary embolism. Clin Chest Med 1994; 15:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/12\">",
"      Chan CK, Hutcheon MA, Hyland RH, et al. Pulmonary tumor embolism: a critical review of clinical, imaging, and hemodynamic features. J Thorac Imaging 1987; 2:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/13\">",
"      Lammi M, Wurzel J, Criner GJ. Pulmonary tumor embolism. Lung 2010; 188:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/14\">",
"      Jorens PG, Van Marck E, Snoeckx A, Parizel PM. Nonthrombotic pulmonary embolism. Eur Respir J 2009; 34:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/15\">",
"      Kridel R, Myit S, Pache JC, Gaspoz JM. Pulmonary tumor embolism: a rare cause of acute right heart failure with elevated D-dimers. J Thorac Oncol 2008; 3:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/16\">",
"      Margolis ML, Jarrell BE. Pulmonary tumor microembolism. South Med J 1985; 78:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/17\">",
"      Daughtry JD, Stewart BH, Golding LA, Groves LK. Pulmonary embolus presenting as the initial manifestation of renal cell carcinoma. Ann Thorac Surg 1977; 24:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/18\">",
"      Wong CH, Suvarna SK, Ciulli F, Leggett RJ. Small cell lung carcinoma presenting as acute cardiovascular collapse due to tumour cell embolisation. Respiration 2000; 67:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/19\">",
"      Crane R, Rudd TG, Dail D. Tumor microembolism: pulmonary perfusion pattern. J Nucl Med 1984; 25:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/20\">",
"      Boudreau RJ, Lisbona R, Sheldon H. Ventilation-perfusion mismatch in tumor embolism. Clin Nucl Med 1982; 7:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/21\">",
"      Schriner RW, Ryu JH, Edwards WD. Microscopic pulmonary tumor embolism causing subacute cor pulmonale: a difficult antemortem diagnosis. Mayo Clin Proc 1991; 66:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/22\">",
"      Chakeres DW, Spiegel PK. Fatal pulmonary hypertension secondary to intravascular metastatic tumor emboli. AJR Am J Roentgenol 1982; 139:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/23\">",
"      Domanski MJ, Cunnion RE, Fernicola DJ, Roberts WC. Fatal cor pulmonale caused by extensive tumor emboli in the small pulmonary arteries without emboli in the major pulmonary arteries or metastases in the pulmonary parenchyma. Am J Cardiol 1993; 72:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/24\">",
"      Sasahara AA, Cannilla JE, Morse RL, et al. Clinical and physiologic studies in pulmonary thromboembolism. Am J Cardiol 1967; 20:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/25\">",
"      Sone T, Yoshikawa K, Fukunaga M. Pulmonary tumor embolism from choriocarcinoma: detection with F-18 FDG positron emission tomography. Clin Nucl Med 2008; 33:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/26\">",
"      Purandare NC, Dua SG, Rangarajan V, et al. Pulmonary artery and femoral vein tumour thromboembolism in a patient with osteogenic sarcoma demonstrated by FDG PET/CT. Eur J Nucl Med Mol Imaging 2010; 37:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/27\">",
"      Masson RG, Ruggieri J. Pulmonary microvascular cytology. A new diagnostic application of the pulmonary artery catheter. Chest 1985; 88:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/28\">",
"      Masson RG, Krikorian J, Lukl P, et al. Pulmonary microvascular cytology in the diagnosis of lymphangitic carcinomatosis. N Engl J Med 1989; 321:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/29\">",
"      Lukl P. Pulmonary microvascular cytology in the dyspneic cancer patient. Merits and caution. Arch Pathol Lab Med 1992; 116:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/30\">",
"      Seagle RL, Nomeir AM, Watts LE, et al. Left atrial myxoma and atrial septal defect with recurrent pulmonary emboli. South Med J 1985; 78:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/31\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 19-1995. A 55 year-old woman with acute respiratory failure and radiographically clear lungs. N Engl J Med 1995; 332:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23270/abstract/32\">",
"      Farrell RM, Bloch J, Marshall VF. Caval umbrella to trap emboli in patients with renal cell carcinoma. Surg Gynecol Obstet 1974; 139:835.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8252 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-629A639819-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_46_23270=[""].join("\n");
var outline_f22_46_23270=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24781406\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24781564\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2576116\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2576236\">",
"      Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2576343\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24781406\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/8252\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8252|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/34/28192\" title=\"diagnostic image 1A\">",
"      Lymphangitic cancer CT I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/45/11987\" title=\"diagnostic image 1B\">",
"      Lymphangitic cancer CT II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8252|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/16/4357\" title=\"picture 1\">",
"      Tumor embolus High",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/5/43090\" title=\"picture 2\">",
"      Tumor embolus Gross",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8252|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/54/19307\" title=\"table 1\">",
"      Tumor embolism malignancies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?30/51/31539?source=related_link\" title=\"calculator 1\">",
"      Calculator: A-a gradient (alveolar-arterial gradient; AaG)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15016?source=related_link\">",
"      Amniotic fluid embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25942?source=related_link\">",
"      Fat embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31353?source=related_link\">",
"      Foreign body granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_46_23271="Alopecia areata 2";
var content_f22_46_23271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Alopecia areata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hair loss is a round patch. Note the absence of scales or inflammation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_46_23271=[""].join("\n");
var outline_f22_46_23271=null;
var title_f22_46_23272="The developing fetus";
var content_f22_46_23272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    The developing fetus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 387px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore, K. The developing human: Clinically oriented embryology, WB Saunders, Philadelphia 1982. Copyright &copy;1982 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_46_23272=[""].join("\n");
var outline_f22_46_23272=null;
var title_f22_46_23273="Dermatologic problems in patients who have undergone liver transplantation";
var content_f22_46_23273=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dermatologic problems in patients who have undergone liver transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/46/23273/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/46/23273/contributors\">",
"     Jean-Fran&ccedil;ois Dufour, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/46/23273/contributors\">",
"     Edmond Schmied, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/46/23273/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/46/23273/contributors\">",
"     Robert S Brown, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/46/23273/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/46/23273/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/46/23273/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have undergone liver transplantation are at risk for developing a number of infectious, neoplastic, drug-induced, and cosmetic dermatologic problems, most of which are related to the immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Their severity can range from benign annoying conditions to dangerous life-threatening diseases.",
"   </p>",
"   <p>",
"    Among all solid organ transplantations, liver transplantation requires the least amount of immunosuppression, sometimes even permitting its complete cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/4\">",
"     4",
"    </a>",
"    ]. As a result, patients who have undergone liver transplantation tend to have fewer dermatologic complications compared with other solid organ recipients. On the other hand, the volume of the transplanted organ is large, leading to the transplantation of relatively more lymphocytes than in kidney or heart transplantation. Because of the immunosuppression, the transplanted lymphocytes proliferate and can rarely trigger graft-versus-host-disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will focus on the natural history of preexisting dermatologic diseases (both related and unrelated to the underlying liver disease after transplantation) and the recognition, treatment, and prevention of dermatologic diseases that appear after liver transplantation. Other complications of liver transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=see_link\">",
"     \"Long-term management of adult liver transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=see_link\">",
"     \"Infectious complications in liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dermatologic conditions observed after liver transplantation can be divided into those related to the underlying liver disease, and those that happen to occur in patients with liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Conditions related to the underlying liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the non-specific mucocutaneous lesions linked to liver cirrhosis, such as palmar erythema, spider nevi, and pruritus, disappear in the weeks following the liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. On the other hand, skin pigmentation, clubbing (",
"    <a class=\"graphic graphic_figure graphicRef52839 \" href=\"UTD.htm?42/58/43951\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/10\">",
"     10",
"    </a>",
"    ], and fingernail changes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/11\">",
"     11",
"    </a>",
"    ] may take several months to regress. Dupuytren's contractures (",
"    <a class=\"graphic graphic_picture graphicRef70486 \" href=\"UTD.htm?35/58/36770\">",
"     picture 1",
"    </a>",
"    ) are usually irreversible.",
"   </p>",
"   <p>",
"    A variety of dermatologic manifestations have been described in association with specific forms of liver disease. Examples included alopecia (",
"    <a class=\"graphic graphic_picture graphicRef87348 \" href=\"UTD.htm?18/0/18439\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/12-15\">",
"     12-15",
"    </a>",
"    ] and vitiligo (",
"    <a class=\"graphic graphic_picture graphicRef74712 \" href=\"UTD.htm?34/31/35312\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63623 \" href=\"UTD.htm?36/54/37730\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/16\">",
"     16",
"    </a>",
"    ] associated with autoimmune hepatitis, the xanthomas and xanthelasmas (",
"    <a class=\"graphic graphic_picture graphicRef67919 \" href=\"UTD.htm?23/14/23778\">",
"     picture 5",
"    </a>",
"    ) observed in chronic cholestatic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/17-19\">",
"     17-19",
"    </a>",
"    ], cryoglobulinemia, and lichen planus (",
"    <a class=\"graphic graphic_picture graphicRef58361 \" href=\"UTD.htm?22/11/22709\">",
"     picture 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76383 \" href=\"UTD.htm?28/42/29346\">",
"     picture 7",
"    </a>",
"    ) associated with hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/20\">",
"     20",
"    </a>",
"    ]. Although their outcomes after liver transplantation have not been well described, the available data suggest that many of these conditions improve (",
"    <a class=\"graphic graphic_table graphicRef60813 \" href=\"UTD.htm?17/12/17613\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/12-36\">",
"     12-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Conditions unrelated to the underlying liver disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis (",
"    <a class=\"graphic graphic_picture graphicRef81412 \" href=\"UTD.htm?39/55/40831\">",
"     picture 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef77308 \" href=\"UTD.htm?37/20/38212\">",
"     picture 9",
"    </a>",
"    ) affects approximately 3 percent of the population worldwide. As a result, it is frequently observed in patients with liver disease, particularly those with alcoholic liver disease since the prevalence of psoriasis is increased among patients who abuse alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/37\">",
"     37",
"    </a>",
"    ]. In a population-based study, alcoholism was a significant risk factor for mortality among patients with psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A contributing factor to complications observed in alcoholic patients with psoriasis may be the observation that alcohol consumption decreases the response to conventional treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/39\">",
"     39",
"    </a>",
"    ]. Furthermore, alcohol consumption and psoriasis itself have been linked to an increased hepatic toxicity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , an important therapeutic option in the treatment of extensive psoriasis, especially when it is accompanied by rheumatologic manifestations. Liver transplantation due to the hepatotoxicity of methotrexate in patients with psoriasis has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic hepatitis C virus infection has also been implicated in the development and the evolution of psoriasis in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/41\">",
"     41",
"    </a>",
"    ], although discordant data have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The immunosuppressive therapy used after hepatic transplantation (eg, steroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) is also effective for the treatment of psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Rapid immunosuppressive tapering may lead to an acute and severe extension of the psoriasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Atopic dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atopic dermatitis (",
"    <a class=\"graphic graphic_picture graphicRef57982 \" href=\"UTD.htm?6/56/7045\">",
"     picture 10",
"    </a>",
"    ) is a chronic inflammatory skin disease that is considered familial with allergic features. It often occurs in patients with other atopic disorders such as asthma and allergic rhinitis. It generally improves following liver transplantation because of immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increased frequency of graft rejection has been observed in atopic individuals who have undergone renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/45\">",
"     45",
"    </a>",
"    ]. Whether this observation also holds true in liver transplantation is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MUCOCUTANEOUS COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin infections and neoplasms are more commonly seen in patients who have undergone liver transplantation compared to patients with other immunosuppressed states, such as AIDS (",
"    <a class=\"graphic graphic_table graphicRef72557 \" href=\"UTD.htm?41/3/42044\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/46-64\">",
"     46-64",
"    </a>",
"    ]. The relatively high incidence of these conditions is principally due to the effects of three factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immunosuppression",
"     </li>",
"     <li>",
"      Infection with human papilloma virus",
"     </li>",
"     <li>",
"      Exposure to sunlight",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a general rule, the time between the transplantation and the appearance of skin tumors is shorter in patients who live in sunny areas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=see_link\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16713?source=see_link\">",
"     \"Skin examination and clinical features of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Squamous cell and basal cell carcinomas (",
"    <a class=\"graphic graphic_picture graphicRef76863 \" href=\"UTD.htm?34/62/35812\">",
"     picture 11",
"    </a>",
"    ) are more frequent than melanomas (",
"    <a class=\"graphic graphic_picture graphicRef74278 \" href=\"UTD.htm?17/61/18389\">",
"     picture 12",
"    </a>",
"    ). The risk increases with the length of the immunosuppression; they can be found in more than 50 percent of recipients 15 years after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/46-53\">",
"     46-53",
"    </a>",
"    ]. Melanomas are 2.5 to 4 times more frequent after liver transplantation than in a non-transplant population [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/55,56,65,66\">",
"     55,56,65,66",
"    </a>",
"    ]. In one report, the outcome for posttransplant melanoma was similar to that of the general population for T1 and T2 tumors (&le;2 mm thickness), but significantly worse for T3 and T4 tumors (&gt;2 mm thickness) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dermatologic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatologic infections after liver transplantation can be challenging. They often involve several infectious agents, such as skin coinfection with herpes virus and cytomegalovirus (",
"    <a class=\"graphic graphic_picture graphicRef67589 \" href=\"UTD.htm?40/55/41840\">",
"     picture 13",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61124 \" href=\"UTD.htm?15/27/15792\">",
"     picture 14",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72502 \" href=\"UTD.htm?29/0/29697\">",
"     picture 15",
"    </a>",
"    ). In the transplant setting, some of these skin lesions lose their characteristic macroscopic appearance, making the diagnosis more difficult than in the nontransplant setting. As a result, systematic microbiologic and histologic tests should not be delayed. Bacterial and viral infections predominate early (less than three months) after transplantation, while rarer bacteria and opportunistic agents, such as fungi, are seen later (",
"    <a class=\"graphic graphic_table graphicRef69874 \" href=\"UTD.htm?37/62/38891\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76657 \" href=\"UTD.htm?13/3/13372\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55662 \" href=\"UTD.htm?22/55/23420\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/1,68-109\">",
"     1,68-109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Drug-induced",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complexity of immunosuppressive regimens often makes it difficult to identify a specific drug as causing a dermatologic complication. However, many of the drugs used in the transplant setting have been associated with mucocutaneous complications (",
"    <a class=\"graphic graphic_table graphicRef56452 \" href=\"UTD.htm?20/48/21259\">",
"     table 6",
"    </a>",
"    ). In renal transplant recipients, conversion from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    improved hypertrichosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/110-112\">",
"     110-112",
"    </a>",
"    ]. Inhibitors of the mTOR kinase such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    have been associated with rash, acne, and even leukocytoclastic vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/113-115\">",
"     113-115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of uncommon skin disorders have been described in a number of case reports (",
"    <a class=\"graphic graphic_picture graphicRef74528 \" href=\"UTD.htm?13/30/13794\">",
"     picture 16",
"    </a>",
"    )&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef67318 \" href=\"UTD.htm?25/26/26028\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/7,116-137\">",
"     7,116-137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following questions may be helpful to estimate a patient's risk for dermatologic complications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Were there pretransplantation dermatologic problems?",
"     </li>",
"     <li>",
"      What is",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      profession?",
"     </li>",
"     <li>",
"      Is",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      skin sensitive to light?",
"     </li>",
"     <li>",
"      What is",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      exposure to sunlight (professional, non-professional)?",
"     </li>",
"     <li>",
"      What is",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      contact with animals?",
"     </li>",
"     <li>",
"      Are serologies for herpes simplex I, herpes simplex II, herpes virus 8, hepatitis C virus, or syphilis positive?",
"     </li>",
"     <li>",
"      What is the degree of immunosuppression?",
"     </li>",
"     <li>",
"      What is the length of the follow-up since the liver transplantation?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After liver transplantation, patients should protect themselves from sunlight. They should be informed about this risk and know that clothes are the best protection. It is common sense to say that darker and thicker clothes provide better protection. Sun creams should be used when exposure to the sun is unavoidable, such as during professional duties. These preparations combine chemical (filter) and physical (screen) agents. To be effective they have to protect against the entire spectrum of ultraviolet radiations (B and A; the latter is more difficult to obtain). Examples of such preparations are Mexoryl and Tinosorb. The cream has to be applied 15 minutes before exposure and should be reapplied every two hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33447?source=see_link\">",
"     \"Selection of sunscreen and sun-protective measures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The skin of patients after transplantation should be examined completely and systematically, including the oral and anal areas. Regular systematic examination of the skin is needed to discover and destroy precancerous lesions such as actinic keratosis (",
"    <a class=\"graphic graphic_picture graphicRef53177 \" href=\"UTD.htm?26/19/26932\">",
"     picture 17",
"    </a>",
"    ), verrucae (",
"    <a class=\"graphic graphic_picture graphicRef72502 \" href=\"UTD.htm?29/0/29697\">",
"     picture 15",
"    </a>",
"    ), and oral leukoplakia (",
"    <a class=\"graphic graphic_picture graphicRef81049 \" href=\"UTD.htm?18/2/18464\">",
"     picture 18",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef60939 \" href=\"UTD.htm?35/48/36608\">",
"     picture 19",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72711 \" href=\"UTD.htm?2/39/2675\">",
"     picture 20",
"    </a>",
"    ). Any suspicious lesion should be seen by a dermatologist. One report suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    was a safe option for the treatment of multiple actinic keratoses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23273/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The early recognition of cutaneous diseases after liver transplantation permits treatment during the mild stages and alerts the transplant hepatologist that the patient may be over-immunosuppressed. As examples, multiple epithelioma, Kaposi's sarcoma, herpetic tumors, and porokeratosis are lesions that should lead to the possibility of a reduction in the immunosuppression. Adequate management of the cosmetic consequences of the immunosuppressive regimen, such as hypertrichosis and sebaceous hyperplasia, enhances the compliance of the patients with the treatment and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    trust in the clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H155947760\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have undergone liver transplantation are at risk for developing a number of infectious, neoplastic, drug-induced, and cosmetic dermatologic problems. Many of the drugs used in the transplant setting have been associated with mucocutaneous complications (",
"      <a class=\"graphic graphic_table graphicRef56452 \" href=\"UTD.htm?20/48/21259\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Drug-induced'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most of the non-specific mucocutaneous lesions linked to liver cirrhosis, such as palmar erythema, spider nevi, and pruritus, disappear in the weeks following the liver transplantation. On the other hand, skin pigmentation, clubbing, and fingernail changes may take several months to regress. Dupuytren's contractures are usually irreversible. A variety of dermatologic manifestations have been described in association with specific forms of liver disease. Although their outcomes after liver transplantation have not been well described, the available data suggest that many of these conditions improve (",
"      <a class=\"graphic graphic_table graphicRef60813 \" href=\"UTD.htm?17/12/17613\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neoplasms are more commonly seen in patients who have undergone liver transplantation. Squamous cell and basal cell carcinomas are more frequent than melanomas. The risk increases with the length of the immunosuppression and increased sun exposure; skin cancer can be found in more than 50 percent of recipients 15 years after transplantation (",
"      <a class=\"graphic graphic_table graphicRef72557 \" href=\"UTD.htm?41/3/42044\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dermatologic infections after liver transplantation can be challenging. They often involve several infectious agents, such as skin coinfection with herpes virus and cytomegalovirus (",
"      <a class=\"graphic graphic_table graphicRef69874 \" href=\"UTD.htm?37/62/38891\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef76657 \" href=\"UTD.htm?13/3/13372\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef55662 \" href=\"UTD.htm?22/55/23420\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Dermatologic infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of uncommon skin disorders have been described in a number of case reports (",
"      <a class=\"graphic graphic_table graphicRef67318 \" href=\"UTD.htm?25/26/26028\">",
"       table 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The skin of patients after transplantation should be examined completely and systematically, including the oral and anal areas. The early recognition of cutaneous diseases after liver transplantation permits treatment during the mild stages and alerts the transplant hepatologist that the patient may be over-immunosuppressed. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/1\">",
"      Hassan G, Khalaf H, Mourad W. Dermatologic complications after liver transplantation: a single-center experience. Transplant Proc 2007; 39:1190.",
"     </a>",
"    </li>",
"    <li>",
"     Euvrard S, Kanitakis J, Claudy A. Skin diseases after organ transplantation. John Libbey Eurotext, Paris 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/3\">",
"      Schmied E, Dufour JF, Euvrard S. Nontumoral dermatologic problems after liver transplantation. Liver Transpl 2004; 10:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/4\">",
"      Ramos HC, Reyes J, Abu-Elmagd K, et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 1995; 59:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/5\">",
"      Redondo P, Espa&ntilde;a A, Herrero JI, et al. Graft-versus-host disease after liver transplantation. J Am Acad Dermatol 1993; 29:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/6\">",
"      Roberts JP, Ascher NL, Lake J, et al. Graft vs. host disease after liver transplantation in humans: a report of four cases. Hepatology 1991; 14:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/7\">",
"      Smith DM, Agura E, Netto G, et al. Liver transplant-associated graft-versus-host disease. Transplantation 2003; 75:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/8\">",
"      Bo��dys H, Pageaux GP, Larrey D, Michel H. [Evolution of cutaneous changes observed in cirrhosis patients before and after liver transplantation]. Pol Arch Med Wewn 1993; 89:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/9\">",
"      Reggiani M, Pauluzzi P, Bellusci R, et al. [Dermatologic problems in patients undergoing liver transplantation]. G Ital Dermatol Venereol 1989; 124:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/10\">",
"      Stoller JK, Moodie D, Schiavone WA, et al. Reduction of intrapulmonary shunt and resolution of digital clubbing associated with primary biliary cirrhosis after liver transplantation. Hepatology 1990; 11:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/11\">",
"      Marinho RT, Perdigoto R. Images in hepatology. Reversible nail changes in primary biliary cirrhosis after liver transplantation. J Hepatol 1999; 30:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/12\">",
"      Sale GE. Alopecia in liver transplant recipients. Br J Dermatol 1997; 136:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/13\">",
"      Misciali C, Peluso AM, Cameli N, Tosti A. Occurrence of alopecia areata in a patient receiving systemic cyclosporine A. Arch Dermatol 1996; 132:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/14\">",
"      Monti M, Barbareschi M, Caputo R. Alopecia universalis in liver transplant patients treated with cyclosporin. Br J Dermatol 1995; 133:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/15\">",
"      Rodriguez Rilo HL, Subbotin VM, Selby RR, Thomson AW. Rapid hair regrowth in refractory alopecia universalis associated with autoimmune disease following liver transplantation and tacrolimus (FK506) therapy. Transplantation 1995; 59:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/16\">",
"      Sallie R, Chiyende J, Tan KC, et al. Fulminant hepatic failure resulting from coexistent Wilson's disease and hepatitis E. Gut 1994; 35:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/17\">",
"      Buckley DA, Higgins EM, du Vivier AW. Resolution of xanthomas in Alagille syndrome after liver transplantation. Pediatr Dermatol 1998; 15:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/18\">",
"      Peters MG, Hoffnagle JH, McGarvey C, et al. Primary biliary cirrhosis: management of an unusual case with severe xanthomata by hepatic transplantation. J Clin Gastroenterol 1989; 11:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/19\">",
"      Schmidt HH, Manns MP. Images in hepatology. Regression of xanthelasmas in a patient with primary biliary cirrhosis after liver transplantation. J Hepatol 1998; 28:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/20\">",
"      Duvoux C, Tran Ngoc A, Intrator L, et al. Hepatitis C virus (HCV)-related cryoglobulinemia after liver transplantation for HCV cirrhosis. Transpl Int 2002; 15:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/21\">",
"      Pham TH, Kaushik S, Lin BP, Jones DB. Case report: acanthosis nigricans in association with primary biliary cirrhosis: resolution after liver transplantation. J Gastroenterol Hepatol 1996; 11:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/22\">",
"      Schoenberger M, Ellis PP. Disappearance of Kayser-Fleischer rings after liver transplantation. Arch Ophthalmol 1979; 97:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/23\">",
"      Oleaga JM, Gardeazabal J, Sanz de Galdeano C, Diaz PJ. Generalized lichen planus associated with primary biliar cirrhosis which resolved after liver transplantation. Acta Derm Venereol 1995; 75:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/24\">",
"      Bastani B, Mistry BM, Nahass GT, et al. Oxalate kinetics and reversal of the complications after orthotopic liver transplantation in a patient with primary hyperoxalosis type 1 awaiting renal transplantation. Am J Nephrol 1999; 19:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/25\">",
"      O'Riordan K, Blei A, Rao MS, Abecassis M. alpha 1-antitrypsin deficiency-associated panniculitis: resolution with intravenous alpha 1-antitrypsin administration and liver transplantation. Transplantation 1997; 63:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/26\">",
"      Polson RJ, Lim CK, Rolles K, et al. The effect of liver transplantation in a 13-year-old boy with erythropoietic protoporphyria. Transplantation 1988; 46:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/27\">",
"      Mion FB, Faure JL, Berger F, et al. Liver transplantation for erythropoietic protoporphyria. Report of a new case with subsequent medium-term follow-up. J Hepatol 1992; 16:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/28\">",
"      Steinm&uuml;ller T, Doss MO, Steffen R, et al. [Liver transplantation in erythrohepatic protoporphyria]. Dtsch Med Wochenschr 1992; 117:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/29\">",
"      Bloomer JR, Weimer MK, Bossenmaier IC, et al. Liver transplantation in a patient with protoporphyria. Gastroenterology 1989; 97:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/30\">",
"      Gournay J, Ferrell LD, Roberts JP, et al. Cryoglobulinemia presenting after liver transplantation. Gastroenterology 1996; 110:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/31\">",
"      Safadi R, Shouval D, E'id A, et al. Hepatitis-C-associated cryoglobulinemia after liver transplantation. Transplant Proc 1997; 29:2684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/32\">",
"      Safadi R, Shouval D, Tur-Kaspa R, et al. Beneficial effect of ribavirin on hepatitis C-associated cryoglobulinemia after liver transplantation. Liver Transpl Surg 1996; 2:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/33\">",
"      Lerut J, Golder S, Mahler F. Improvement of Raynaud's phenomenon after liver transplantation for end-stage primary biliary cirrhosis. Hepatogastroenterology 1995; 42:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/34\">",
"      Meerman L, Haagsma EB, Gouw AS, et al. Long-term follow-up after liver transplantation for erythropoietic protoporphyria. Eur J Gastroenterol Hepatol 1999; 11:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/35\">",
"      Abrahamian GA, Cosimi AB, Farrell ML, et al. Prevalence of hepatitis C virus-associated mixed cryoglobulinemia after liver transplantation. Liver Transpl 2000; 6:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/36\">",
"      McGuire BM, Bonkovsky HL, Carithers RL Jr, et al. Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl 2005; 11:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/37\">",
"      Higgins EM, du Vivier AW. Cutaneous disease and alcohol misuse. Br Med Bull 1994; 50:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/38\">",
"      Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999; 135:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/39\">",
"      Gupta MA, Schork NJ, Gupta AK, Ellis CN. Alcohol intake and treatment responsiveness of psoriasis: a prospective study. J Am Acad Dermatol 1993; 28:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/40\">",
"      Gilbert SC, Klintmalm G, Menter A, Silverman A. Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. A word of caution in light of the expanding use of this 'steroid-sparing' agent. Arch Intern Med 1990; 150:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/41\">",
"      Yamamoto T, Katayama I, Nishioka K. Psoriasis and hepatitis C virus. Acta Derm Venereol 1995; 75:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/42\">",
"      Taglione E, Vatteroni ML, Martini P, et al. Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol 1999; 26:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/43\">",
"      Jegasothy BV, Ackerman CD, Todo S, et al. Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992; 128:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/44\">",
"      Meinardi MM, Westerhof W, Bos JD. Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A. Br J Dermatol 1987; 116:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/45\">",
"      Seung LM, Lorincz AL. Incidence of acute renal transplant rejection in atopic individuals. Arch Dermatol 1994; 130:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/46\">",
"      Jain AB, Yee LD, Nalesnik MA, et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998; 66:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/47\">",
"      Jonas S, Rayes N, Neumann U, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997; 80:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/48\">",
"      Kelly DM, Emre S, Guy SR, et al. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer 1998; 83:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/49\">",
"      Levy M, Backman L, Husberg B, et al. De novo malignancy following liver transplantation: a single-center study. Transplant Proc 1993; 25:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/50\">",
"      Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 1996; 2:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/51\">",
"      Sheil AG, Disney AP, Mathew TH, et al. Cancer development in cadaveric donor renal allograft recipients treated with azathioprine (AZA) or cyclosporine (CyA) or AZA/CyA. Transplant Proc 1991; 23:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/52\">",
"      Frezza EE, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997; 44:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/53\">",
"      Christiansen TN, Freije JE, Neuburg M, Roza A. Cutaneous squamous cell carcinoma metastatic to the parotid gland in a transplant patient. Clin Transplant 1996; 10:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/54\">",
"      McGregor JM, Yu CC, Lu QL, et al. Posttransplant cutaneous lymphoma. J Am Acad Dermatol 1993; 29:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/55\">",
"      L&eacute;v&ecirc;que L, Dalac S, Dompmartin A, et al. [Melanoma in organ transplant patients]. Ann Dermatol Venereol 2000; 127:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/56\">",
"      Elder GJ, Hersey P, Branley P. Remission of transplanted melanoma--clinical course and tumour cell characterisation. Clin Transplant 1997; 11:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/57\">",
"      Rezeig MA, Fashir BM, Hainau B, Al Ashgar HI. Kaposi's sarcoma in liver transplant recipients on FK506: two case reports. Transplantation 1997; 63:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/58\">",
"      Halmos O, Inturri P, Galligioni A, et al. Two cases of Kaposi's sarcoma in renal and liver transplant recipients treated with interferon. Clin Transplant 1996; 10:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/59\">",
"      Colina F, L&oacute;pez-R&iacute;os F, Lumbreras C, et al. Kaposi's sarcoma developing in a liver graft. Transplantation 1996; 61:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/60\">",
"      Besnard V, Euvrard S, Kanitakis J, et al. Kaposi's sarcoma after liver transplantation. Dermatology 1996; 193:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/61\">",
"      Alkan S, Karcher DS, Ortiz A, et al. Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus in organ transplant patients with immunosuppression. Br J Haematol 1997; 96:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/62\">",
"      Bismuth H, Samuel D, Venancie PY, et al. Development of Kaposi's sarcoma in liver transplant recipients: characteristics, management, and outcome. Transplant Proc 1991; 23:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/63\">",
"      Hertzler G, Gordon SM, Piratzky J, et al. Case report: fulminant Kaposi's sarcoma after orthotopic liver transplantation. Am J Med Sci 1995; 309:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/64\">",
"      Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001; 34:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/65\">",
"      Mithoefer AB, Supran S, Freeman RB. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl 2002; 8:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/66\">",
"      Otley CC, Pittelkow MR. Skin cancer in liver transplant recipients. Liver Transpl 2000; 6:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/67\">",
"      Matin RN, Mesher D, Proby CM, et al. Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases. Am J Transplant 2008; 8:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/68\">",
"      Elenitsas R, Cohen BA. Generalized eruption in a liver transplant patient. CMV. Arch Dermatol 1990; 126:1498, 1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/69\">",
"      Patterson JW, Broecker AH, Kornstein MJ, Mills AS. Cutaneous cytomegalovirus infection in a liver transplant patient. Diagnosis by in situ DNA hybridization. Am J Dermatopathol 1988; 10:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/70\">",
"      Itin PH. Oral hairy leukoplakia--10 years on. Dermatology 1993; 187:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/71\">",
"      Eisenberg E, Krutchkoff D, Yamase H. Incidental oral hairy leukoplakia in immunocompetent persons. A report of two cases. Oral Surg Oral Med Oral Pathol 1992; 74:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/72\">",
"      Tomlanovich SJ, Sabatte-Caspillo J, Melzer J, et al. The incidence and impact of herpes simplex virus infections in the first month following renal transplantation. Transplant Proc 1989; 21:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/73\">",
"      Euvrard S. [Infectious cutaneous pathology after organ transplantation]. Ann Dermatol Venereol 1998; 125:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/74\">",
"      Coelho JC, Wiederkehr JC, Campos AC, et al. [Acute pancreatitis caused by varicella-zoster virus after liver transplantation]. J Chir (Paris) 1994; 131:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/75\">",
"      Barr BB, Benton EC, McLaren K, et al. Papillomavirus infection and skin cancer in renal allograft recipients. Lancet 1989; 2:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/76\">",
"      Euvrard S, Chardonnet Y, Pouteil-Noble C, et al. Association of skin malignancies with various and multiple carcinogenic and noncarcinogenic human papillomaviruses in renal transplant recipients. Cancer 1993; 72:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/77\">",
"      Boxman IL, Berkhout RJ, Mulder LH, et al. Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 1997; 108:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/78\">",
"      Patel R, Roberts GD, Keating MR, Paya CV. Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis 1994; 19:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/79\">",
"      Raby N, Forbes G, Williams R. Nocardia infection in patients with liver transplants or chronic liver disease: radiologic findings. Radiology 1990; 174:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/80\">",
"      Forbes GM, Harvey FA, Philpott-Howard JN, et al. Nocardiosis in liver transplantation: variation in presentation, diagnosis and therapy. J Infect 1990; 20:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/81\">",
"      Larson AM, Chan GC, Wartelle CF, et al. Infection complicating percutaneous liver biopsy in liver transplant recipients. Hepatology 1997; 26:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/82\">",
"      Euvrard S, Katinakis J, Chouvet B, et al. Botryomycose cutan&eacute;e staphylococcique chez un enfant greff&eacute; r&eacute;nal. Nouv Dermatol 1996; 15:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/83\">",
"      Strauss G, Mogensen AM, Rasmussen A, Kirkegaard P. Staphylococcal scalded skin syndrome in a liver transplant patient. Liver Transpl Surg 1997; 3:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/84\">",
"      Petersen LR, Mead RH, Perlroth MG. Unusual manifestations of secondary syphilis occurring after orthotopic liver transplantation. Am J Med 1983; 75:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/85\">",
"      Radentz WH. Opportunistic fungal infections in immunocompromised hosts. J Am Acad Dermatol 1989; 20:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/86\">",
"      Foulet F, Duvoux C, de Bi&egrave;vre C, et al. Cutaneous phaeohyphomycosis caused by Veronaea bothryosa in a liver transplant recipient successfully treated with itraconazole. Clin Infect Dis 1999; 29:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/87\">",
"      Laumaill&eacute; C, Le Gall F, Degeilh B, et al. [Cutaneous Alternaria infectoria infection after liver transplantation]. Ann Pathol 1998; 18:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/88\">",
"      Carpenter CF, Subramanian AK. Images in clinical medicine. Cutaneous zygomycosis (Mucormycosis). N Engl J Med 1999; 341:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/89\">",
"      Woods SG, Elewski BE. Zosteriform zygomycosis. J Am Acad Dermatol 1995; 32:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/90\">",
"      Singh N, Rihs JD, Gayowski T, Yu VL. Cutaneous cryptococcosis mimicking bacterial cellulitis in a liver transplant recipient: case report and review in solid organ transplant recipients. Clin Transplant 1994; 8:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/91\">",
"      Redondo-Bell&oacute;n P, Idoate M, Rubio M, Ignacio Herrero J. Chromoblastomycosis produced by Aureobasidium pullulans in an immunosuppressed patient. Arch Dermatol 1997; 133:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/92\">",
"      Stiller MJ, Teperman L, Rosenthal SA, et al. Primary cutaneous infection by Aspergillus ustus in a 62-year-old liver transplant recipient. J Am Acad Dermatol 1994; 31:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/93\">",
"      Le Conte P, Blanloeil Y, Michel P, et al. Cutaneous aspergillosis in a patient with orthotopic hepatic transplantation. Transplantation 1992; 53:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/94\">",
"      Benedict LM, Kusne S, Torre-Cisneros J, Hunt SJ. Primary cutaneous fungal infection after solid-organ transplantation: report of five cases and review. Clin Infect Dis 1992; 15:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/95\">",
"      Rela M, Heaton ND, Vougas V, et al. Gangrene of the anterior abdominal wall after orthotopic liver transplantation: invasive cutaneous candidiasis. Postgrad Med J 1993; 69:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/96\">",
"      Repiso T, Martin N, Huguet P, et al. Cutaneous alternariosis in a liver transplant recipient. Clin Infect Dis 1993; 16:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/97\">",
"      King D, Cheever LW, Hood A, et al. Primary invasive cutaneous Microsporum canis infections in immunocompromised patients. J Clin Microbiol 1996; 34:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/98\">",
"      Lugo-Janer G, S&aacute;nchez JL, Santiago-Delpin E. Prevalence and clinical spectrum of skin diseases in kidney transplant recipients. J Am Acad Dermatol 1991; 24:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/99\">",
"      Nathan DL, Singh S, Kestenbaum TM, Casparian JM. Cutaneous Mycobacterium chelonae in a liver transplant patient. J Am Acad Dermatol 2000; 43:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/100\">",
"      Hunger RE, Paredes BE, Quattroppani C, et al. Primary cutaneous cryptococcosis in a patient with systemic immunosuppression after liver transplantation. Dermatology 2000; 200:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/101\">",
"      Bissig KD, Zimmermann A, Bernasch D, et al. Herpes simplex virus hepatitis 4 years after liver transplantation. J Gastroenterol 2003; 38:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/102\">",
"      Bonatti H, Mendez J, Guerrero I, et al. Disseminated Bartonella infection following liver transplantation. Transpl Int 2006; 19:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/103\">",
"      Luque P, Garc&iacute;a-Gil FA, Larraga J, et al. Treatment of cutaneous infection by Alternaria alternata with voriconazole in a liver transplant patient. Transplant Proc 2006; 38:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/104\">",
"      Van Schooneveld T, Freifeld A, Lesiak B, et al. Paecilomyces lilacinus infection in a liver transplant patient: case report and review of the literature. Transpl Infect Dis 2008; 10:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/105\">",
"      Garrison AP, Procop GW, Vincek V, et al. A case of subcutaneous Mycoleptodiscus indicus infection in a liver transplant recipient successfully treated with antifungal therapy. Transpl Infect Dis 2008; 10:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/106\">",
"      Parra IH, Galimberti R, Galimberti G, et al. Lymphocutaneous nocardiosis and cutaneous pheohyphomycosis in a liver transplant recipient. Int J Dermatol 2008; 47:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/107\">",
"      Halpern M, Balbi E, Carius L, et al. Cellulitis and nodular skin lesions due to Fusarium spp in liver transplant: case report. Transplant Proc 2010; 42:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/108\">",
"      Lau SK, Curreem SO, Ngan AH, et al. First report of disseminated Mycobacterium skin infections in two liver transplant recipients and rapid diagnosis by hsp65 gene sequencing. J Clin Microbiol 2011; 49:3733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/109\">",
"      Psarros G, Riddell J 4th, Gandhi T, et al. Bartonella henselae infections in solid organ transplant recipients: report of 5 cases and review of the literature. Medicine (Baltimore) 2012; 91:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/110\">",
"      Thorp M, DeMattos A, Bennett W, et al. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. Transplantation 2000; 69:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/111\">",
"      Reyes J, Jain A, Mazariegos G, et al. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. Transplantation 2000; 69:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/112\">",
"      Hasenbein W, Albani J, Englert C, et al. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation. Pediatr Transplant 2006; 10:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/113\">",
"      Schaffellner S, Jakoby E, Kniepeiss D, et al. Center experience in liver transplantation (LTX): management of dermal side effects caused by sirolimus. Int Immunopharmacol 2005; 5:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/114\">",
"      L&uuml;bbe J, Sorg O, Mal&eacute; PJ, et al. Sirolimus-induced inflammatory papules with acquired reactive perforating collagenosis. Dermatology 2008; 216:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/115\">",
"      Tracey C, Hawley C, Griffin AD, et al. Generalized, pruritic, ulcerating maculopapular rash necessitating cessation of sirolimus in a liver transplantation patient. Liver Transpl 2005; 11:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/116\">",
"      Jucgl&agrave; A, Sais G, Curco N, et al. Calcinosis cutis following liver transplantation: a complication of intravenous calcium administration. Br J Dermatol 1995; 132:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/117\">",
"      Hern&aacute;ndez-Cano N, De Lucas R, L&aacute;zaro TE, et al. Erythema elevatum diutinum after liver transplantation: disappearance of the lesions associated with a reduction in cyclosporin dosage. Pediatr Dermatol 1998; 15:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/118\">",
"      Sheth AP, Esterly NB, Rabinowitz LG, Poh-Fitzpatrick MB. Cutaneous porphyrialike photosensitivity after liver transplantation. Arch Dermatol 1994; 130:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/119\">",
"      Blemker AL, Dean RA, Weaver DC, et al. Transient porphyrinemia in a liver transplant recipient. Arch Dermatol 1991; 127:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/120\">",
"      Kanitakis J, Euvrard S, Faure M, Claudy A. Porokeratosis and immunosuppression. Eur J Dermatol 1998; 8:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/121\">",
"      Raychaudhuri SP, Smoller BR. Porokeratosis in immunosuppressed and nonimmunosuppressed patients. Int J Dermatol 1992; 31:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/122\">",
"      Bencini PL, Tarantino A, Grimalt R, et al. Porokeratosis and immunosuppression. Br J Dermatol 1995; 132:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/123\">",
"      Kettner SC, Gonano C, Seebach F, et al. Endogenous heparin-like substances significantly impair coagulation in patients undergoing orthotopic liver transplantation. Anesth Analg 1998; 86:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/124\">",
"      Singh N, Gayowski T, Yu VL. Herpes zoster-associated idiopathic thrombocytopenic purpura in a liver transplant recipient: a case report and overview. Transpl Int 1995; 8:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/125\">",
"      Assy N, Rosenthal E, Hazani A, et al. Human parvovirus B19 infection associated with idiopathic thrombocytopenic purpura in a child following liver transplantation. J Hepatol 1997; 27:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/126\">",
"      Yoshida EM, Mandl LA, Erb SR, et al. Idiopathic thrombocytopenic purpura in a liver transplant recipient with previous primary biliary cirrhosis. J Clin Gastroenterol 1997; 24:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/127\">",
"      Fickert P, Trauner M, Sill H, et al. Successful steroid treatment of idiopathic thrombocytopenic purpura after orthotopic liver transplantation for primary biliary cirrhosis. Am J Gastroenterol 1998; 93:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/128\">",
"      Takatsuki M, Uemoto S, Kurokawa T, et al. Idiopathic thrombocytopenic purpura after a living-related liver transplantation. Transplantation 1999; 67:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/129\">",
"      Holman MJ, Gonwa TA, Cooper B, et al. FK506-associated thrombotic thrombocytopenic purpura. Transplantation 1993; 55:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/130\">",
"      Burdick JF, Vogelsang GB, Smith WJ, et al. Severe graft-versus-host disease in a liver-transplant recipient. N Engl J Med 1988; 318:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/131\">",
"      Pageaux GP, Perrigault PF, Fabre JM, et al. Lethal acute graft-versus-host disease in a liver transplant recipient: relations with cell migration and chimerism. Clin Transplant 1995; 9:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/132\">",
"      Neumann UP, Kaisers U, Langrehr JM, et al. Fatal graft-versus-host-disease: a grave complication after orthotopic liver transplantation. Transplant Proc 1994; 26:3616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/133\">",
"      Schmuth M, Vogel W, Weinlich G, et al. Cutaneous lesions as the presenting sign of acute graft-versus-host disease following liver transplantation. Br J Dermatol 1999; 141:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/134\">",
"      Derancourt C, Senser M, Atallah L, et al. [Granuloma annulare of the photoexposed areas in two liver transplant recipients]. Ann Dermatol Venereol 2000; 127:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/135\">",
"      Lateo S, Charlton F, Hudson M, Lawrence CM. Cutaneous calcification following liver transplantation. Clin Exp Dermatol 2005; 30:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/136\">",
"      Neau-Cransac M, Lepreux S, Labreze C, et al. Uncommon localization of calcinosis cutis after liver transplantation. Dermatology 2005; 211:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/137\">",
"      Meves A, el-Azhary RA, Talwalkar JA, et al. Acute graft-versus-host disease after liver transplantation diagnosed by fluorescent in situ hybridization testing of skin biopsy specimens. J Am Acad Dermatol 2006; 55:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23273/abstract/138\">",
"      Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007; 157 Suppl 2:25.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4594 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_46_23273=[""].join("\n");
var outline_f22_46_23273=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H155947760\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Conditions related to the underlying liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Conditions unrelated to the underlying liver disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Psoriasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Atopic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MUCOCUTANEOUS COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dermatologic infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Drug-induced",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H155947760\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4594\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4594|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/58/43951\" title=\"figure 1\">",
"      Clubbing of the fingers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4594|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/58/36770\" title=\"picture 1\">",
"      Dupuytrens contracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/0/18439\" title=\"picture 2\">",
"      Alopecia areata 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/31/35312\" title=\"picture 3\">",
"      Vitiligo - elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/54/37730\" title=\"picture 4\">",
"      Vitiligo - hands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/14/23778\" title=\"picture 5\">",
"      Xanthelasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/11/22709\" title=\"picture 6\">",
"      Lichen planus hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/42/29346\" title=\"picture 7\">",
"      Lichen planus wrists fair skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/55/40831\" title=\"picture 8\">",
"      Plaque type psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/20/38212\" title=\"picture 9\">",
"      Psoriasis legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/56/7045\" title=\"picture 10\">",
"      Atopic dermatitis antecubit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/62/35812\" title=\"picture 11\">",
"      Superficial basal cell CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/61/18389\" title=\"picture 12\">",
"      Melanoma- superficial spreading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/55/41840\" title=\"picture 13\">",
"      Herpes zoster OLT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/27/15792\" title=\"picture 14\">",
"      Cutaneous aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/0/29697\" title=\"picture 15\">",
"      Multiple verrucae OLT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/30/13794\" title=\"picture 16\">",
"      Porphyria cutanea tarda",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/19/26932\" title=\"picture 17\">",
"      Actinic keratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/2/18464\" title=\"picture 18\">",
"      Leukoplakia - buccal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/48/36608\" title=\"picture 19\">",
"      Leukoplakia - palate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/39/2675\" title=\"picture 20\">",
"      Leukoplakia - tongue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4594|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/12/17613\" title=\"table 1\">",
"      History skin lesions after OLT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/3/42044\" title=\"table 2\">",
"      Skin tumors after OLT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/62/38891\" title=\"table 3\">",
"      Bacterial skin infections OLT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/3/13372\" title=\"table 4\">",
"      Viral skin infections after OLT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/55/23420\" title=\"table 5\">",
"      Fungal skin infections OLT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/48/21259\" title=\"table 6\">",
"      Drug-induced skin disorders OLT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/26/26028\" title=\"table 7\">",
"      Misc dermatologic disorders OLT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=related_link\">",
"      Infectious complications in liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=related_link\">",
"      Long-term management of adult liver transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33447?source=related_link\">",
"      Selection of sunscreen and sun-protective measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16713?source=related_link\">",
"      Skin examination and clinical features of melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_46_23274="Allergy to penicillins";
var content_f22_46_23274=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Allergy to penicillins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/46/23274/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/46/23274/contributors\">",
"     Roland Solensky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/46/23274/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/46/23274/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/46/23274/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/46/23274/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/46/23274/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin is the most commonly reported medication allergy, and in all of its forms is self-reported by about 5 to 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, in large-scale studies of penicillin skin testing, approximately 85 to 90 percent of these individuals are found not to have positive skin tests and are able to tolerate penicillins [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ]. In addition, the prevalence of IgE-mediated penicillin allergy, the type of allergy which can involve life-threatening anaphylaxis, appears to have declined over the last two decades based on the rate of positive penicillin skin tests [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, risk factors, diagnosis, and management of the most common types of reactions to penicillins will be discussed here. The procedure for skin testing to penicillins, as well as the use of structurally-related antibiotics in patients with past reactions to penicillins is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=see_link\">",
"     \"Penicillin skin testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=see_link\">",
"     \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A drug allergic (or hypersensitivity) reaction is defined as a specific immunologic reaction to a drug. The classification and pathogenesis of drug allergies are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=see_link\">",
"     \"Drug allergy: Classification and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=see_link\">",
"     \"Drug allergy: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Penicillins can cause any of the four types of Gell and Coombs immunologic hypersensitivity reactions (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"     table 1",
"    </a>",
"    ), although IgE-mediated reactions (type I) and delayed cutaneous reactions (mostly type IV) are most commonly encountered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3592171\">",
"    <span class=\"h2\">",
"     Immediate versus delayed reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Allergy Organization (WAO) has recommended categorizing immunologic drug reactions based upon the timing of the appearance of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/9\">",
"     9",
"    </a>",
"    ]. This system defines two general types of reactions: immediate and delayed. This approach is intended to distinguish IgE-mediated (type I reactions), which account for many immediate reactions, from other types, because these reactions carry the risk of life-threatening anaphylaxis if the patient is reexposed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate reactions classically begin within one hour of the first administered dose and may begin within minutes. However, some IgE-mediated reactions appear after one hour, particularly if the drug was administered orally. Taking the medication with food may further slow absorption. Nevertheless, this period of one hour identifies many of these reactions. When allergic sensitization first develops, the initial symptoms may appear during the latter days of treatment (ie, not following first dose of the course), but usually within an hour of a dose, and then escalate rapidly.",
"     </li>",
"     <li>",
"      Delayed reactions appear after multiple doses of treatment, typically after days or weeks of administration. Most delayed reactions begin after six hours and typically after days of treatment. As an example, delayed reactions to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      classically start on day 7 to 10 of treatment, and may even begin 1 to 3 days after cessation of treatment. These reactions may be caused by several different mechanisms, but they are not IgE-mediated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1965026\">",
"    <span class=\"h1\">",
"     IMMEDIATE REACTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1965034\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many immediate reactions are Type I, IgE-mediated reactions. This type of reaction presents with various combinations of pruritus, flushing, urticaria, angioedema, wheezing, laryngeal edema, abdominal distress with emesis or diarrhea, and hypotension. The full spectrum of signs and symptoms possible with IgE-mediated reactions is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"UTD.htm?20/36/21068\">",
"     table 2",
"    </a>",
"    ). The urticarial lesions associated with IgE-mediated reactions are composed of intensely pruritic, raised, red plaques, which appear in one area, resolve over the course of hours, and then reappear elsewhere (",
"    <a class=\"graphic graphic_picture graphicRef72519 \" href=\"UTD.htm?29/2/29728\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191336\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;No studies have prospectively evaluated the rates at which patients become sensitized (ie, develop penicillin-specific IgE) during penicillin treatment, and statistics about mild immediate reactions are sparse. However, data are available about anaphylaxis, which may be defined as a severe allergic reaction that is rapid in onset and may cause death, and is the most severe form of immediate reaction (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"UTD.htm?20/36/21068\">",
"     table 2",
"    </a>",
"    ). Penicillin-induced anaphylaxis is uncommon, occurring with an incidence of between one and four episodes per 10,000 administrations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. The diagnosis and treatment of anaphylaxis, from all causes, is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1965552\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with immediate reactions may become allergic to the core ring structure that is common to all penicillins, or, much less commonly, to an epitope which includes the R-group side chains that distinguish different penicillins from one another. The portion of the molecule to which the patient has made IgE antibodies determines patterns of cross-reactivity with other related drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1965559\">",
"    <span class=\"h3\">",
"     Allergenic beta-lactam structures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most allergic patients, the principal immune response is directed against a new antigenic determinant formed after the core beta-lactam ring structure combines with lysine residues in proteins. Under physiologic conditions, penicillins spontaneously degrade to a number of reactive intermediates that act as haptens and covalently bind to tissue and serum proteins. These complexes of proteins and drug intermediates may elicit various immune responses, including the production of specific IgE antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. About 95 percent of penicillin degrades to the penicilloyl moiety, which is referred to as the \"major antigenic determinant\" (",
"    <a class=\"graphic graphic_figure graphicRef67647 \" href=\"UTD.htm?6/58/7086\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The remaining portion of penicillin degrades to several other derivatives, of which penicilloate and penilloate are the most important in inducing allergic responses (",
"    <a class=\"graphic graphic_figure graphicRef67647 \" href=\"UTD.htm?6/58/7086\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/13\">",
"     13",
"    </a>",
"    ]. Penicilloate and penilloate are called \"minor antigenic determinants.\" Penicillin itself is also considered a minor antigenic determinant, since it is required in skin testing to detect all IgE penicillin antibodies. Although called minor determinants because they are formed less frequently than penicilloyl antigens, they may provoke severe allergic responses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=see_link&amp;anchor=H27040356#H27040356\">",
"     \"Penicillin skin testing\", section on 'Skin testing reagents and concentrations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1965566\">",
"    <span class=\"h3\">",
"     Side chain specific reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients form IgE antibodies which can recognize the R-group side chains rather than the core ring structure. These individuals develop immediate-type reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    but are able to tolerate penicillin, and are said to be selectively allergic to these aminopenicillins [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, selective IgE-mediated allergy to the aminopenicillins appears to be uncommon. In one medical center, 1429 patients with a history of reactions to penicillins underwent skin testing with the major and minor antigenic determinants,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      . Less than one percent (0.35 percent) were selectively allergic to amoxicillin [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Using a similar protocol, two other US centers reported comparable findings of patients selectively skin test-positive to aminopenicillins &ndash; 2 of 1754 (0.11 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/20\">",
"       20",
"      </a>",
"      ] and 14 of 1068 (1.3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/21\">",
"       21",
"      </a>",
"      ]. The largest experience in the US is 5006 patients evaluated in similar fashion at a large",
"      <span class=\"nowrap\">",
"       allergy/immunology",
"      </span>",
"      practice, and only 7 (0.14 percent) were selectively allergic to aminopenicillins [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/22\">",
"       22",
"      </a>",
"      ]. The diagnosis of selective allergy to aminopenicillins using skin testing is described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=see_link&amp;anchor=H22605979#H22605979\">",
"       \"Penicillin skin testing\", section on 'Aminopenicillins'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The experience from southern Europe is different, in that a third or more of patients are selectively sensitive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      based upon skin testing [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. The reasons for this are not known, although amoxicillin is available without a prescription in some European countries, and accounts for a sizeable majority of all antibiotic use.",
"     </li>",
"     <li>",
"      Side-chain specific sensitization to anti-pseudomonal penicillins has been observed among patients with cystic fibrosis, who often receive frequent high-dose parenteral courses of semisynthetic penicillins [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Finally, patients who reacted to the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    may be allergic to clavulanate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Clavulanate allergy can be diagnosed with skin testing to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    and clavulanate separately, as reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=see_link&amp;anchor=H667452#H667452\">",
"     \"Penicillin skin testing\", section on 'Clavulanate testing in patient reactive to amoxicillin/clavulanate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1966521\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of risk factors have been identified for the development of immediate reactions to penicillin and antibiotic in general:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Age",
"      </strong>",
"      &mdash; Patients between the ages of 20 and 49 appear to be at greatest risk of having immediate allergic (particularly anaphylactic) reactions to penicillin [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/10\">",
"       10",
"      </a>",
"      ]. This observation may reflect age-dependent differences in immune responses to medications or may be an artifact related to usage patterns.",
"     </li>",
"     <li>",
"      <strong>",
"       Frequency and route of administration",
"      </strong>",
"      &mdash; Frequent, repeated courses of the penicillin favor the development of allergic sensitization [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/28\">",
"       28",
"      </a>",
"      ]. The route of administration of antigens is also important in determining the type of immune response generated [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/29\">",
"       29",
"      </a>",
"      ]. Topically applied penicillin is highly sensitizing and for that reason has not been in clinical use for decades. Penicillin administration via the parenteral route seems to be more sensitizing for the development of type I allergies compared to oral administration, and it is also most likely to result in anaphylaxis (in sensitized individuals). The vast majority of anaphylactic deaths have occurred in patients treated with intramuscular or intravenous, rather than oral, penicillin preparations [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/10\">",
"       10",
"      </a>",
"      ]. Dose may also be a factor in such cases, since parenteral doses are often higher than those administered orally.",
"      <br/>",
"      <br/>",
"      Theories about frequency and route of administration have never been studied in a prospective fashion, although they are supported by the observation that patients with cystic fibrosis (who require frequent treatment with intravenous antibiotics) are particularly prone to developing IgE-mediated antibiotic allergies [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Multiple drug allergy syndrome",
"      </strong>",
"      &mdash; The term multiple drug allergy syndrome may be assigned to individuals who have experienced allergic reactions (either IgE- or non-IgE-mediated) to two or more non-cross-reacting medications. A number of studies support the theory that patients who develop an allergy to one medication are more likely to react to a second unrelated compound [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/31-36\">",
"       31-36",
"      </a>",
"      ]. Hence, patients who have experienced allergic reactions to drugs other than penicillins are probably at increased risk of reacting to penicillins. The reasons why certain patients have a heightened propensity to generate allergic reactions to drugs have not been identified, but could include genetic as well as exposure factors.",
"     </li>",
"     <li>",
"      <strong>",
"       Hereditary factors",
"      </strong>",
"      &mdash; Genetic factors may play a role in the expression of penicillin and other antibiotic allergies, but the evidence is limited. In the Chinese population, particular HLA-DRB genotypes were found to be associated with IgE-mediated penicillin allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/37\">",
"       37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Other evidence for the involvement of genetic factors is derived from retrospective, survey-based studies [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]. For example, children of parents who reported an antibiotic allergy were 15 times more likely to be antibiotic-allergic (by history) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/38\">",
"       38",
"      </a>",
"      ]. Similarly, surveyed patients with a history of antibiotic allergy were nine times more likely to report a family history of drug allergy among first-degree relatives [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/39\">",
"       39",
"      </a>",
"      ]. However, the results of survey-based studies are limited by a reliance on patient history (which is known to be a poor predictor of drug allergy) and by lack of confirmatory testing or provocative challenges.",
"     </li>",
"     <li>",
"      <strong>",
"       Other allergic diseases",
"      </strong>",
"      &mdash; Patients with other allergic diseases (or a family history of allergic disease) seem to become sensitized (ie, develop drug-specific IgE) to penicillin at the",
"      <strong>",
"       same",
"      </strong>",
"      rate as other people [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/6,10,41-43\">",
"       6,10,41-43",
"      </a>",
"      ]. However, once sensitized, patients with asthma (in particular) are at greater risk for serious reactions and anaphylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1966255\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of immediate reactions to penicillin begins with a detailed clinical history, skin testing if available, in vitro testing (in some cases), and possibly graded challenge. A general discussion of the diagnosis of drug allergy is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link\">",
"     \"An approach to the patient with drug allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1968131\">",
"    <span class=\"h2\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary purpose of the history is to assess what type of reaction the patient likely experienced in the past, and to detect severe drug reactions, such as SJS, TEN, or anaphylaxis. The history of a drug reaction should ascertain the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The timing of onset of the reaction (both from the precipitating dose, as well as from the initiation of that course of therapy)",
"     </li>",
"     <li>",
"      Each exact agent reportedly associated with a reaction, and the indication for its use",
"     </li>",
"     <li>",
"      The signs and symptoms involved, as precisely as possible",
"     </li>",
"     <li>",
"      The dose and route of medication taken (if known)",
"     </li>",
"     <li>",
"      Other concurrent medications, especially if they were new or temporary",
"     </li>",
"     <li>",
"      Any treatment given and response to that treatment (including the duration of reaction)",
"     </li>",
"     <li>",
"      Any prior or subsequent history of exposure to the same drug or structurally similar drugs, with or without reactions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is sometimes helpful to know when the various penicillins became available. Patients who report that they reacted to an injection of \"penicillin\" typically received benzylpenicillin (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    ). Penicillin VK has been used since the 1960s.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     Ampicillin",
"    </a>",
"    was developed in the early 1960s and began to be used widely in the 1970s.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     Amoxicillin",
"    </a>",
"    was developed in the early 1970s and widely used beginning in the 1980s. Other semisynthetic penicillins with targeted microbial specificities for staphylococcus and pseudomonas were introduced in the 1970s and 1980s.",
"   </p>",
"   <p>",
"    No further evaluation is needed if the reaction is clearly not allergic (eg, the patient had simple antibiotic-associated vaginitis) or the patient did not actually have a reaction (eg, family history of penicillin allergy but the patient has never taken penicillin, etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1968138\">",
"    <span class=\"h3\">",
"     Accuracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the importance of the clinical history, it has been demonstrated in several studies that the presence of IgE-mediated penicillin allergy cannot be accurately predicted based upon history alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/44-48\">",
"     44-48",
"    </a>",
"    ]. Patients with convincing reaction histories to penicillin are more likely to be allergic than patients with vague reaction histories (eg, descriptions of reactions that did NOT include pruritus,",
"    <span class=\"nowrap\">",
"     hives/angioedema,",
"    </span>",
"    bronchospasm, or anaphylaxis) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/6,43,49,50\">",
"     6,43,49,50",
"    </a>",
"    ]. However, vague or incomplete reaction histories cannot be discounted because some of those patients also have IgE-mediated allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/6,43,44,48,49\">",
"     6,43,44,48,49",
"    </a>",
"    ]. In a review of the published literature, one-third of patients with a history of penicillin allergy who were skin test-positive had vague reaction histories [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are likely multiple reasons that the clinical history is a poor predictor of current penicillin allergy. Patients may have reacted as children and know about the reaction only through parental reports, and many patients are unable to describe cutaneous symptoms in an accurate way. However, the most important factor is probably the gradual loss of penicillin IgE over time as demonstrated in prospective studies, leading in &gt;80 percent of patients to negative skin tests and safe retreatment, even in those who had serious systemic reactions in the past.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1968145\">",
"    <span class=\"h3\">",
"     Time elapsed since the reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time elapsed since the last reaction is important because penicillin-specific IgE antibodies decrease over time, and therefore patients with recent reactions are more likely to be allergic than patients with distant reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 50 percent of patients with IgE-mediated penicillin allergy have lost the sensitivity 5 years after their last reaction.",
"     </li>",
"     <li>",
"      Approximately 80 percent of patients with IgE-mediated penicillin allergy have lost the sensitivity after 10 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, because the history is often unreliable and the allergy can be lost over time, most patients who present with past reactions require further evaluation to determine if IgE-mediated penicillin allergy is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1968152\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to an allergy specialist for diagnostic testing should be considered for any patient with a history of penicillin allergy consistent with a possible IgE-mediated mechanism. Patients with a history of penicillin allergy are commonly denied treatment with all beta-lactams, and they are more likely to be treated with broad-spectrum antibiotics such as quinolones and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/1,53-57\">",
"     1,53-57",
"    </a>",
"    ]. Evaluation by an allergist for possible penicillin allergy is most important for the following patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those who report reactions to two or more classes of antibiotics, since their antimicrobial treatment choices are even more limited.",
"     </li>",
"     <li>",
"      Those who require frequent antibiotic therapy, such as for sinusitis, bronchitis, urinary tract infections, etc.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diagnostic testing is appropriate for patients with past immediate reactions, and is also useful in cases of reactions that were likely delayed but for which the history is vague or not particularly clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1968768\">",
"    <span class=\"h2\">",
"     Penicillin skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin skin testing is the preferred method of evaluation and diagnosis of immediate reactions. Penicillin skin testing is rapid, sensitive, and cost effective. Results are obtained in less than an hour with minimal patient discomfort, although this type of testing is usually performed by allergy specialists, so referral is required.",
"   </p>",
"   <p>",
"    Skin testing (sometimes called &ldquo;immediate&rdquo; skin testing) is a bioassay performed on the skin that detects the presence of allergen-specific IgE on a patient's mast cells. Patients who have drug-specific IgE detected with skin testing are at high risk for type I, IgE-mediated immediate allergic reactions, including anaphylaxis.",
"   </p>",
"   <p>",
"    It is also indicated in the evaluation of delayed cutaneous reactions that involved urticaria, as well as any reaction for which the clinical history is too vague to be meaningful. In this setting, skin testing is used to exclude immediate reactions and thus narrow the differential diagnosis.",
"   </p>",
"   <p>",
"    The indications, safety, technique, and interpretation of skin testing to penicillins and aminopenicillins are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=see_link\">",
"     \"Penicillin skin testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1968775\">",
"    <span class=\"h2\">",
"     When penicillin skin testing is not possible",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin skin testing may not be possible in all situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Penicillin skin testing requires training and knowledge to perform and interpret correctly and should be done by an allergy specialist whenever possible.",
"     </li>",
"     <li>",
"      If the skin testing reagent to the important breakdown products of penicillin (the major determinant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/56/17285?source=see_link\">",
"       penicilloyl-polylysine",
"      </a>",
"      , available in the United States as Pre-Pen",
"      <sup>",
"       &reg;",
"      </sup>",
"      , ALK-Abello) is not available, skin testing with penicillin alone lacks sufficient sensitivity and is not recommended. (See",
"      <a class=\"local\" href=\"#H1965559\">",
"       'Allergenic beta-lactam structures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If either of the above conditions is true, graded challenge is the preferred approach to diagnosis. In vitro tests are another option, but are of limited clinical utility. (See",
"    <a class=\"local\" href=\"#H1968782\">",
"     'In vitro tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Graded challenge carries more risk than skin testing (which is low risk), and should be performed only in patients who have an anticipated need for penicillins in the near future, or in those who are \"running out of options\" for antibiotic treatment. (See",
"    <a class=\"local\" href=\"#H1968789\">",
"     'Graded challenge (test dosing)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1968782\">",
"    <span class=\"h3\">",
"     In vitro tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro immunoassays (ELISA or RAST tests) for specific IgE to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/46/23269?source=see_link\">",
"     penicillin V",
"    </a>",
"    , penicilloyl,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    are commercially available, but these assays are of limited clinical use because their predictive values are not well defined. The sensitivity of in vitro tests for penicillin-specific IgE was as low as 45 percent compared to skin testing, when performed in academic settings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historically, a positive penicillin in vitro test result in the context of an appropriate reaction history was felt to suggest the presence of an IgE-mediated allergy. However, findings of a study question the utility of the available in vitro immunoassays. In a prospective series of 150 consecutive patients with a history of penicillin allergy, both skin testing and in vitro immunoCAP testing were performed, followed by oral challenge if skin test was negative [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/60\">",
"     60",
"    </a>",
"    ]. Four patients had positive in vitro tests, yet all tolerated the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    challenge, proving these tests to be false positive. There were six skin test-positive patients (none of whom were also immunoCAP positive), who were not challenged. Hence a positive commercial in vitro test is not as useful as once thought. A negative in vitro test result is also problematic because it lacks the negative predictive value of skin testing. Thus, we do not obtain in vitro immunoassays in most patients.",
"   </p>",
"   <p>",
"    The basophil activation test is another in vitro test that has been studied for diagnosis of penicillin and other beta-lactam allergies. However, the very limited number of publications available suggests that this test is also inferior to skin testing [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1968789\">",
"    <span class=\"h3\">",
"     Graded challenge (test dosing)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graded challenge, also known as test dosing, refers to cautious administration of a drug to a patient who is believed",
"    <strong>",
"     unlikely",
"    </strong>",
"    to be allergic to the medication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/63\">",
"     63",
"    </a>",
"    ]. Graded challenge does not modify the allergic response to the drug. Therefore, patients who tolerate a drug during graded challenge prove that they are not allergic. An overview of graded drug challenges is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link&amp;anchor=H30#H30\">",
"     \"An approach to the patient with drug allergy\", section on 'Graded challenge'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of penicillin skin testing, graded challenge is appropriate when the patient's likelihood of being allergic is low. Examples include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who had a non-life-threatening reaction to penicillin more than 10 years ago and have not been subsequently reexposed.",
"     </li>",
"     <li>",
"      Patients with well documented histories of a delayed-onset cutaneous eruption.",
"     </li>",
"     <li>",
"      Patients with vague reaction histories that lack any features suggestive of an IgE-mediated allergy (",
"      <a class=\"graphic graphic_table graphicRef66333 \" href=\"UTD.htm?20/36/21068\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, if a patient&rsquo;s history is vague but some element of it suggests an IgE-mediated reaction (eg, &ldquo;I think my mother said that I couldn&rsquo;t breathe&rdquo;), then the more cautious approach of performing a rapid drug desensitization is warranted (assuming skin testing is not available). (See",
"    <a class=\"local\" href=\"#H1969477\">",
"     'Desensitization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1968870\">",
"    <span class=\"h4\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most graded challenges can safely be carried out in an office without intravenous access, but with preparedness to treat potential allergic reactions including anaphylaxis. The pace of the challenge and degree of caution exercised depends on the likelihood the patient may be allergic, the patient's medical stability, and the clinician's experience and comfort level with the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link&amp;anchor=H34#H34\">",
"     \"An approach to the patient with drug allergy\", section on 'Protocols'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should",
"    <strong>",
"     not",
"    </strong>",
"    be pretreated with antihistamines or glucocorticoids because these agents may mask early signs of an allergic reaction. Treatment with beta-adrenergic-blocking medications should be withheld for 24 hours before challenge if feasible, as these medications can interfere with treatment of anaphylaxis, should a reaction occur. Patients with asthma, chronic obstructive lung disease or other pulmonary diseases should be optimally controlled prior to undergoing challenge.",
"   </p>",
"   <p>",
"    Challenges to exclude immediate reactions can be performed in a variety of ways. In low-risk patients, the starting dose is usually",
"    <span class=\"nowrap\">",
"     1/100",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     1/10",
"    </span>",
"    of the full dose. Tenfold increasing doses are administered every 30 to 60 minutes until the full therapeutic dose is reached.",
"   </p>",
"   <p>",
"    As an example, a penicillin graded challenge could be performed as follows, with doses prepared from a standard oral suspension diluted 10-fold and then 100-fold:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/46/23269?source=see_link\">",
"       Penicillin V",
"      </a>",
"      : 5 mg, 50 mg, and 500 mg given orally at 60 minute intervals",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1968877\">",
"    <span class=\"h4\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graded challenges can require experience to interpret properly. A minority of patients develop nonspecific symptoms during the procedure, which can mimic symptoms of true allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/64\">",
"     64",
"    </a>",
"    ]. Most commonly these include perioral tingling, pruritus without urticaria, throat and lip discomfort, headache, tachycardia, and nausea. These may be anxiety related, and spending time with the patient explaining the safety of challenge procedures in advance may help to reduce the incidence of these nonspecific reactions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient develops convincing signs and symptoms consistent with an immediate reaction during or shortly after the graded challenge (within a few hours of receiving the full dose), no further penicillin should be given and symptoms should be treated appropriately. These patients should be diagnosed with IgE-mediated penicillin allergy and if they require a penicillin subsequently, it should be administered via a formal desensitization. (See",
"      <a class=\"local\" href=\"#H1969477\">",
"       'Desensitization'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If only subjective symptoms are reported, repeat challenge employing placebo controls and masked observations may occasionally be warranted.",
"     </li>",
"     <li>",
"      Patients with a negative challenge may still develop delayed reactions to the drug in question, but these should not be serious. This was illustrated in a multicenter study of 118 history-positive patients who had both negative skin tests and negative challenges to beta-lactams and were subsequently treated with a beta-lactam [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/65\">",
"       65",
"      </a>",
"      ]. The negative predictive value of the evaluation was 94 percent for any type of reaction. Nine patients experienced symptoms with reexposure, all of which were mild and delayed (beginning &gt;1 hour after administration). Symptoms consisted of urticaria in five patients, exanthema in three, and one undefined cutaneous reaction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1968884\">",
"    <span class=\"h4\">",
"     Risk of resensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin resensitization is the redevelopment of penicillin-specific IgE in patients who had lost their sensitivity. Resensitization may be determined by the number of patients who convert their penicillin skin tests from negative (before the challenge) to positive (after the challenge). Another way to measure resensitization is to assess the number of patients with a history of penicillin allergy who tolerate two or more courses of penicillins, who can therefore be assumed to not have been resensitized by the initial course.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following",
"      <strong>",
"       oral",
"      </strong>",
"      administration - Using the methods just described, most studies of penicillin resensitization after oral challenge or after a single course of an oral penicillin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      showed resensitization rates between 0 and 3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/4,66-69\">",
"       4,66-69",
"      </a>",
"      ], which are comparable to the rate of primary sensitization.",
"      <br/>",
"      <br/>",
"      One study evaluated resensitization after repeated courses of oral penicillin in 53 adult patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/68\">",
"       68",
"      </a>",
"      ]. Patients with a convincing history of penicillin allergy and initially negative penicillin skin tests were challenged with three consecutive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/46/23269?source=see_link\">",
"       penicillin V",
"      </a>",
"      courses and underwent three repeat penicillin skin tests; none converted to a positive skin test during this process [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/68\">",
"       68",
"      </a>",
"      ]. Based on these data, it is not routinely necessary to repeat skin testing in a patient with past penicillin reactions who has tolerated a subsequent course of oral penicillin. Similarly, if penicillin skin testing is not available and patients with a history of penicillin allergy are given and tolerate penicillin via graded challenge, no special precautions are required for future penicillin treatment courses.",
"     </li>",
"     <li>",
"      Following",
"      <strong>",
"       IV or IM",
"      </strong>",
"      administration - Resensitization following parenteral administration of penicillin may be more common (rates of 0 to 20 percent have been reported) but these data are derived from fewer, smaller scale studies [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/70-73\">",
"       70-73",
"      </a>",
"      ]. Therefore, repeat skin testing (or cautious administration of penicillins if skin testing in not available) may be necessary for patients with a history of penicillin allergy who have tolerated a parenteral course of penicillin, or whose initial penicillin reaction was acute and severe.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1969463\">",
"    <span class=\"h2\">",
"     Options for future treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have been diagnosed with a past immediate reaction to penicillin have two options: avoidance of all penicillins (although related drugs, such as cephalosporins, may be tolerated) or treatment with penicillin using a desensitization protocol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1969470\">",
"    <span class=\"h3\">",
"     Avoidance of all penicillins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with past immediate reactions to penicillins should avoid all penicillins (ie, including the aminopenicillins and newer semisynthetic penicillins, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    ) in the future, unless an evaluation is performed to define other related medications that can be safely administered to that individual. The use of related classes of antibiotics in patients allergic to penicillins is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=see_link\">",
"     \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a patient with a past immediate reaction to penicillin absolutely requires treatment with a penicillin in the future because no other equally-effective antibiotic is available, then desensitization may be appropriate, as described in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1969477\">",
"    <span class=\"h3\">",
"     Desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug desensitization is a procedure which",
"    <strong>",
"     temporarily",
"    </strong>",
"    alters the immune response to the medication and results in short-term tolerance, allowing the patient with immediate allergy to receive an uninterrupted course of the medication safely. Drug desensitization renders mast cells unresponsive to the drug in question, although the exact immunologic mechanism is not understood [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/63\">",
"     63",
"    </a>",
"    ]. Drug desensitization is effective as long as the patient is receiving the drug, although the patient&rsquo;s sensitivity returns shortly after the drug is cleared from the body. Among all antibiotics, penicillin desensitization is supported by the largest body of published evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/74-79\">",
"     74-79",
"    </a>",
"    ]. Desensitization is reviewed briefly here and in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"     \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1969545\">",
"    <span class=\"h4\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization should be considered in patients who are proven (by positive skin testing or in vitro tests) or are strongly suspected to have an immediate, IgE-mediated penicillin allergy AND for whom there are no acceptable alternate antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1969552\">",
"    <span class=\"h4\">",
"     Safety issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug desensitization should only be performed by clinicians trained in the technique (usually allergy specialists), in a hospital setting (or outpatient setting under close observation), with intravenous access and necessary medications, personnel, and equipment to treat anaphylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link&amp;anchor=H10#H10\">",
"     \"Rapid drug desensitization for immediate hypersensitivity reactions\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Penicillin desensitization has been safely performed in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Desensitization should not be attempted in patients with histories of exfoliative reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis because even small doses of the drug may induce severe progressive reactions. Desensitization is also not appropriate for patients with histories of hemolytic anemia or interstitial nephritis, because these reactions depend upon IgG antibodies and cannot be \"desensitized\" by this method.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1969559\">",
"    <span class=\"h4\">",
"     Protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization can be performed by oral, intravenous, or subcutaneous routes. The oral route is preferred if feasible because it is thought to be safer than parenteral administration.",
"   </p>",
"   <p>",
"    Oral penicillin desensitization may be used even if subsequent therapy will be parenteral. The tables list representative protocols for oral and intravenous penicillin desensitization (",
"    <a class=\"graphic graphic_table graphicRef79351 \" href=\"UTD.htm?30/63/31740\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80213 \" href=\"UTD.htm?7/31/7678\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Studies on penicillin desensitization have given rise to several principles of management [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/75-78\">",
"     75-78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A safe starting dose for desensitization in most patients is",
"      <span class=\"nowrap\">",
"       1/10,000",
"      </span>",
"      of the normal therapeutic concentration. For patients with exquisite sensitivity, a dose that did not produce a positive reaction during skin testing can be used instead.",
"     </li>",
"     <li>",
"      Compared to graded challenge, desensitization involves more gradual increases in dose, administered serially at relatively short time intervals. Doubling the dose every 15 minutes until the recommended dose is reached is effective in nearly all instances.",
"     </li>",
"     <li>",
"      In order for the patient to remain desensitized, it is necessary for the drug to remain continually present in the bloodstream. In the case of oral penicillin, if treatment is discontinued for more than 24 to 48 hours, the patient is again at risk of developing anaphylaxis. If future treatment is again needed, desensitization will need to be performed again.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1969566\">",
"    <span class=\"h4\">",
"     Management of symptoms during desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;If symptoms arise during the procedure, dosing should not be advanced until the symptoms have been treated and have resolved. Treatment usually involves antihistamines for pruritus or urticaria, inhaled bronchodilators for chest tightness or wheezing, or epinephrine for uncommon systemic reactions. Once the symptoms have resolved, the protocol is resumed with the step that was tolerated (ie, the step before the one that caused the reaction).",
"   </p>",
"   <p>",
"    Management of symptoms during intravenous desensitization protocols is reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link&amp;anchor=H25#H25\">",
"     \"Rapid drug desensitization for immediate hypersensitivity reactions\", section on 'Management of symptoms during desensitization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1969573\">",
"    <span class=\"h4\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall success rate of penicillin desensitization depends upon the protocol used, the sensitivity of the patient, and the expertise of the supervising clinician in managing any symptoms that occur and adjusting the procedure accordingly. In experienced hands, the overwhelming majority of all desensitizations for antibiotics are successful.",
"   </p>",
"   <p>",
"    Allergic reactions occur in about a third of patients (one-third of those during the desensitization procedure and two-thirds later during treatment, after desensitization). While most of these reactions are mild, some may be serious and require prompt treatment. However, no fatal or life-threatening reactions have been reported.",
"   </p>",
"   <p>",
"    It is critical to ensure that patients who have received a penicillin via desensitization and finished the treatment understand that they are still allergic to penicillin. The patient must be counseled to avoid penicillins in the future, and that repeat desensitization must be performed if penicillin is required again.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1966217\">",
"    <span class=\"h1\">",
"     DELAYED REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The category of delayed reactions includes an array of reaction types, ranging from common and generally mild cutaneous reactions to rare life-threatening systemic reactions. The immunologic mechanisms underlying the different types of delayed reactions are variable and in some cases, not fully characterized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=see_link&amp;anchor=H20#H20\">",
"     \"Drug allergy: Classification and clinical features\", section on 'Type III reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=see_link&amp;anchor=H26#H26\">",
"     \"Drug allergy: Classification and clinical features\", section on 'Type IV Reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6674398\">",
"    <span class=\"h2\">",
"     Cutaneous reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common allergic reactions to penicillins are delayed cutaneous reactions that are believed to be mediated by T cells in the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. These drug eruptions do not involve fever, systemic symptoms, or evidence of specific organ involvement, aside from the skin. Immunohistological examination of the lesions reveals a cellular in���ltrate, mostly perivascular and consisting mostly of T cells, and apoptosis of a few basal keratinocytes. The majority of the T cells are CD4+ with fewer CD8+ cells. There is an increase in several serum cytokines such as IFN-&gamma;, IL-5, and TNF-a as well as perforin- and granzyme B-containing T cells. These observations have led to the hypothesis that cytotoxic CD4+ T cells that bind to MHC-II mediate most of these rashes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1971062\">",
"    <span class=\"h3\">",
"     Relationship with viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of concurrent systemic viral infections may predispose to delayed cutaneous reactions, particularly in children. The best described example is the occurrence of a nonpruritic morbilliform rash in more than 90 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    during acute infections with Epstein Barr virus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/82\">",
"     82",
"    </a>",
"    ]. Nonpruritic maculopapular rashes that develop during the course of therapy are reported in 3 to 7 percent of children given ampicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/83\">",
"     83",
"    </a>",
"    ]. The mechanism by which viral infections modify immune responses to antibiotics is not clear. One theory proposes that the release of interferons during viral infections leads to increased expression of MHC receptors (along with processed drug) on antigen presenting cells in the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 88 children presenting to the emergency department with delayed cutaneous reactions while taking beta-lactam antibiotics, all patients were tested for common childhood viral infections and then later evaluated for drug allergy with testing followed by drug challenge (regardless of test results) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/84\">",
"     84",
"    </a>",
"    ]. Reactions were morbilliform rashes (41 patients) or urticarial rashes (47 patients) (without other symptoms of anaphylaxis). Sixty-six percent had one or more positive viral studies, suggesting that viral infection is important in the pathogenesis of many drug-related eruptions in children. When the children were later challenged with the culprit antibiotic, only six children experienced mild reactions to the drug upon rechallenge (four with urticaria, two with maculopapular rashes), confirming allergy. Patients with HIV infection also have higher rates of reactions to various antibiotics, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1966232\">",
"    <span class=\"h4\">",
"     Maculopapular cutaneous eruptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maculopapular or morbilliform cutaneous eruptions are typically flat and the individual lesions are relatively fixed, although the area involved tends to expand over several days (",
"    <a class=\"graphic graphic_picture graphicRef70062 \" href=\"UTD.htm?31/30/32239\">",
"     picture 2",
"    </a>",
"    ). Pruritus may or may not be a feature. These rashes, which are believed to be mediated by T cells, are more prevalent in children and are more commonly caused by the aminopenicillins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , compared with penicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/84,86-88\">",
"     84,86-88",
"    </a>",
"    ]. Nonpruritic maculopapular rashes that develop during the course of therapy are reported in 3 to 7 percent of children given ampicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The onset of the eruption is usually within two weeks of beginning therapy, and within days of reexposure if the patient had taken the medication on previous occasions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. Occasionally, an eruption to penicillins may begin as late as three weeks after beginning the antibiotic, or first appear up to two weeks after the therapy was completed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1966239\">",
"    <span class=\"h4\">",
"     Delayed urticarial eruptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed urticarial eruptions (sometimes with associated angioedema),",
"    <strong>",
"     without other symptoms of anaphylaxis",
"    </strong>",
"    , are another common cutaneous reaction to penicillins [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/63\">",
"     63",
"    </a>",
"    ]. These reactions are particularly prevalent in children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/84\">",
"     84",
"    </a>",
"    ]. Symptoms begin more than an hour after the last administered dose. However, IgE-mediated allergy must also be considered in patients with isolated urticaria. An evaluation for IgE-mediated allergy should be performed before future use of penicillins and related drugs can be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1972778\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed cutaneous reactions resolve once the culprit drug is discontinued. Resolution is usually apparent within 7 to 14 days, although symptoms may worsen for a few days even after the drug is stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/91\">",
"     91",
"    </a>",
"    ]. Oral antihistamines may be administered at age-appropriate doses if there is a pruritic component. Oral glucocorticoids may be considered in patients with severe eruptions who do not respond to or are unable to tolerate antihistamines.",
"   </p>",
"   <p>",
"    A drug may be continued in spite of a delayed cutaneous reaction, in rare instances, when no alternative therapy is available [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/92\">",
"     92",
"    </a>",
"    ]. Antihistamines are helpful in controlling symptoms in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1970858\">",
"    <span class=\"h2\">",
"     Rare systemic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin has also been associated with various rare delayed-onset systemic reactions, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum sickness (Gell and Coombs type III)",
"     </li>",
"     <li>",
"      Drug fever [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/93,94\">",
"       93,94",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Stevens-Johnson syndrome (SJS)",
"     </li>",
"     <li>",
"      Toxic epidermal necrolysis (TEN)",
"     </li>",
"     <li>",
"      Drug rash with or without eosinophilia but including systemic",
"      <span class=\"nowrap\">",
"       symptoms/drug-induced",
"      </span>",
"      hypersensitivity syndrome",
"      <span class=\"nowrap\">",
"       (DRESS/DiHS)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/95\">",
"       95",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Acute generalized exanthematous pustulosis (AGEP) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/96-98\">",
"       96-98",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These reactions, caused by penicillins and other drugs, as well as the evaluation and treatment of patients with them, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26663?source=see_link&amp;anchor=H9#H9\">",
"     \"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Approach to diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to diagnosing delayed forms of penicillin allergy is based upon clinical history, in most cases. In the United States, neither in vitro (eg, lymphocyte activation tests) nor skin testing (intradermal testing with delayed reading or patch testing) is widely utilized, although these techniques are more commonly employed in Europe. A general discussion of the diagnosis of drug allergy is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link&amp;anchor=H22#H22\">",
"     \"An approach to the patient with drug allergy\", section on 'Objective testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193959\">",
"    <span class=\"h3\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with past delayed reactions to penicillins, the history should focus on symptoms and concomitant illnesses. A primary focus is the detection of severe drug reactions, such as SJS or TEN. The history of a drug reaction should ascertain the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The timing of onset of the reaction (both from the precipitating dose, as well as from the initiation of that course of therapy)",
"     </li>",
"     <li>",
"      Each exact drug reportedly associated with a reaction, and the indication for its use",
"     </li>",
"     <li>",
"      Whether the patient had symptoms of a viral illness at the time",
"     </li>",
"     <li>",
"      The signs and symptoms involved, and whether there was any blistering or exfoliation of the skin or mucous membrane involvement",
"     </li>",
"     <li>",
"      The dose and route of medication taken (if known)",
"     </li>",
"     <li>",
"      Other concurrent medications, especially if they were new or temporary",
"     </li>",
"     <li>",
"      Any treatment given and response to that treatment (including the duration of reaction)",
"     </li>",
"     <li>",
"      Any prior or subsequent history of exposure to the same drug or structurally similar drugs, with or without reactions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasionally, a clinician has witnessed a patient&rsquo;s reaction, or the reaction is very clearly documented in the patient&rsquo;s medical record. If the reaction was delayed-onset rash that did not itch or involve urticaria, and there were no other systemic symptoms, then it is reasonable to conclude that the reaction was a delayed maculopapular reaction and no further diagnostic testing is needed. (See",
"    <a class=\"local\" href=\"#H667335\">",
"     'Options for treatment in future'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    No further evaluation is needed if the reaction is clearly not allergic (eg, the patient had simple antibiotic-associated vaginitis) or the patient did not actually have a reaction (eg, family history of penicillin allergy but the patient has never taken penicillin, etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with clear histories of severe non-IgE-mediated reactions such as drug-induced hypersensitivity syndrome (DiHS or DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or other exfoliating dermatoses should not receive penicillins again under any circumstances, and need not undergo diagnostic testing. Patients with Stevens-Johnson syndrome or erythema multiforme are usually managed with avoidance also. These severe types of drug reactions are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=see_link&amp;anchor=H26#H26\">",
"     \"Drug allergy: Classification and clinical features\", section on 'Type IV Reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41334?source=see_link\">",
"     \"Treatment of erythema multiforme\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H667335\">",
"    <span class=\"h2\">",
"     Options for treatment in future",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1973926\">",
"    <span class=\"h3\">",
"     Cutaneous reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient clearly describes a delayed-onset eruption that did not itch or involve urticaria, was not accompanied by any systemic symptoms, and did not involve blistering or exfoliation of the skin, then it can be reasonably assumed that the patient had a delayed maculopapular cutaneous reaction. Such patients can be treated with the same or other penicillins in the future, with the recognition that such reactions may recur.",
"   </p>",
"   <p>",
"    This level of certainty about the reaction history is only possible if the clinician observed the reaction first-hand, or if there is clear documentation in the medical record. The more distant a reaction, the more uncertain are its manifestations, and the more difficult it is to obtain the medical record. If there is any doubt about the nature of the previous reaction, caution and objective allergy evaluation are warranted.",
"   </p>",
"   <p>",
"    Safe readministration with the same or similar drugs is well documented in children, in whom delayed cutaneous eruptions regularly occur in the setting of viral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/84\">",
"     84",
"    </a>",
"    ]. In the study of 88 children with delayed urticarial or maculopapular rashes on beta-lactam (mostly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ) antibiotics described previously, only 6 of 88 (7 percent) reacted again when rechallenged with the same antibiotic two months after the original reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/46/23274/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1971062\">",
"     'Relationship with viral infections'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H668477\">",
"    <span class=\"h4\">",
"     Concomitant antihistamine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have experienced multiple drug reactions, there may be some value in administering a nonsedating antihistamine during treatment with antibiotics. This approach has not been studied formally, but there is a clinical impression that it may have some value in preventing mild, nonspecific cutaneous reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1973941\">",
"    <span class=\"h3\">",
"     Systemic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with clear histories of severe non-IgE-mediated reactions such as drug-induced hypersensitivity syndrome (DiHS or DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or other exfoliating dermatoses should not receive penicillins again under any usual circumstances. Patients with erythema multiforme minor and drug fever are usually managed with avoidance also. These severe types of drug reactions are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=see_link&amp;anchor=H26#H26\">",
"     \"Drug allergy: Classification and clinical features\", section on 'Type IV Reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41334?source=see_link\">",
"     \"Treatment of erythema multiforme\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/37/22098?source=see_link\">",
"       \"Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergy to penicillin is the most commonly-reported medication allergy, although approximately 85 to 90 percent of patients who report allergic reactions to penicillins either were never allergic or had an earlier allergy that resolved. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Allergic reactions to penicillins may be categorized based on the time of onset of symptoms (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Immediate reactions",
"      </strong>",
"      begin within an hour of the first administered dose. These reactions are usually type I, IgE-mediated reactions that may escalate to life-threatening anaphylaxis (",
"      <a class=\"graphic graphic_table graphicRef66333 \" href=\"UTD.htm?20/36/21068\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Delayed reactions",
"      </strong>",
"      begin after multiple doses, typically after days or weeks of treatment, and usually consist of relatively harmless cutaneous reactions (",
"      <a class=\"graphic graphic_picture graphicRef70062 \" href=\"UTD.htm?31/30/32239\">",
"       picture 2",
"      </a>",
"      ), although rare delayed systemic reactions also exist and can be severe.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with immediate reactions may have IgE antibodies directed against the core of the penicillin molecule complexed to proteins. Less commonly, IgE recognizes the R-group side chains, which differ among the various penicillins. Patients with side chain allergies are typically tolerant of benzylpenicillin, but react to one of the aminopenicillins, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H1965552\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of immediate allergic reactions to penicillin is based on clinical history, skin testing when available, and sometimes graded challenge (see",
"      <a class=\"local\" href=\"#H1966255\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The time elapsed since the patient's last reaction is important in assessing the risk of a recurrent reaction, as patients with IgE-mediated allergy may lose the sensitivity over time if they are not reexposed. Only 20 percent of patients with confirmed IgE-mediated penicillin allergy remain allergic after 10 years of avoidance. (See",
"      <a class=\"local\" href=\"#H1968131\">",
"       'Clinical history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Penicillin skin testing is the preferred method of evaluating patients with possible immediate reactions because it is rapid, sensitive, and associated with minimal patient discomfort, although referral is needed because this type of testing is usually performed by allergy specialists. (See",
"      <a class=\"local\" href=\"#H1968768\">",
"       'Penicillin skin testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In vitro tests, such as immunoassays for penicillin-specific IgE or basophil activation tests, are inferior to skin testing, and are of limited value. (See",
"      <a class=\"local\" href=\"#H1968768\">",
"       'Penicillin skin testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If skin testing is not available and an equivalent alternative antimicrobial does not exist, patients with a low likelihood of allergy based upon clinical history, time elapsed since the reaction, and possible in vitro testing may be diagnosed via graded challenge. Patients who tolerate graded challenge prove that they are not acutely allergic. Challenges should be performed in a setting equipped with the staff and equipment to treat possible allergic reactions, including anaphylaxis. (See",
"      <a class=\"local\" href=\"#H1968789\">",
"       'Graded challenge (test dosing)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with past immediate reactions who are found to remain sensitive, either by skin testing or challenge, the options for future treatment include use of unrelated antibiotics (ie, avoidance of penicillins) or treatment with penicillins via desensitization. (See",
"      <a class=\"local\" href=\"#H1969463\">",
"       'Options for future treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delayed cutaneous reactions (maculopapular exanthems and less commonly urticarial eruptions) are the most common form of allergic reaction to penicillins. These are usually mild and often related to a concomitant viral infection, especially in children. (See",
"      <a class=\"local\" href=\"#H6674398\">",
"       'Cutaneous reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of delayed cutaneous reactions is largely based upon the clinical history. Skin testing for immediate reactions should be performed if the reaction included urticaria or angioedema, or if the history is vague and future penicillin use is desired. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with past delayed systemic reactions, such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), hypersensitivity syndrome (DiHS or DRESS), or other exfoliating dermatoses should not receive penicillins again under any circumstances, because reexposure can trigger recurrent symptoms. Patients with erythema multiforme minor or drug fever are usually managed with avoidance also. (See",
"      <a class=\"local\" href=\"#H667335\">",
"       'Options for treatment in future'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/1\">",
"      Lee CE, Zembower TR, Fotis MA, et al. The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch Intern Med 2000; 160:2819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/2\">",
"      Park M, Markus P, Matesic D, Li JT. Safety and effectiveness of a preoperative allergy clinic in decreasing vancomycin use in patients with a history of penicillin allergy. Ann Allergy Asthma Immunol 2006; 97:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/3\">",
"      Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010; 105:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/4\">",
"      Mendelson LM, Ressler C, Rosen JP, Selcow JE. Routine elective penicillin allergy skin testing in children and adolescents: study of sensitization. J Allergy Clin Immunol 1984; 73:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/5\">",
"      Sogn DD, Evans R 3rd, Shepherd GM, et al. Results of the National Institute of Allergy and Infectious Diseases Collaborative Clinical Trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. Arch Intern Med 1992; 152:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/6\">",
"      Gadde J, Spence M, Wheeler B, Adkinson NF Jr. Clinical experience with penicillin skin testing in a large inner-city STD clinic. JAMA 1993; 270:2456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/7\">",
"      Jost BC, Wedner HJ, Bloomberg GR. Elective penicillin skin testing in a pediatric outpatient setting. Ann Allergy Asthma Immunol 2006; 97:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/8\">",
"      Macy E, Schatz M, Lin C, Poon KY. The falling rate of positive penicillin skin tests from 1995 to 2007. Perm J 2009; 13:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/9\">",
"      Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/10\">",
"      Idsoe O, Guthe T, Willcox RR, de Weck AL. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bull World Health Organ 1968; 38:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/11\">",
"      Allergic reactions to long-term benzathine penicillin prophylaxis for rheumatic fever. International Rheumatic Fever Study Group. Lancet 1991; 337:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/12\">",
"      Napoli DC, Neeno TA. Anaphylaxis to benzathine penicillin G. Pediatr Asthma Allergy Immunol 2000; 14:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/13\">",
"      Levine BB, Redmond AP. Minor haptenic determinant-specific reagins of penicillin hypersensitivity in man. Int Arch Allergy Appl Immunol 1969; 35:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/14\">",
"      LEVINE BB, OVARY Z. Studies on the mechanism of the formation of the penicillin antigen. III. The N-(D-alpha-benzylpenicilloyl) group as an antigenic determinant responsible for hypersensitivity to penicillin G. J Exp Med 1961; 114:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/15\">",
"      PARKER CW, SHAPIRO J, KERN M, EISEN HN. Hypersensitivity to penicillenic acid derivatives in human beings with penicillin allergy. J Exp Med 1962; 115:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/16\">",
"      Blanca M, Vega JM, Garcia J, et al. Allergy to penicillin with good tolerance to other penicillins; study of the incidence in subjects allergic to beta-lactams. Clin Exp Allergy 1990; 20:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/17\">",
"      Vega JM, Blanca M, Garc&iacute;a JJ, et al. Immediate allergic reactions to amoxicillin. Allergy 1994; 49:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/18\">",
"      Macy E, Burchette RJ. Oral antibiotic adverse reactions after penicillin skin testing: multi-year follow-up. Allergy 2002; 57:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/19\">",
"      Macy E, Richter PK, Falkoff R, Zeiger R. Skin testing with penicilloate and penilloate prepared by an improved method: amoxicillin oral challenge in patients with negative skin test responses to penicillin reagents. J Allergy Clin Immunol 1997; 100:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/20\">",
"      Park MA, Matesic D, Markus PJ, Li JT. Female sex as a risk factor for penicillin allergy. Ann Allergy Asthma Immunol 2007; 99:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/21\">",
"      Lin E, Saxon A, Riedl M. Penicillin allergy: value of including amoxicillin as a determinant in penicillin skin testing. Int Arch Allergy Immunol 2010; 152:313.",
"     </a>",
"    </li>",
"    <li>",
"     Mendelson L, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/23\">",
"      Bousquet PJ, Co-Minh HB, Arnoux B, et al. Importance of mixture of minor determinants and benzylpenicilloyl poly-L-lysine skin testing in the diagnosis of beta-lactam allergy. J Allergy Clin Immunol 2005; 115:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/24\">",
"      Romano A, Bousquet-Rouanet L, Viola M, et al. Benzylpenicillin skin testing is still important in diagnosing immediate hypersensitivity reactions to penicillins. Allergy 2009; 64:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/25\">",
"      Moss RB, Babin S, Hsu YP, et al. Allergy to semisynthetic penicillins in cystic fibrosis. J Pediatr 1984; 104:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/26\">",
"      Fernandez-Rivas M, Perez Carral C, Cuevas M, et al. Selective allergic reactions to clavulanic acid. J Allergy Clin Immunol 1995; 95:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/27\">",
"      Torres MJ, Ariza A, Mayorga C, et al. Clavulanic acid can be the component in amoxicillin-clavulanic acid responsible for immediate hypersensitivity reactions. J Allergy Clin Immunol 2010; 125:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/28\">",
"      Adkinson NF Jr. Risk factors for drug allergy. J Allergy Clin Immunol 1984; 74:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/29\">",
"      Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992; 34:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/30\">",
"      Moss RB. Drug allergy in cystic fibrosis. Clin Rev Allergy 1991; 9:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/31\">",
"      Moseley EK, Sullivan TJ. Allergic reactions to antimicrobial drugs in patients with a history of prior drug allergy. J Allergy Clin Immunol 1991; 87:226 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/32\">",
"      Smith JW, Johnson JE, Cluff LE. Studies on the epidemiology of adverse drug reactions. II. An evaluation of penicillin allergy. N Engl J Med 1966; 274:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/33\">",
"      Sullivan TJ, Ong RC, Gilliam LK. Studies of the multiple drug allergy syndrome. J Allergy Clin Immunol 1989; 83:270 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/34\">",
"      Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003; 349:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/35\">",
"      Apter AJ, Kinman JL, Bilker WB, et al. Is there cross-reactivity between penicillins and cephalosporins? Am J Med 2006; 119:354.e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/36\">",
"      Asero R. Detection of patients with multiple drug allergy syndrome by elective tolerance tests. Ann Allergy Asthma Immunol 1998; 80:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/37\">",
"      Yang J, Qiao HL, Zhang YW, et al. HLA-DRB genotype and specific IgE responses in patients with allergies to penicillins. Chin Med J (Engl) 2006; 119:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/38\">",
"      Attaway NJ, Jasin HM, Sullivan TJ. Familial drug allergy. J Allergy Clin Immunol 1991; 87:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/39\">",
"      Kurtz KM, Beatty TL, Adkinson NF Jr. Evidence for familial aggregation of immunologic drug reactions. J Allergy Clin Immunol 2000; 105:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/40\">",
"      Apter AJ, Schelleman H, Walker A, et al. Clinical and genetic risk factors of self-reported penicillin allergy. J Allergy Clin Immunol 2008; 122:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/41\">",
"      KERN RA, WIMBERLEY NA Jr. Penicillin reactions; their nature, growing importance, recognition, management and prevention. Am J Med Sci 1953; 226:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/42\">",
"      Levine BB. Immunologic mechanisms of penicillin allergy. A haptenic model system for the study of allergic diseases of man. N Engl J Med 1966; 275:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/43\">",
"      Green GR, Rosenblum AH, Sweet LC. Evaluation of penicillin hypersensitivity: value of clinical history and skin testing with penicilloyl-polylysine and penicillin G. A cooperative prospective study of the penicillin study group of the American Academy of Allergy. J Allergy Clin Immunol 1977; 60:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/44\">",
"      Stember RH. Prevalence of skin test reactivity in patients with convincing, vague, and unacceptable histories of penicillin allergy. Allergy Asthma Proc 2005; 26:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/45\">",
"      Wong BB, Keith PK, Waserman S. Clinical history as a predictor of penicillin skin test outcome. Ann Allergy Asthma Immunol 2006; 97:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/46\">",
"      Solensky R, Earl HS, Gruchalla RS. Penicillin allergy: prevalence of vague history in skin test-positive patients. Ann Allergy Asthma Immunol 2000; 85:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/47\">",
"      Pichichero ME, Pichichero DM. Diagnosis of penicillin, amoxicillin, and cephalosporin allergy: reliability of examination assessed by skin testing and oral challenge. J Pediatr 1998; 132:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/48\">",
"      Kalogeromitros D, Rigopoulos D, Gregoriou S, et al. Penicillin hypersensitivity: value of clinical history and skin testing in daily practice. Allergy Asthma Proc 2004; 25:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/49\">",
"      Adkinson NF Jr, Thompson WL, Maddrey WC, Lichtenstein LM. Routine use of penicillin skin testing on an inpatient service. N Engl J Med 1971; 285:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/50\">",
"      Van Dellen RG, Gleich GJ. Penicillin skin tests as predictive and diagnostic aids in penicillin allergy. Med Clin North Am 1970; 54:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/51\">",
"      Sullivan TJ, Wedner HJ, Shatz GS, et al. Skin testing to detect penicillin allergy. J Allergy Clin Immunol 1981; 68:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/52\">",
"      Blanca M, Torres MJ, Garc&iacute;a JJ, et al. Natural evolution of skin test sensitivity in patients allergic to beta-lactam antibiotics. J Allergy Clin Immunol 1999; 103:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/53\">",
"      Solensky R, Earl HS, Gruchalla RS. Clinical approach to penicillin-allergic patients: a survey. Ann Allergy Asthma Immunol 2000; 84:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/54\">",
"      Puchner TC Jr, Zacharisen MC. A survey of antibiotic prescribing and knowledge of penicillin allergy. Ann Allergy Asthma Immunol 2002; 88:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/55\">",
"      Kwan T, Lin F, Ngai B, Loeb M. Vancomycin use in 2 Ontario tertiary care hospitals: a survey. Clin Invest Med 1999; 22:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/56\">",
"      Cieslak PR, Strausbaugh LJ, Fleming DW, Ling JM. Vancomycin in Oregon: who's using it and why. Infect Control Hosp Epidemiol 1999; 20:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/57\">",
"      MacLaughlin EJ, Saseen JJ, Malone DC. Costs of beta-lactam allergies: selection and costs of antibiotics for patients with a reported beta-lactam allergy. Arch Fam Med 2000; 9:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/58\">",
"      Romano A, Di Fonso M, Papa G, et al. Evaluation of adverse cutaneous reactions to aminopenicillins with emphasis on those manifested by maculopapular rashes. Allergy 1995; 50:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/59\">",
"      Patriarca G, Schiavino D, Romano A, et al. Status of patch and other skin tests in diagnosis of systemic penicillin allergy. Allergol Immunopathol (Madr) 1987; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/60\">",
"      Macy E, Goldberg B, Poon KY. Use of commercial anti-penicillin IgE fluorometric enzyme immunoassays to diagnose penicillin allergy. Ann Allergy Asthma Immunol 2010; 105:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/61\">",
"      Sanz ML, Gamboa PM, Ant&eacute;para I, et al. Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics. Clin Exp Allergy 2002; 32:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/62\">",
"      Torres MJ, Padial A, Mayorga C, et al. The diagnostic interpretation of basophil activation test in immediate allergic reactions to betalactams. Clin Exp Allergy 2004; 34:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/63\">",
"      Solensky R. Drug desensitization. Immunol Allergy Clin North Am 2004; 24:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/64\">",
"      Liccardi G, Senna G, Russo M, et al. Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions. J Investig Allergol Clin Immunol 2004; 14:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/65\">",
"      Demoly P, Romano A, Botelho C, et al. Determining the negative predictive value of provocation tests with beta-lactams. Allergy 2010; 65:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/66\">",
"      Macy E. Elective penicillin skin testing and amoxicillin challenge: effect on outpatient antibiotic use, cost, and clinical outcomes. J Allergy Clin Immunol 1998; 102:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/67\">",
"      Macy E, Mangat R, Burchette RJ. Penicillin skin testing in advance of need: multiyear follow-up in 568 test result-negative subjects exposed to oral penicillins. J Allergy Clin Immunol 2003; 111:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/68\">",
"      Solensky R, Earl HS, Gruchalla RS. Lack of penicillin resensitization in patients with a history of penicillin allergy after receiving repeated penicillin courses. Arch Intern Med 2002; 162:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/69\">",
"      Hershkovich J, Broides A, Kirjner L, et al. Beta lactam allergy and resensitization in children with suspected beta lactam allergy. Clin Exp Allergy 2009; 39:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/70\">",
"      Perencevich EN, Weller PF, Samore MH, Harris AD. Benefits of negative penicillin skin test results persist during subsequent hospital admissions. Clin Infect Dis 2001; 32:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/71\">",
"      Parker PJ, Parrinello JT, Condemi JJ, Rosenfeld SI. Penicillin resensitization among hospitalized patients. J Allergy Clin Immunol 1991; 88:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/72\">",
"      Lopez-Serrano MC, Caballero MT, Barranco P, Martinez-Alzamora F. Booster responses in the study of allergic reactions to beta-lactam antibiotics. J Investig Allergol Clin Immunol 1996; 6:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/73\">",
"      Bittner A, Greenberger PA. Incidence of resensitization after tolerating penicillin treatment in penicillin-allergic patients. Allergy Asthma Proc 2004; 25:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/74\">",
"      Borish L, Tamir R, Rosenwasser LJ. Intravenous desensitization to beta-lactam antibiotics. J Allergy Clin Immunol 1987; 80:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/75\">",
"      Stark BJ, Earl HS, Gross GN, et al. Acute and chronic desensitization of penicillin-allergic patients using oral penicillin. J Allergy Clin Immunol 1987; 79:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/76\">",
"      Sullivan TJ, Yecies LD, Shatz GS, et al. Desensitization of patients allergic to penicillin using orally administered beta-lactam antibiotics. J Allergy Clin Immunol 1982; 69:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/77\">",
"      Sullivan TJ. Antigen-specific desensitization of patients allergic to penicillin. J Allergy Clin Immunol 1982; 69:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/78\">",
"      Wendel GD Jr, Stark BJ, Jamison RB, et al. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med 1985; 312:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/79\">",
"      Chisholm CA, Katz VL, McDonald TL, Bowes WA Jr. Penicillin desensitization in the treatment of syphilis during pregnancy. Am J Perinatol 1997; 14:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/80\">",
"      Blanca-L&oacute;pez N, Zapatero L, Alonso E, et al. Skin testing and drug provocation in the diagnosis of nonimmediate reactions to aminopenicillins in children. Allergy 2009; 64:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/81\">",
"      Romano A, Blanca M, Torres MJ, et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy 2004; 59:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/82\">",
"      Patel BM. Skin rash with infectious mononucleosis and ampicillin. Pediatrics 1967; 40:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/83\">",
"      Bass JW, Crowley DM, Steele RW, et al. Adverse effects of orally administered ampicillin. J Pediatr 1973; 83:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/84\">",
"      Caubet JC, Kaiser L, Lema&icirc;tre B, et al. The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. J Allergy Clin Immunol 2011; 127:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/85\">",
"      Pirmohamed M, Park BK. HIV and drug allergy. Curr Opin Allergy Clin Immunol 2001; 1:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/86\">",
"      Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256:3358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/87\">",
"      Arndt KA, Jick H. Rates of cutaneous reactions to drugs. A report from the Boston Collaborative Drug Surveillance Program. JAMA 1976; 235:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/88\">",
"      Ibia EO, Schwartz RH, Wiedermann BL. Antibiotic rashes in children: a survey in a private practice setting. Arch Dermatol 2000; 136:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/89\">",
"      Yawalkar N. Drug-induced exanthems. Toxicology 2005; 209:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/90\">",
"      Segal AR, Doherty KM, Leggott J, Zlotoff B. Cutaneous reactions to drugs in children. Pediatrics 2007; 120:e1082.",
"     </a>",
"    </li>",
"    <li>",
"     Shear NH, Knowles SR, Shapiro L. Cutaneous reactions to drugs. In: Fitzpatrick's dermatology in general medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw Hill, 2008. p.355.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/92\">",
"      Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/93\">",
"      Patel RA, Gallagher JC. Drug fever. Pharmacotherapy 2010; 30:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/94\">",
"      Linares T, Fern&aacute;ndez A, Soto MT, et al. Drug fever caused by piperacillin-tazobactam. J Investig Allergol Clin Immunol 2011; 21:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/95\">",
"      Jurado-Palomo J, Caba&ntilde;as R, Prior N, et al. Use of the lymphocyte transformation test in the diagnosis of DRESS syndrome induced by ceftriaxone and piperacillin-tazobactam: two case reports. J Investig Allergol Clin Immunol 2010; 20:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/96\">",
"      Matsumoto Y, Okubo Y, Yamamoto T, et al. Case of acute generalized exanthematous pustulosis caused by ampicillin/cloxacillin sodium in a pregnant woman. J Dermatol 2008; 35:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/97\">",
"      Talati S, Lala M, Kapupara H, Thet Z. Acute generalized exanthematous pustulosis: a rare clinical entity with use of piperacillin/tazobactam. Am J Ther 2009; 16:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/46/23274/abstract/98\">",
"      Riten K, Shahina Q, Jeannette J, Palma-Diaz MF. A severe case of acute generalized exanthematous pustulosis (AGEP) in a child after the administration of amoxicillin-clavulanic acid: brief report. Pediatr Dermatol 2009; 26:623.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2073 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_46_23274=[""].join("\n");
var outline_f22_46_23274=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3592171\">",
"      Immediate versus delayed reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1965026\">",
"      IMMEDIATE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1965034\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H191336\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1965552\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1965559\">",
"      - Allergenic beta-lactam structures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1965566\">",
"      - Side chain specific reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1966521\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1966255\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1968131\">",
"      Clinical history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1968138\">",
"      - Accuracy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1968145\">",
"      - Time elapsed since the reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1968152\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1968768\">",
"      Penicillin skin testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1968775\">",
"      When penicillin skin testing is not possible",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1968782\">",
"      - In vitro tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1968789\">",
"      - Graded challenge (test dosing)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1968870\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1968877\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1968884\">",
"      Risk of resensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1969463\">",
"      Options for future treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1969470\">",
"      - Avoidance of all penicillins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1969477\">",
"      - Desensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1969545\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1969552\">",
"      Safety issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1969559\">",
"      Protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1969566\">",
"      Management of symptoms during desensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1969573\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1966217\">",
"      DELAYED REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6674398\">",
"      Cutaneous reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1971062\">",
"      - Relationship with viral infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1966232\">",
"      Maculopapular cutaneous eruptions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1966239\">",
"      Delayed urticarial eruptions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1972778\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1970858\">",
"      Rare systemic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193959\">",
"      - Clinical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H667335\">",
"      Options for treatment in future",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1973926\">",
"      - Cutaneous reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H668477\">",
"      Concomitant antihistamine therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1973941\">",
"      - Systemic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2073\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2073|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/58/7086\" title=\"figure 1\">",
"      PCN major minor det",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2073|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/2/29728\" title=\"picture 1\">",
"      Urticaria 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/30/32239\" title=\"picture 2\">",
"      Morbilliform eruption 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2073|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/11/13500\" title=\"table 1\">",
"      Types allergic reactions SS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/36/21068\" title=\"table 2\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/63/31740\" title=\"table 3\">",
"      Beta-lactam oral desensitization protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/31/7678\" title=\"table 4\">",
"      PCN desens IV pump",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=related_link\">",
"      An approach to the patient with drug allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26663?source=related_link\">",
"      Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=related_link\">",
"      Drug allergy: Classification and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=related_link\">",
"      Drug allergy: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/37/22098?source=related_link\">",
"      Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=related_link\">",
"      Penicillin skin testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=related_link\">",
"      Rapid drug desensitization for immediate hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41334?source=related_link\">",
"      Treatment of erythema multiforme",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_46_23275="Timing of surgical prophylaxis";
var content_f22_46_23275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Timing of prophylactic antibiotic administration and subsequent rates of SSIs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Time of administration*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent with SSI",
"       </td>",
"       <td class=\"subtitle1\">",
"        Odds ratio",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        95 percent CI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early",
"       </td>",
"       <td>",
"        3.8",
"       </td>",
"       <td>",
"        4.3",
"       </td>",
"       <td>",
"        1.8-10.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preoperative",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perioperative",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"       <td>",
"        2.1",
"       </td>",
"       <td>",
"        0.6-7.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postoperative",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"       <td>",
"        5.8",
"       </td>",
"       <td>",
"        2.4-13.8",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SSI: surgical site infection.",
"     <br>",
"      * \"Early\" denotes 2 to 24 hours before incision; \"preoperative\" 0 to 2 hours before incision; \"perioperative\" within 3 hours after incision; and \"postoperative\" more than 3 hours after incision.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Odds ratio determined by logistic-regression analysis.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Classen DC, Evans RS, Pestotnik SL, et al, N Engl J Med 1992; 326:281.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_46_23275=[""].join("\n");
var outline_f22_46_23275=null;
var title_f22_46_23276="Differential diagnosis of MS";
var content_f22_46_23276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of multiple sclerosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inflammatory disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute disseminated encephalomyelitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beh&ccedil;et disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomatosis angiitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuromyelitis optica (Devic disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraneoplastic encephalomyelopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyarteritis nodosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sj&ouml;gren syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infectious disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Human immunodeficiency virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lyme neuroborreliosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurosyphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive multifocal leukoencephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tropical spastic paraparesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Genetic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Granulomatous disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphomatoid granulomatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disease of myelin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenoleukodystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adult metachromatic leukodystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arnold-Chiari malformation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Compressive spinal cord lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular malformations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin B12 deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinocerebellar disorders",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_46_23276=[""].join("\n");
var outline_f22_46_23276=null;
var title_f22_46_23277="Diet stages RYGBP";
var content_f22_46_23277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diet recommendations after Roux en Y Gastric Bypass and Gastric Sleeve Procedures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Diet stage*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Begin",
"      </td>",
"      <td class=\"subtitle1\">",
"       Fluids/food",
"      </td>",
"      <td class=\"subtitle1\">",
"       Guidelines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Stage I",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &nbsp;",
"      </td>",
"      <td>",
"       Post-op day 1 and 2",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         Clear liquids:",
"        </strong>",
"       </p>",
"       <p>",
"        Non-carbonated; no calories",
"       </p>",
"       <p>",
"        No sugar; no caffeine",
"       </p>",
"      </td>",
"      <td>",
"       Post-op day 1 patients undergo a gastrogaffin swallow test for leak; once tested, begin sips of clear liquids",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Stage II",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"7\">",
"       See table on supplementation after Roux-en-Y gastric bypass and Gastric Sleeve.",
"      </td>",
"      <td rowspan=\"7\">",
"       Post-op day 3 (discharge diet)",
"      </td>",
"      <td rowspan=\"7\">",
"       <p>",
"        <strong>",
"         Clear liquids:",
"        </strong>",
"       </p>",
"       <p>",
"        Variety of no sugar liquids or artificially sweetened liquids",
"       </p>",
"       <p>",
"        Encourage patients to have salty fluids at home",
"       </p>",
"       <p>",
"        Solid liquids: sugar free ice pops",
"       </p>",
"       <p>",
"        <strong>",
"         Plus GBP full liquids:",
"        </strong>",
"       </p>",
"       <p>",
"        Less than 25 grams sugar per serving; protein rich liquids (limit 25-30 grams protein per serving of added powders)",
"       </p>",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Patients should consume a minimum of 48-64 ounces of total fluids per day; 24-32 ounces or more ounces clear liquids; plus 24-32 ounces of any combination of full liquids:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - 1 percent or skim milk plain or mixed with:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Whey or soy protein powder (limit 30 g protein per serving)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Whey isolates if lactose intolerant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Lactaid milk or soy milk mix with soy protein powder",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Light yogurt, no fruit chunks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Plain yogurt; Greek yogurt",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Stage III",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Week I",
"      </td>",
"      <td>",
"       Post-op day 10-14*",
"      </td>",
"      <td>",
"       <p>",
"        Increase GBP clear liquids (total liquids 48-64 plus ounces per day) and replace full liquids with soft, moist, diced, ground or pureed protein sources as tolerated",
"       </p>",
"       <p>",
"        <strong>",
"         Stage III week one:",
"        </strong>",
"        Eggs, ground meats, poultry, soft, moist fish, added gravy, bouillon, light mayo to moisten, cooked bean, hearty bean soups, cottage cheese, low fat cheese, yogurt",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Protein food choices are encouraged for 3-6 small meals per day; patients may only be able to tolerate a couple of Tbs. at each meal/snack. Protein should be moist and ground, pureed or diced.",
"       </p>",
"       <p>",
"        Encourage patients not to drink with meals and to wait &sim;30 minutes after each meal before resuming fluids",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Week 2",
"      </td>",
"      <td>",
"       4-weeks post-op",
"      </td>",
"      <td>",
"       Advance diet as tolerated; if protein foods; add well-cooked, soft vegetables; and, soft and/or peeled fruit. Always eat protein first.",
"      </td>",
"      <td>",
"       Adequate hydration is essential and a priority for all patients during the rapid weight loss phase",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <p>",
"        Week 3",
"       </p>",
"       <p>",
"        May switch to pill form of supplement",
"       </p>",
"      </td>",
"      <td>",
"       5-weeks post-op",
"      </td>",
"      <td>",
"       Continue to consume protein with some fruit or vegetable at each meal; some people tolerate salads one month post-op",
"      </td>",
"      <td>",
"       <strong>",
"        AVOID",
"       </strong>",
"       rice, bread and pasta until patient is comfortably consuming 60 grams protein per day and fruits/vegetables",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Stage IV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vitamin and mineral supplement daily&bull;",
"      </td>",
"      <td>",
"       As hunger increases and more food is tolerated",
"      </td>",
"      <td>",
"       Healthy solid food diet",
"      </td>",
"      <td>",
"       Healthy, balanced diet consisting of adequate protein, fruits, vegetables and whole grains; calorie needs based on height, weight, age",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * There is no standardization of diet stages, there are a wide variety of diet protocols varying from how long patients stay on each stage and what types of fluids/foods are recommended. Dietary advancement is based on nutritional needs and increasing tolerance for dietary texture, meaning that soft foods should be introduced successfully before any hard solids are allowed.",
"     <br>",
"      &bull; Nutritional labs should be drawn 2, 6, 12 months and yearly indefinitely; bone density test at baseline and every 2 years.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Table provided with permission: Sue Cummings, MS, RD, LDN; MGH Weight Center, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_46_23277=[""].join("\n");
var outline_f22_46_23277=null;
var title_f22_46_23278="Dysuria adolescent male";
var content_f22_46_23278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dysuria in the adolescent male without conjunctivitis, arthritis, or generalized rash",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 520px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_46_23278=[""].join("\n");
var outline_f22_46_23278=null;
var title_f22_46_23279="TEE 4 chamber view tricuspid valve vegetation";
var content_f22_46_23279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/73652/tricvege_conv.mp4?title=TEE+4+chamber+view+tricuspid+valve+vegetation\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiogram (TEE) mid-esophageal 4 chamber view showing a tricuspid valve vegetation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transesophageal echocardiography showing a large vegetation in the tricuspid valve in a patient with subacute bacterial endocarditis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Roberto Lang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_46_23279=[""].join("\n");
var outline_f22_46_23279=null;
